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Gram-positive bacterial infections have risen over recent years and current antibiotic treatments 
are not always sufficient to control these infections.  Specifically, antibiotics target bacteria 
themselves, but not the bacterially secreted proteins that contribute to bacterial pathogenesis and 
host tissue damage (i.e. virulence factors).  These virulence factors may linger after bacteria are 
eradicated, making their interaction with the host important to understand for the development of 
novel therapeutics to supplement antibiotics.  One class of virulence factors studied in our 
laboratory is a large pore-forming toxin family known as the cholesterol-dependent cytolysins 
(CDC). These exotoxins are secreted by over twenty species of gram-positive bacteria and have 
been shown to contribute to the virulence of the bacteria that secrete them.  We are interested in 
exploring the pathways initiated by CDC in host innate immune cells such as macrophages and 
dendritic cells.  These cells would be expected to first encounter CDC after bacterial infection 
and therefore, pathways initiated in these cells by CDC could be targeted for the benefit of the 
host. 
We have characterized the mechanism of mature IL-1beta secretion induced by CDC 
tetanolysin O (TLO) from LPS-primed murine bone marrow-derived macrophages (BMDM).  
This process is dependent on TLO dose and relies on the caspase-1-containing NLRP3 
inflammasome as well as associated signaling pathways, which include ion fluxes and iPLA2 
and cathepsin B activities.  Furthermore, TLO induces different cell death programs in BMDM 
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 v 
that are dependent on TLO dose.  High TLO doses induce conventional necrotic cell death while 
low TLO doses cause NLRP3 inflammasome-dependent and cathepsin B-dependent necrotic cell 
death that is characterized by lactate dehydrogenase (LDH) and high mobility group box 1 
(HMGB1) release.  Both IL-1beta and HMGB1 are pro-inflammatory cytokines that contribute 
to inflammation and may be useful therapeutic targets, in addition to the inflammasome.  Finally, 
susceptibility to CDC-induced cell killing varies based on cell type.  In order to determine 
pathways that might explain these differences, we created a variant murine dendritic cell line 
resistant to pore formation.  Though this cell line has been characterized to some degree, future 
studies will be needed to pinpoint the pathways responsible for the phenotype observed. 
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 1 
1.0  INTRODUCTION 
In recent years, the incidence of gram-positive bacterial infections has dramatically risen.  
Current treatments, which mainly include antibiotics, eradicate the infecting bacteria, but their 
heavy use can lead to bacterial resistance.  Moreover, virulence factors (e.g. toxins) already 
released into the host remain behind, wreaking havoc on the immune system.  New therapies 
directly targeting these toxins are needed and initial steps must be made to understand their 
mechanisms of action on immune cells.  Additionally, there exists an urgency to develop new 
gram-positive bacterial treatments in the event of a bioterror attack utilizing toxin-secreting 
pathogens such as B. anthracis (anthrax).  Though much data has accumulated on the effects of 
virulence factors on immune cells, there still remains a gap in knowledge regarding the effects of 
a family of bacterial exotoxins known as cholesterol-dependent cytolysins (CDC).  Specifically, 
it is important to understand the impact of these toxins on innate immune phagocytes, which 
would most likely first encounter CDC-secreting bacteria.  Particularly, our laboratory is 
interested in studying the innate immune sensors that recognize these toxin virulence factors and 
their associated downstream pathways.  The next two sections will review the current knowledge 
regarding this toxin family, including pathways activated in innate immune cells with a focus on 
the activation of a proinflammatory molecular complex known as the inflammasome.  
 2 
1.1 CHOLESTEROL-DEPENDENT CYTOLYSINS 
There are two major classes of bacterial toxins: endotoxins and exotoxins (Grandel & 
Grimminger, 2003).  Endotoxins are released from the outer membrane of the cell wall of Gram-
negative bacteria upon lysis or during cell division and are fairly similar regardless of the 
bacterial strain.  On the other hand, exotoxins are secreted into the surrounding environment by 
live bacteria and distinct exotoxins are produced by different genera.  These latter toxins 
comprise three classes: type I toxins bind surface receptors and initiate signaling, type II toxins 
form channels in the lipid bilayer, and type III toxins allow passage of an enzymatic component 
into the host cell for modification of a target molecule (Henderson et al., 1997).  Of particular 
interest is a subclass of type II exotoxins known as the cholesterol-dependent cytolysin (CDC) 
family (containing 27 known members (Billington et al., 2000; Palmer, 2001; Shannon et al., 
2003; Gelber et al., 2008) – see Figure 1-1), which is specific to gram-positive bacteria.   
 
 3 
 
Figure 1-1: The family of cholesterol-dependent cytolysins.   
The 5 bacterial genera represented above are broken down into individual species of bacteria that secrete a specific 
cholesterol-dependent cytolysin (CDC).  The abbreviations for the full length CDC name are also provided. 
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1.1.1 CDC structure and pore formation process 
Members of the CDC family share 30-60% primary amino acid sequence homology (Billington 
et al., 2000), which affords them some similarities in function.  Most notably, these 471-571 
amino acid (47-60 kDa) proteins (Palmer, 2001) are well established in their ability to form pores 
in host cell membranes, a process that relies on cholesterol binding.  Each monomer is rich in β-
sheets and contains four domains.  Collectively, these domains are responsible for cholesterol-
binding (domain 4), oligomerization (domains 1 and 4), membrane insertion (domain 3), and 
membrane-spanning (domain 2) (Rossjohn et al., 1997; Billington et al., 2000).  Domain 4 also 
contains a conserved undecapeptide sequence that includes three tryptophan residues important 
for membrane binding and insertion, as well as a cysteine residue, which was originally thought 
to be required for toxin activation when in a reduced state.  Thus, these toxins were formerly 
known as thiol-activated cytolysins (TACYs), but have been renamed cholesterol-dependent 
cytolysins (CDC) given that thiol activation may not be required for cytolytic activity (Pinkney 
et al., 1989; Saunders et al., 1989; Billington et al., 2000). 
  It has been reported that 40-80 monomers oligomerize to form transmembrane pores up 
to 30nm in diameter, allowing passage of ions and macromolecules (Billington et al., 2000; 
Palmer, 2001; Tweten, 2005).  The pore formation process begins by toxin binding to membrane 
cholesterol.  The close localization of toxin monomers in cholesterol-rich regions enables them 
to diffuse laterally and oligomerize into a pre-pore complex that does not insert its 
transmembrane β-barrel into the membrane to form a full-sized pore until the requisite number of 
monomers has joined the ring (Shepard et al., 2000; Tilley et al., 2005).  However, arc-like 
oligomers have also been observed to insert into membranes and it has been speculated that arcs 
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may represent premature insertion of the pre-pore complex.  Other pore-forming toxins (PFTs), 
such as Aeromonas hydrophila aerolysin or Staphylococcus aureus α-hemolysin (also known as 
α-toxin), have also been shown to assemble pre-pore complexes before membrane insertion.  
Unlike CDC, only seven monomers contribute to each pore (Chakraborty et al., 1990; Wilmsen 
et al., 1992; van der Goot et al., 1993; Valeva et al., 1997).    
1.1.2 Unique members of the CDC family 
Though cholesterol is the major “receptor” for most CDC, the human late-stage complement 
receptor CD59 has been identified as the specific receptor for the CDC intermedilysin (ILY) 
(Giddings et al., 2004) and is required for ILY-induced pore formation.  However, it has been 
shown that the presence of cholesterol is important for the insertion of ILY into the membrane 
after binding to CD59 (Soltani et al., 2007).  Accordingly, the undecapeptide sequence of ILY 
diverges from the highly conserved sequence of many other CDC in that it lacks a third 
tryptophan residue.  This change in sequence is thought to prevent thiol activation.  In addition to 
ILY, CDC pyolysin (PLO) and seeligerilysin O (LSO) also show variation in the undecapeptide 
sequence.  The recently identified CDC vaginolysin (VLY) has also shown specificity for CD59, 
and a proline residue in the undecapeptide sequence is critical for pore formation and 
cytotoxicity (Gelber et al., 2008).       
In addition to its cytolytic function, the CDC pneumolysin (PLY) possesses the unique 
ability to activate complement in the absence of specific antibodies (Mitchell et al., 1991; 
Rossjohn et al., 1998).  This activity is conferred to PLY because of a sequence in domain 4 
responsible for binding to the Fc region of IgG.  Moreover, domain 4 of PLY forms a β-
 6 
sandwich similar to the Fc potion of IgG.  Normally, aggregated Fc regions promote complement 
fixation, suggesting that PLY-Fc aggregates could play a similar role in activating complement. 
Lastly, the CDC listeriolysin O (LLO) stands apart from other CDC family members in 
its ability to help Listeria monocytogenes escape from the phagolysosome of phagocytic cells 
(e.g. macrophages) (Nomura et al., 2007) in order to replicate and spread.  This bacterium is 
acknowledged to be the only true intracellular pathogen to produce a CDC.  LLO is highly active 
at an acidic pH since it must function in the phagolysosome, which is highly acidic.  
Furthermore, LLO is degraded in the cytosol once the bacteria have escaped due to PEST 
(peptide sequence rich in proline (P), glutamic acid (E), serine (S), and threonine (T)) sequence 
recognition.  It should also be noted that LLO is capable of binding cholesterol and forming 
pores in the plasma membrane of the J774 macrophage cell line at non-acidic pH (7.4) (Bavdek 
et al., 2007).  This phenomenon could be physiologically relevant if bystander cells were 
exposed to the released contents of dead infected cells or to LLO from extracellular Listeria.  
1.1.3 Lethal effects of CDC 
Lethal doses of CDC lead to irreparable damage and subsequent death.  On the organismal level, 
it has been shown that CDC confer virulence to the bacteria that express them.  For example, 
mice infected intravenously (i.v.) with a PLY-negative pneumococci strain survive longer than 
those infected with wild type pneumococci (D39 strain) (Benton et al., 1995).  Similar findings 
have been observed with wild type versus mutant pyolysin-secreting A. pyogenes strains as well 
as wild type and mutant PLY-secreting strains (Berry et al., 1995; Jost et al., 1999).  However, 
the role of anthrolysin O (ALO) in the virulence of B. anthracis is unclear.  It has been shown 
that immunization of mice with ALO or a genetic toxoid results in protection against the toxin 
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but not the bacterium itself (Cowan et al., 2007).  On the other hand, mice pre-treated with a 
combination of monoclonal antibodies to recombinant ALO followed by infection with a lethal 
i.v. dose of B. anthracis survived longer than mice not treated with ALO-specific antibodies 
(Nakouzi et al., 2008).  Lastly, the lethal effects of CDC alone can be observed in mice injected 
i.v. with 100 pmol of various purified CDC that undergo death within seconds (Watanabe et al., 
2006).  Thus, CDC can elicit rapid death in mice and in many cases contribute to the virulence of 
the bacteria that secrete them. 
As expected from the results of the mouse studies, CDC have lethal effects on the cellular 
level as well.  Initial studies on the cytolytic nature of CDC were conducted using sheep 
erythrocytes with the release of hemoglobin as a measure of the amount of hemolysis induced.  
For instance, one such study showed that ALO exhibits dose-dependent hemolytic activity 
against sheep erythrocytes (Shannon et al., 2003).  Another common method to measure cell 
death is the uptake of cell impermeable fluorescent dyes such as trypan blue or propidium iodide 
(PI).  Mosser and Rest (Mosser & Rest, 2006) showed that certain concentrations of ALO could 
induce the uptake of trypan blue by neutrophils, THP-1 monocytes, lymphocytes, monocyte-
derived macrophages, and several epithelial cell lines.  Interestingly, different toxin doses were 
required to elicit cell death depending on the cell type.  It is unclear if surface membrane 
cholesterol content is the only factor that plays a role or if unknown receptors or pathways also 
contribute to sensitivity to CDC death. 
More extensive studies have been conducted to determine the types of cell death induced 
by purified CDC or CDC in the context of a bacterial infection.  Much of this work has focused 
on cells of the nervous system as well as on phagocytic cells of the immune system, which are 
among the first cells to encounter CDC-secreting bacteria.  Specifically, macrophages initially 
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phagocytose invading bacteria at the site of infection.  It has been observed that high doses of 
purified PLY induce apoptosis in macrophages via a TLR4-dependent mechanism (Srivastava et 
al., 2005).  TLR4 is a putative receptor for CDC, as will be discussed in section 1.1.6.  In studies 
with purified LLO, macrophage cell death is characterized by lactate dehydrogenase (LDH) 
release and phosphatidylserine (PS) flip, which may be indicative of late-stage apoptosis 
(Zwaferink et al., 2008).  However, the role of CDC in macrophage cell death during infection 
with whole bacteria is less clear cut.   
LLO is required for the escape of Listeria from macrophage phagosomes, which leads to 
caspase-1 activation and subsequent cell death as measured by dye uptake (Cervantes et al., 
2008).  It is not clear if LLO plays any additional roles in this cell death process apart from 
enabling Listeria to escape.  With a different CDC-secreting pathogen, Goldmann, et al. found 
that S. pyogenes infection results in caspase-1-independent, but reactive oxygen species (ROS)– 
and calpain-dependent oncosis in macrophages (Goldmann et al., 2009).  LDH release is 
dependent on CDC streptolysin O (SLO) expression by S. pyogenes, but its role in other aspects 
of the oncotic cell death process was not determined.  Lastly, Group A streptococcus (GAS) 
infection induces caspase-1-dependent apoptosis.  SLO is necessary and sufficient for this cell 
death process in macrophages, though the dependence of caspase-1 activation on SLO was not 
studied (Timmer et al., 2009).  It appears that the type of cell death that a single cell type (i.e. 
macrophage) undergoes varies based on the CDC family member and pathogen that secretes it.  
Other conditions such as CDC dose and presence of other bacterial factors derived from the 
CDC-producing source most likely also play a role in the skewing of the cell death pathway.  To 
further complicate matters, cell death processes in general encompass distinct pathways that can 
no longer be referred to simply as apoptosis or necrosis.  Instead, a spectrum of unique pathways 
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that share some similarities have been suggested, including apoptosis, autophagy, pyroptosis, 
pyronecrosis, and oncosis (Fink & Cookson, 2005; Willingham et al., 2007).  To summarize, the 
role of CDC as an inducer of cell death must be more clearly defined in terms of the type(s) of 
cell death initiated and the specificity of these death pathways depending on cell type.      
1.1.4 Pore sensing and resealing processes 
Though high doses of CDC are lethal to cells and ultimately to the host, cells are capable of 
recovering from sublethal or sublytic doses.  This phenomenon was first observed by Walev and 
collaborators who treated THP-1 monocytes, COS cells, a human keratinocyte (HaCat) or 
endothelial cell line with various doses of SLO.  They then measured the ability of cells to 
recover their cellular ATP content, which represented recovery of metabolic activity, or to 
exclude PI dye as a measure of pore resealing activity (Walev et al., 2001a; Walev et al., 2001b).  
Cells were capable of recovering after treatment with low doses of SLO in a calcium-dependent 
manner, but could not recover after stimulation with high doses of SLO.  It has been reported for 
toxins that induce smaller pores, such as alpha toxin, that p38 MAPK activity is essential for 
pore resealing, but SLO-induced pores reseal regardless of p38 activity (Husmann et al., 2006).  
Instead, a calcium-dependent endocytic process is required for repair of SLO-induced membrane 
damage (Idone et al., 2008).  Thus, different PFTs rely on different mechanisms of membrane 
repair possibly due to the size of the pores created by these toxins.  Interestingly, recovery from 
aerolysin requires a caspase-1-dependent process for the activation of sterol regulatory element 
binding proteins (SREBPs) that are involved in lipid biosynthesis (Gurcel et al., 2006).  This 
pathway has not been studied for CDC or alpha toxin. 
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 Though p38 MAPK activation is not required for resealing of CDC pores, it may be 
important for the sensing of osmotic stress (Uhlik et al., 2003).  It has been reported by multiple 
groups that CDC activate this kinase (Husmann et al., 2006; Ratner et al., 2006; Kloft et al., 
2009) and Kloft, et al. suggested that loss of cellular potassium in response to CDC leads to the 
activation of p38 (Kloft et al., 2009).  Additionally, Ratner, et al. showed that sublytic doses of 
PLY, SLO, and ALO induced p38 phosphorylation in epithelial cell lines and subsequent 
downstream IL-8 chemokine release (Ratner et al., 2006).  Pore formation and the presence of 
extracellular divalent cations were essential for p38 activation, which was inhibited by the 
presence of high molecular weight dextran, an osmoprotectant.  These findings suggested to the 
authors that epithelial cells may sense a breach in membrane integrity induced by CDC and 
initiate p38 MAPK activation for the sensing of osmotic stress.  Furthermore, downstream IL-8 
secretion would enable the recruitment of innate immune cells such as neutrophils to the location 
of the CDC-secreting bacteria as an immune defense mechanism.  In addition to p38 activation, 
CDC have also been implicated in NF-κB activation as a possible result of pore sensing.  Walev, 
et al. reported that pore resealing after SLO membrane perforation was followed by NF-κB 
activation and the release of IL-6 and IL-8 from keratinocytes and endothelial cells (Walev et al., 
2001b).  Thus, stress activated kinase and transcription factor activation seem to play major roles 
in the defense of host cells against stress induced by CDC.   
CDC have also been shown to elicit ion fluxes, particularly calcium fluxes, in a pore-
dependent manner (Our lab (data not shown) and (Gekara et al., 2007)).  As discussed above, 
calcium flux is important for the initiation of endocytosis and pore resealing after CDC 
disruption of the membrane.  Additionally, we have recently discovered that calcium influx is 
required for a sublytic dose of CDC to induce mature IL-1β release, a process that is presumably 
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enabled through initial CDC pore formation.  Calcium influx may contribute to the activation of 
the NLRP3 inflammasome, which is required for CDC-induced secretion of IL-1β (see section 
1.2 and Chapter 2).  Thus, the calcium flux response may serve as a general mechanism for pore-
dependent cell sensing of CDC.   
1.1.5 Sublytic effects of CDC 
As demonstrated above, immune cells are capable of initiating signaling pathways for the benefit 
of the host upon interaction with CDC.  For this to occur, the toxin dose must be sublethal, 
allowing cells to recover from membrane attack and remain metabolically active long enough to 
create a proinflammatory environment for the recruitment of other immune cells to the local site 
of infection.  On the other hand, sublytic doses of CDC have also been reported to inhibit key 
functions of immune cells required to combat bacterial infection.  This dichotomy demonstrates 
that there is a fine line between the ability of the host immune system to respond to a bacterial 
threat and the ability of the pathogen to use its virulence factors to evade detection.  To date, the 
sublytic effects of many CDC family members (SLO, PLY, LLO, PFO, ALY to name a few) 
have been characterized and include, but are not limited to: (1) Transcription factor activation 
(NF-κB, p38 MAPK), (2) Cytokine (IL-1α, IL-1β, TNF-α, IL-6, IL-12, IFN-γ) and chemokine 
(IL-8, MCP-1) expression in or secretion from human monocytes, human keratinocytes, murine 
macrophages, murine NK cells, or human epithelial cells, (3) Nitric oxide induction in murine 
macrophages, and (4) Inhibition of chemotaxis, migration, respiratory burst, and bacteriocidal 
activity of human neutrophils and monocytes (for a minireview see (Billington et al., 2000)).  
These sublytic effects of CDC can occur in a pore-dependent manner (discussed in the previous 
section) or can be elicited through pore-independent processes.  One such example of the latter 
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process is the ability of CDC to activate Toll-like receptor 4 (TLR4).  This interaction may be 
responsible for many of the sublytic effects mentioned above as will be discussed below. 
1.1.6 CDC and TLR4 activation 
TLR4 is a pattern recognition receptor (PRR) that belongs to a family of transmembrane 
receptors that recognizes pathogen-associated molecular patterns (PAMPs) present on bacteria 
and viruses.  Commonly characterized TLR agonists are bacterial cell wall components (TLRs 1, 
2, 4, 6), flagellins (TLR5), viral dsRNA and poly(I:C) (TLR3), small anti-viral compounds 
(TLR7), and CpG DNA (TLR9) (Martin & Wesche, 2002; Kumar et al., 2009a).  TLR2, binding 
mostly Gram-positive endotoxins (i.e. PGN), and TLR4, typically binding Gram-negative 
endotoxins (i.e. LPS), have been described as the prototypes for this type of receptor.  Ligation 
of TLR4 initiates either MyD88-dependent or MyD88-independent signaling pathways that lead 
to transcription of proinflammatory cytokines (Akira et al., 2001; Medzhitov, 2001; Netea et al., 
2004).  Several studies have shown that CDC activate TLR4 and this occurs independently of 
cytolytic activity as TLR4 activity is retained in the presence of cholesterol or for mutant CDC 
lacking domain 4.  For example, NF-κB translocation and pro-inflammatory cytokine (TNF-α, 
IL-6) secretion occurred when PLY (Malley et al., 2003), ALO (Park et al., 2004a), or 
seeligeriolysin O (LSO) (Ito et al., 2005) acted on mouse peritoneal macrophages, mouse bone 
marrow-derived macrophages (BMDM), or mouse peritoneal exudate cells (PECs) and the 
RAW267.4 mouse macrophage line, respectively.  This effect was TLR4-dependent as CDC 
elicited responses only from macrophages from TLR4-positive mice and not TLR4-deficient 
mice.  Direct binding of CDC to TLR4 was not addressed in these studies, but a study by 
Srivastava, et al., using ELISA, showed that TLR4 and PLY, but not TLR2 and PLY, were 
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capable of interacting (Srivastava et al., 2005).  TLR4 activation by CDC ultimately leads to 
promotion of inflammation and protection of the host against infection (Malley et al., 2003).  All 
of these studies conducted on mouse macrophages suggest that CDC play an important role in 
stimulating innate immunity during Gram-positive bacterial infection through TLR4 activation.   
1.1.7 Lipid raft aggregation and signaling 
Another mode of pore-independent signaling initiated by CDC is through lipid raft aggregation.  
Gekara, et al. observed in J774 macrophages via microscopy that LLO oligomerization 
aggregated lipid rafts (Gekara et al., 2005).  They further demonstrated that LLO could induce 
the tyrosine phosphorylation of non-receptor tyrosine kinases Lyn and Syk.  This lipid raft 
aggregation and tyrosine phosphorylation process was independent of LLO’s cytolytic activity as 
cholesterol-treated LLO also induced the same effect.  The authors put forth a model whereby 
LLO could directly bind cholesterol in rafts or cholesterol-bound LLO would be targeted to lipid 
raft regions (Gekara & Weiss, 2004).  The clustering of rafts would then lead to the activation of 
signaling molecules such as kinases, which presumably become activated by the non-specific 
activation of receptors or the kinases themselves clustered within the rafts.  The downstream 
outcomes of these signaling pathways were not addressed, but it might be expected that typical 
downstream events of Lyn and Syk signaling would occur.  For example, increased phagocytosis 
in macrophages after Syk signaling might be expected (Tohyama & Yamamura, 2009). 
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1.1.8 Other CDC-induced signaling pathways 
Aside from the CDC-induced signaling pathways and outcomes discussed above, there are a few 
others that warrant some discussion.  In addition to cytokine and chemokine responses, which 
would be expected to occur downstream of p38 MAPK or NF-κB activation, CDC have been 
implicated in actin remodeling, microtubule bundling and stabilization, and histone 
modifications.  In the first study, sublytic doses of PLY induced rapid activation of Rho and Rac 
GTPases that resulted in formation of actin stress fibers, filopodia, and lamellipodia (Iliev et al., 
2007).  Furthermore, small GTPase activation and actin remodeling could be inhibited by free 
cholesterol and a voltage-gated calcium channel inhibitor, suggesting that PLY pore formation 
and calcium influx were critical for these processes.  A second study by the same group showed 
that sublytic doses of PLY induce rapid bundling and increase acetylation of microtubules, which 
is a hallmark of microtubule stabilization (Iliev et al., 2009).  This process depended on 
cholesterol and Src kinase activity, but not pore formation, calcium influx, cell death, RhoA, 
Rac1, PKCζ, or actin cytoskeletal changes.  The authors postulated that PLY-induced 
microtubule bundling and stabilization might allow pneumococci to evade host cell phagocytic 
machinery and phagosome formation.  It should be noted that these two aforementioned studies 
were conducted on neuronal cells and it is unknown if immune cells, specifically phagocytes, 
respond in a similar way to CDC.   
The third study (Hamon et al., 2007) focused on the ability of  LLO to cause the 
dephosphorylation of Ser10 on histone H3 and the deacetylation of histone H4  in a cholesterol-
dependent manner.  Global transcription levels changed as a result of these changes and, 
interestingly, the same subset of genes appeared to be targets for both H3 and H4 modifications.  
These studies, in addition to those addressed above, show that sublytic doses of CDC have a 
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diverse array of effects that are both dependent and independent of CDC-induced pore formation.  
Many of these studies may account for sublytic effects observed to date, but there may be 
unknown pathways responsible for these effects, as well as other completely novel pathways that 
have yet to be discovered.  Ultimately, understanding the different pathways induced in immune 
cells both by sublytic and lytic doses of CDC could provide key direction for the generation of 
specific antibacterial therapies.      
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1.2 THE INFLAMMASOME 
The innate immune system has evolved to recognize a wide variety of pathogens including 
viruses, bacteria, and fungi.  Many immune cell types such as macrophages, monocytes, 
dendritic cells (DC), and neutrophils express germline-encoded receptors known as pattern-
recognition receptors (PRRs).  These PRRs recognize conserved motifs on pathogens known as 
pathogen-associated molecular patterns (PAMPs). A major family of PRRs is the Toll-like 
receptor (TLR) family, which was briefly reviewed in section 1.1.6.  These receptors recognize a 
wide variety of pathogen-related cell wall components, RNAs, and DNAs, and localize to the 
plasma membrane as well as to endocytic compartments where these components would be 
likely to interact with their receptors.   
In recent years, it has been recognized that the immune system, in addition to sensing 
PAMPs, may also sense danger-associated molecular patterns (DAMPs).  Matzinger proposed a 
‘danger model’ where antigen presenting cells (APCs) are activated by endogenous danger or 
alarm signals released from injured or dying cells exposed to pathogens, toxins, mechanical 
damage, or cell stress (Matzinger, 2002).  These signals can initiate exogenous signaling through 
receptors such as TLRs for the downstream generation of endogenous pro-inflammatory 
mediators.  However, it should be noted that the recognition of some DAMPs by TLRs is 
controversial.  For instance, TLR4 recognition of host heat shock proteins has been questioned 
(Tsan & Gao, 2004).  The newly identified cytoplasmic NOD-like receptors (NLRs), another 
class of PRRs, appear to recognize both PAMPs as well as DAMPs and will be reviewed below.  
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It should also be mentioned that the RIG-like helicases (RLHs), which include RIG-I and 
MDA5, sense viral RNA in the cytoplasm, but this family will not be further discussed here.  
1.2.1 The NOD-like receptor family 
The NOD-like receptor (NLR) family consists of various cytosolic proteins involved in innate 
immune sensing.  These proteins have three major domains: (1) A ligand-sensing, leucine-rich 
repeat (LRR) domain, (2) A domain conserved in NAIP, CIITA, HET-E and TP-1 (NACHT) for 
oligomerization, and (3) An effector domain that consists of a pyrin domain (PYD), caspase 
recruitment domain (CARD), or baculovirus IAP repeat domain (BIR) (Girardin et al., 2002; 
Inohara et al., 2002; Inohara & Nunez, 2003; Tschopp et al., 2003).  The NLR family of proteins 
can be divided into the NACHT, LRR, and PYD-containing proteins (NALPs, now known as 
NLR proteins or NLRPs) with 14 members, ICE-protease-activating factor (IPAF, now known as 
NLRC4) and NAIP, and the nucleotide oligomerization domain (NOD) proteins with 6 members 
(NODs 1-5 and MHC class II transcription activator CIITA) (Martinon et al., 2009).  NLRs 
combine with other proteins to form molecular platforms involved in proinflammatory responses, 
namely (1) the NOD signalosome composed of oligomerized NOD1 or NOD2 that activates 
kinase RIP2 and NF-κB signaling and (2) the inflammasomes that lead to the activation of 
inflammatory caspases and processing of immature pro-IL-1β and pro-IL-18 to their mature 
forms (Martinon et al., 2009).  There are two steps for the final secretion of mature IL-1β and IL-
18.  The first step requires TLR priming (e.g. LPS) for the production of the pro forms of both 
cytokines.  In the second step, the inflammasome must be activated such that active caspase-1 
can cleave these immature cytokines to their mature forms before release from the cell.  There 
are three prototypical inflammasomes (NLRC4, NLRP1, and NLRP3) that have been fairly well-
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studied in recent years.  Their structure, function, and the stimuli that activate them will be 
discussed below.  
1.2.2 The NLRC4 inflammasome 
The NLR family, CARD domain containing 4 (NLRC4) inflammasome, formerly known as the 
IPAF inflammasome, consists of the NLR IPAF that recruits caspase-1 via homotypic CARD-
CARD interactions and may require the adaptor ASC, though its role remains unclear (Martinon 
et al., 2009).  This inflammasome is involved in the recognition of virulence factors from Gram-
negative bacteria.  Many studies have shown that the NLRC4 inflammasome recognizes Gram-
negative bacteria such as Salmonella typhimurium (Mariathasan et al., 2004), Shigella flexneri 
(Suzuki et al., 2007), Legionella pneumophila (Amer et al., 2006; Lightfield et al., 2008), and 
Pseudomonas aeruginosa (Sutterwala et al., 2007; Miao et al., 2008).  Uniquely, recognition of 
L. pneumophila requires both NLRs NAIP5 and IPAF for inflammasome formation (Lightfield et 
al., 2008).  Most Gram-negative pathogens require type III secretion systems (T3SS) or type IV 
secretion systems (T4SS) for the injection of factors such as flagellin into the host cytosol (Miao 
et al., 2007).  Flagellin is a major component identified so far that activates the NLRC4 
inflammasome and this recognition process is independent of TLR5, which recognizes 
extracellular flagellin (Amer et al., 2006; Franchi et al., 2006). 
Recognition of flagellin leads to NLRC4 inflammasome- and ASC-dependent caspase-1 
activation and the maturation of IL-1β (Amer et al., 2006; Franchi et al., 2006), which is 
important for the recruitment of innate immune cells such as neutrophils to the site of local 
infection (Jones et al., 2005).  Flagellin recognition is also critical for NLRC4– and NAIP5-
dependent phagosome maturation and restriction of L. pneumophila replication inside 
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macrophages (Coers et al., 2007; Lamkanfi et al., 2007; Vinzing et al., 2008).  Recently, Akhter, 
et al. have determined that flagellin from L. pneumophila activates caspase-7 in a manner 
dependent on the NLRC4 inflammasome, caspase-1 activation, and NAIP5 (Akhter et al., 2009).  
The authors observed that caspase-7-deficient macrophages were less able to clear bacterial 
infection via delivery of intracellular bacteria to lysosomes than wild type macrophages.  
Caspase-7 has previously been identified as a substrate of caspase-1-containing inflammasomes 
such as NLRC4 (Lamkanfi et al., 2008).  Lastly, NLRC4 has been linked to ASC-independent 
pyroptosis (Suzuki et al., 2007; Case et al., 2009), a cell death marked by caspase-1 activation, 
as well as ASC-independent inhibition of autophagy (Suzuki et al., 2007), a normal process 
where the cell degrades its own components using lysosomal machinery.   
1.2.3 The NLRP1 inflammasome 
The NLR family, pyrin domain containing 1 (NLRP1) inflammasome, formerly known as the 
NALP1 inflammasome, consists of NLR family NLRP1, ASC, and caspase-1 (Martinon et al., 
2009).  Humans have a single NLRP1 gene whereas mice have three Nlrp1 paralogs, including 
Nlrp1a, Nlrp1b, and Nlrp1c.  Using a cell-free system, human NLRP1 has been shown to 
oligomerize with caspase-1 in the presence of microbial muramyl dipeptide (MDP) and form an 
inflammasome complex that does not require ASC, though ASC can enhance caspase-1 
activation (Faustin et al., 2007).  The mechanism that MDP uses to trigger NLRP1 
oligomerization is unknown.  In mice, Nlrp1b has been identified as the gene that encodes for a 
product that is involved in the recognition of metalloprotease lethal toxin (LT) from B. anthracis 
(Boyden & Dietrich, 2006).  NLRP1b inflammasome recognition of LT results in ASC-
independent caspase-1 activation and involves lysosomal membrane permeabilization (LMP) and 
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the activity of lysosomal protease cathepsin B (Averette et al., 2009; Newman et al., 2009).  
Moreover, Newman, et al. found that LT-induced LMP led to cytolysis and this cell death could 
be inhibited with CA-074-Me, a cathepsin B inhibitor.  Interestingly, knocking down cathepsin B 
with siRNA had no effect on LT-induced cell death, suggesting that the pharmacological 
inhibitor was blocking other cellular proteases.  Lastly, recent work by Hsu, et al. (Hsu et al., 
2008) has shown that NLRP1 complexes with NLR NOD2, a protein that senses MDP, and 
caspase-1.  Interestingly, the authors also showed that B. anthracis infection, as well as LT alone, 
induced IL-1β secretion in a NOD2- and caspase-1-dependent way.   
1.2.4 The NLRP3 inflammasome 
The NLR family, pyrin domain containing 3 (NLRP3), formerly known as NALP3 and 
cryopyrin, inflammasome is the most well studied of the inflammasomes.  This molecular 
complex consists of NLRP3, ASC, and caspase-1 with the major downstream pathway being 
maturation of IL-1β and IL-18 (Martinon et al., 2009).  There have been many stimulators of the 
NLRP3 inflammasome identified to date. Initial studies identified the DAMP adenosine 
triphosphate (ATP) and K+ ionophores nigericin and maitotoxin as second stimuli (after TLR 
priming) to activate caspase-1 and induce IL-1β and IL-18 secretion in a NLRP3-dependent way 
in murine macrophages (Mariathasan et al., 2006).  The authors additionally identified 
Staphylococcus aureus and Listeria monocytogenes as inducers of the NLRP3 inflammasome.  
Interestingly, L. monocytogenes was only capable of inducing IL-1β release in the presence of 
CDC LLO, suggesting that the intracellular bacterium had to escape from the phagosome before 
recognition by NLRP3.  Around the same time, two other studies were published identifying 
additional second stimuli of the NLRP3 inflammasome.  Kanneganti, et al. (Kanneganti et al., 
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2006b) showed that bacterial RNA and small antiviral compounds activated caspase-1 and 
induced IL-1β and IL-18 secretion in a NLRP3-dependent manner.  NLRP3-dependent caspase-1 
activation and IL-1β and IL-18 release could also be initiated by gout-associated monosodium 
urate (MSU) crystals and calcium pyrophosphate dehydrate (CPPD) crystals (Martinon et al., 
2006).   
As many of these various stimulators of the NLRP3 inflammasome were identified, a 
looming question as to the mechanism of NLRP3 activation began to dominate.  All NLR family 
proteins contain ligand-sensing leucine-rich repeats (LRRs) that would be expected to recognize 
PAMPs or DAMPs.  However, this has been difficult to directly demonstrate.  Thus far, three 
major pathways in which the inflammasome may become activated have been postulated.  All 
pathways share commonalities such as K+ efflux and NLRP3 and caspase-1 activation for IL-1β 
and IL-18 release, but differ in the upstream recognition of PAMPs and DAMPs.  The first 
model was put forth by Kanneganti, et al. (Kanneganti et al., 2007) who suggested that PAMPs 
enter cells through pores or channels in the plasma membrane, formed due to damage from 
bacterial toxins, cell stress, or DAMPs, and directly interact with NLRP3 within the cytoplasm.  
The authors showed that various bacterial species alone could not induce caspase-1 activation 
and required cytosolic entry via pores induced by CDC SLO or hemichannel protein pannexin-1.  
SLO at the concentrations tested or pannexin-1 channel formation alone were also not capable of 
inducing caspase-1 activation.  However, it should be noted that in another study, SLO was 
capable of inducing caspase-1 activation in LPS-primed macrophages (Harder et al., 2009).  It is 
unclear if this activation occurred as a direct result of SLO activity or if SLO solely served as a 
conduit for LPS entry.  As for the role of pannexin-1, it is thought that ATP activates its 
purinergic receptor P2X7, leading to downstream pannexin-1 channel formation (most likely in 
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endosomes), PAMP escape from endosomes into the cytosol, and subsequent recognition of 
these PAMPs by the NLRP3 inflammasome.  Pelegrin and Surprenant (Pelegrin & Surprenant, 
2006) have found a role for pannexin-1 in nigericin and maitotoxin-induced caspase-1 activation, 
but the mechanism is unclear.  At this time, direct or indirect recognition of PAMPs by NLRP3 
has not yet been demonstrated.     
The second major model of NLRP3 inflammasome activation summarized by 
Willingham and Ting (Willingham & Ting, 2008) suggested that large particulates or crystals 
could be phagocytosed and physically disrupt lysosomal membranes leading to cathepsin B 
release.  This protease could then activate NLRP3 through an unknown mechanism and bring 
about NLRP3 inflammasome activation.  This model was supported by two similar studies.  
Hornung, et al. (Hornung et al., 2008) demonstrated that silica crystals and aluminum salt (alum) 
crystals were phagocytosed by human PBMC and lead to lysosomal destabilization as assessed 
by the loss of lysosomal acidity.  These crystals were also capable of inducing cathepsin B- and 
NLRP3-dependent IL-1β release.  In the other study, Halle, et al. (Halle et al., 2008) showed that 
fibrillar peptide amyloid-β (Aβ) was also phagocytosed and induced lysosomal damage.  Using 
confocal microscopy, they showed that lysosomal disruption led to the release of cathepsin B 
into the cytoplasm, which was required (as was NLRP3) for caspase-1 activity and IL-1β release.  
Cathepsin B has been implicated in the activation of caspase-1 either through direct cleavage or 
via the activity of caspase-11 (Schotte et al., 1998; Vancompernolle et al., 1998).  Together, 
these studies provided a potential pathway in which sterile inflammation could occur in the 
absence of any pathogenic threat.  It might also explain how the NLRP3 inflammasome is 
capable of recognizing some second stimuli that are unlikely to be recognized by the LRRs of 
NLRP3 due to sheer physical shape and size. 
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The third model postulated is known as the frustrated phagocytosis model.  This model 
also focuses on large particulates and crystals, but states that they are too large to be 
phagocytosed and as a result, undergo “frustrated phagocytosis.”  Instead of being internalized, 
these particulates and crystals stay at the cell surface while the cell continually attempts and fails 
to phagocytose them.  This process generates the production of reactive oxygen species (ROS) 
that are required for the activation of caspase-1 and release of IL-1β.  In the context of the 
inflammasome, this concept was first suggested by Dostert, et al. (Dostert et al., 2008) who 
showed that asbestos, silica, and MSU crystals induced IL-1β secretion from monocytes and 
macrophages in a NLRP3 inflammasome-dependent manner.  Furthermore, asbestos and MSU 
crystals required K+ efflux, actin polymerization (most likely for endocytosis), NAPDH oxidase, 
and the generation of ROS to activate caspase-1 and induce IL-1β secretion. Other studies have 
also shown a similar pathway induced by non-particulate, NLRP3 inflammasome-activating 
agents such as ATP and nigericin.  Hewinson, et al. (Hewinson et al., 2008) demonstrated that 
ATP causes the generation of reactive oxygen and nitrogen species (RNOS) in a NADPH 
oxidase- and superoxide dismutase (SOD)-dependent way and this process was required for 
ATP-induced IL-1β release.  Nigericin-induced caspase-1 activation and IL-1β release was also 
dependent on RNOS generation.  Likewise, Meissner, et al. (Meissner et al., 2008) showed that 
SOD1 activity was essential for ATP-induced caspase-1 activation and IL-1β and IL-18 secretion 
through the control of caspase-1.  This control was exerted through redox-sensitive cysteine 
residues on caspase-1 such that high superoxide production in the absence of SOD1 led to 
decreased redox potential and inhibition of caspase-1.  Thus, this model can apply to both large 
particulate structures as well as smaller molecules and may serve as a more general method for 
NLRP3 inflammasome activation. 
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Though there are limited data, another general mechanism that may tie into NLRP3 
inflammasome activation would involve the activation of non-receptor tyrosine kinases such as 
Syk.  A study by Gross, et al. (Gross et al., 2009) reported that Candida albicans induces IL-1β 
secretion from bone marrow-derived dendritic cells (BMDC) in a manner dependent on K+ 
efflux, ROS production, and the activation of the NLRP3 inflammasome, which includes 
caspase-1 activation.  Furthermore, Syk kinase signaling was required for pro-IL-1β synthesis 
and caspase-1 activation in this system.  Another known second stimulator of the NLRP3 
inflammasome, crystalline MSU, has also been shown to induce Syk activation in BMDC (Ng et 
al., 2008), but the link between Syk and components of the NLRP3 inflammasome was not 
studied.  Lastly, malarial hemozoin has recently been identified as another second stimulator of 
the NLRP3 inflammasome that results in caspase-1 activation and IL-1β secretion, which is 
dependent on ROS production, potassium efflux, and cathepsin B (Tiemi Shio et al., 2009).  Like 
C. albicans and MSU crystals, malarial hemozoin was also capable of inducing Syk activation 
and this activity was critical in the release of mature IL-1β. 
Lastly, though there is accumulating evidence as to the ways in which the NLRP3 
inflammasome may become activated, there is little understanding of the factors that regulate 
NLRP3 in its inactive state.  However, a study by Mayor, et al. (Mayor et al., 2007) identified 
heat shock protein 90 (HSP90) and ubiquitin ligase-associated protein SGT1 as such regulators.  
In general, both of these proteins were observed to interact with many other NLRs with a 
particularly strong interaction observed with NLRP3.  Specifically, the SGT1-HSP90 complex 
interacted with the NLRP3 LRR domain and the presence of HSP90 was critical to stabilize 
NLRP3 and prevent its degradation, presumably by the proteasome.  Furthermore, both 
regulatory proteins were required for NLRP3 inflammasome function after cell stimulation with 
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known inflammasome stimulators.  These data suggested that the SGT1-HSP90 complex 
maintains NLRP3 in an inactive state until recognition of an activating signal.  Subsequently, 
NLRP3 can dissociate from SGT1 and HSP90 followed by association with caspase-1 and ASC.           
In summary, much remains to be elucidated regarding the regulation of NLRP3, but the 
list of NLRP3 inflammasome activators continues to grow.  Not all of the stimulators could be 
discussed here, but they include: pore-forming agents (ATP (Mariathasan et al., 2006), nigericin 
(Mariathasan et al., 2006), maitotoxin (Mariathasan et al., 2006), TLO (Chu et al., 2009), SLO 
(Harder et al., 2009), S. aureus α-hemolysin (Craven et al., 2009)), bacteria (S. aureus 
(Mariathasan et al., 2006; Munoz-Planillo et al., 2009), L. monocytogenes (Mariathasan et al., 
2006), K. pneumoniae (Willingham et al., 2009)), viruses (influenza (Kanneganti et al., 2006a; 
Allen et al., 2009)), aggregated peptides (Aβ (Halle et al., 2008)), crystals and particulates (silica 
(Dostert et al., 2008), MSU (Dostert et al., 2008), CPPD (Martinon et al., 2006), asbestos 
(Dostert et al., 2008), alum (Eisenbarth et al., 2008; Li et al., 2008)), yeasts (C. albicans (Gross 
et al., 2009)), and malarial hemozoin (Tiemi Shio et al., 2009) (See also Figure 3-1).  The 
mechanisms of NLRP3 inflammasome activation employed by these stimuli may stand 
independently or overlap to some degree and include components such as K+ efflux, Ca2+ influx, 
Syk kinase activation, RNOS generation and associated signaling pathways, and/or lysosomal 
destabilization and cathepsin B release.  Some of these pathways and stimuli are diagrammed in 
Figure 1-2.  The interplay between these pathways and the stimuli that invoke them may become 
clearer in time.  Some of the current work in this field has also begun to focus on NLRP3 
function independently of the inflammasome complex as will be briefly discussed in the next 
section.    
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Figure 1-2: NLRP3 inflammasome activation mechanisms.  
The release of proinflammatory cytokines IL-1β and IL-18 require two signals for production and release.  The first 
signal is initiated by PAMPs that bind TLRs and initiate the transcription and translation of the inactive pro forms of 
these cytokines.  The second signal includes many stimuli such as large crystals, pore-forming toxins, or ATP that 
activate the NLRP3 inflammasome for caspase-1 cleavage of these cytokines to their mature forms before release.  
These second stimuli may activate the inflammasome through a frustrated phagocytosis and ROS production 
pathway, a lysosomal disruption and cathepsin B release pathway, or a pannexin-1 or toxin-induced channel 
pathway.   
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1.2.5 Inflammasome-independent NLRP3 functions  
NLRP3 has been described to play a role in a type of cell death known as pyronecrosis.  This cell 
death process is dependent on NLRP3 and cathepsin B, but is caspase-1-independent and 
characterized by the loss of an intact plasma membrane, which leads to spilling of cellular 
contents that promote inflammation.  It should be noted that pyronecrosis differs from another 
form of cell death known as pyroptosis (Bergsbaken et al., 2009), a proinflammatory 
programmed cell death characterized by caspase-1 activation, the secretion of mature IL-1β and 
IL-18, and cell lysis for the release of inflammatory contents.  Initial studies conducted by 
Willingham, et al. (Willingham et al., 2007; Willingham et al., 2009) showed that both S. 
flexneri and K. pneumoniae induced pyronecrosis, marked by lactate dehydrogenase (LDH) and 
high mobility group box 1 (HMGB1) release, in monocytes and macrophages.  These studies 
were particularly novel because they demonstrated that NLRP3 could function independently of 
its inflammasome function.  In another study, it was demonstrated that S. aureus α-hemolysin 
also induced pyronecrotic cell death of monocytes that was marked by NLRP3-dependent, but 
caspase-1-independent HMGB1 release (Craven et al., 2009).  The mechanism of NLRP3 action 
in pyronecrosis has yet to be defined.  It is likely that future studies will address this issue as well 
as identify unknown inflammasome-independent NLRP3 functions.  
1.2.6 The role of IL-1 in immunity 
As discussed above, one of the major outcomes of inflammasome activation is the generation of 
IL-1β.  The IL-1 family contains 11 known members including agonists IL-1α, IL-1β, IL-18, 
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FIL-1ε, IL-1H2, IL-1ε, and IL-33, receptor antagonist IL-1Ra and possibly IL-1Hy2, and anti-
inflammatory FIL1δ and IL-1H4/IL-1ζ (Dinarello, 2009).  The IL-1 receptor (IL-1R) family is 
also diverse, consisting of 10 members that serve as ligand-binding α chains and coreceptor β 
chains, decoy receptors, or inhibitory receptors (Boraschi & Tagliabue, 2006; Dinarello, 2009).  
Activation of IL-1 and IL-18 receptors results in signaling through adaptors MyD88 and Tollip, 
IL-1 receptor-associated kinases (IRAKs), and TRAF-6, which leads to downstream activation of 
transcription factors such as p38 MAPK, JNK, and NK-κB (Dunne & O'Neill, 2003; Dinarello, 
2009).  These signaling pathways share many similar components to the TLR pathways 
discussed above.   
Once activated, IL-1R signaling pathways induce cyclooxygenase type 2 (COX-2) 
(Lyons-Giordano et al., 1993; Pang & Knox, 1997), type 2 phospholipase A (Lyons-Giordano et 
al., 1993), and inducible nitric oxide synthase (iNOS) (Mendes et al., 2001), which together lead 
to production of prostaglandin-E2 (PGE2) (Pang & Knox, 1997), platelet activating factor 
(Bussolino et al., 1986), and nitric oxide (NO) (Palmer et al., 1993) [(Dinarello, 2009)].  These 
changes are manifested as fever, lowered pain threshold, vasodilation, and hypotension.  In 
particular, IL-1β has been shown to increase adhesion molecule expression on mesenchymal and 
endothelial cells and to induce cytokine secretion, which attracts inflammatory cells (e.g. 
neutrophils) from the circulation into the tissues that propagate IL-1-induced inflammation 
(Dinarello, 2009).  In terms of adaptive immunity, IL-1 together with an antigen or mitogen can 
act as a costimulator of T cell function (Lichtman et al., 1988).  IL-1 has also been shown to 
contribute to Th2 polarization using murine models of asthma (Nakae et al., 2003), to induce 
antibody production (Nakae et al., 2001), and seems to be essential for the generation of Th17 
responses in mice and humans (Sutton et al., 2006; Acosta-Rodriguez et al., 2007).  IL-1 family 
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member IL-18 also participates in adaptive immune responses by synergizing with IL-12 and IL-
15 for IFN-γ production, a process crucial for Th1 responses.  On the other hand, in the absence 
of IL-12, IL-18 drives Th2 responses (Hoshino et al., 2001; Nakanishi et al., 2001a, b).  Thus, 
IL-1 family members play key roles in inducing inflammation for the generation of robust 
immune responses.          
1.2.7 Diseases associated with IL-1 and the inflammasome 
Though IL-1 is critical in eliciting inflammation and subsequent immunity, excessive 
inflammation can be detrimental to host tissues.  Endogenous IL-1 and IL-18 antagonists exist to 
control inflammation such that damage to the host is limited.  For example, IL-1 receptor 
antagonist (IL-1Ra) specifically targets IL-1α and IL-1β by binding to the IL-1R1 receptor and 
blocking subsequent signaling (Arend, 1990).  These mechanisms are usually sufficient to 
control inflammation in people with normal IL-1 pathways intact.  However, there are patients 
with autoinflammatory diseases marked by chronic inflammation that can be due to disorders in 
IL-1β activation as well as problems with NK-κB activation, protein folding, complement, 
cytokine signaling, and macrophage activation (Masters et al., 2009).  These diseases can be 
distinguished from autoimmune disorders in that they lack associations with class II MHC 
haplotypes, occur periodically, and can be triggered by environmental sources (Dinarello, 2009).  
One underlying mechanism for excessive IL-1β production is mutations in the NLRP3/CIAS1 
gene, which encodes the NLRP3 protein.  These mutations result in the formation of CIAS1-
associated periodic syndromes (CAPS) such as familial cold autoinflammatory syndrome 
(FCAS) (Hoffman et al., 2001), Muckle-Wells syndrome (MWS) (Hoffman et al., 2001), and 
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neonatal-onset Multi-inflammatory disease (NOMID) (Aksentijevich et al., 2002), which is also 
known as Chronic Infantile Neurologic Cutaneous Articular Syndrome (CINCA).   
Targeting and neutralizing IL-1β has been a major goal in controlling inflammation in 
patients with IL-1β autoinflammatory disorders.  One highly promising treatment to achieve this 
is a recombinant, nonglycosylated form of IL-1Ra known commercially as anakinra (Mertens & 
Singh, 2009).  So far, it has only been indicated for the treatment of rheumatoid arthritis, but 
clinical trials suggest that it could benefit patients with autoinflammatory disorders (Leslie et al., 
2006; Maksimovic et al., 2008).  Thus, conducting basic research on the mechanisms of 
inflammasome activation and IL-1β secretion could be crucial for the development of additional 
therapies to target overactive inflammation.  These therapies could potentially benefit patients 
with autoinflammatory disorders as well as those undergoing sepsis due to bacterial infection.    
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1.3 STATEMENT OF THE PROBLEM 
The incidence of bacterial infections is on the rise.  In particular, gram-positive bacterial 
infections have become a problem in hospitals, where many patients are immunocompromised. 
Control of infection is often difficult not only because of a compromised immune system, but 
also because of the increased resistance of bacteria to antibiotic treatments.  As a result of 
uncontrolled infection in these patients, sepsis can occur, which ultimately leads to mortality.  
The bacterial factors that contribute to sepsis and gram-positive bacterial infection, in general, 
have remained unclear, largely due to basic research being focused on gram-negative sepsis.  
Thus, it is important to understand, on a basic level, how these bacterial products contribute to 
the virulence and pathogenesis of their gram-positive bacterial source.  Moreover, it is equally 
important to study the response of the host innate immune system to these bacterial proteins. 
At the beginning of our studies, it was known that some cholesterol-dependent cytolysins 
(CDC) added to the virulence of the bacteria that expressed them.  These CDC were also 
examined for their ability to elicit host immune responses when applied to immune cells in 
sublytic amounts.  One effect observed was the ability of CDC to elicit pro-inflammatory 
cytokine IL-1β from macrophages, but the mechanism of IL-1β release was not identified.  
Within the past decade, a general mechanism for IL-1β secretion was discovered: activation of a 
caspase-1-containing inflammasome complex.  We hypothesized that inflammasome complex 
activation was responsible for CDC-induced IL-1β secretion.  To test this hypothesis, we have 
employed pharmacological inhibitors against components of an inflammasome pathway and 
murine macrophages lacking inflammasome components.   
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Another major interest for our laboratory has been to understand the cell death pathways 
elicited by CDC.  Though there is some knowledge regarding these cell death mechanisms, there 
could be variation due to the host cell type, CDC family member, CDC dose, and CDC in the 
context of whole bacteria.  One such example is that the exposure of different cell types, 
including many immune cell types, to one specific CDC resulted in differences in susceptibility.  
We chose to focus our studies on CDC-induced cell death of macrophages and the role that 
NLRP3, an inflammasome component, might play in the cell death process.  NLRP3 has been 
implicated in a form of cell death known as pyronecrosis and we hypothesized that NLRP3 also 
played a role in CDC-induced cell death of murine macrophages.  Furthermore, to explore 
additional mechanisms involved in CDC-induced cell death, we isolated and characterized a 
CDC-resistant murine dendritic cell line.  We have addressed these hypotheses herein. 
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2.0  CHOLESTEROL-DEPENDENT CYTOLYSINS INDUCE RAPID RELEASE OF 
MATURE IL-1ΒETA FROM MURINE MACROPHAGES IN A NLRP3 
INFLAMMASOME AND CATHEPSIN B-DEPENDENT MANNER 
2.1 AUTHORS AND THEIR CONTRIBUTIONS 
This study was published in the Journal of Leukocyte Biology in the November 2009 issue 
(86(5): 1227-38.).  Copyright permission was granted by the Journal of Leukocyte Biology for 
reuse of this publication within this dissertation.  Jessica Chu (Immunology Graduate Program, 
University of Pittsburgh School of Medicine) generated the majority of the data and prepared the 
manuscript.  L. Michael Thomas (Immunology Graduate Program, University of Pittsburgh 
School of Medicine) provided help with bone marrow derived macrophage (BMDM) culture, 
Simon C. Watkins (Departments of Cell Biology and Physiology and Immunology, University of 
Pittsburgh School of Medicine) and Russell D. Salter (Department of Immunology, University of 
Pittsburgh School of Medicine) collected the confocal imaging data, and Luigi Franchi 
(Department of Pathology and Comprehensive Cancer Center, University of Michigan Medical 
School) and Gabriel Núñez (Department of Pathology and Comprehensive Cancer Center, 
University of Michigan Medical School) provided the NLRP3 knockout mouse bones and 
caspase-1 p10 antibody.  All authors contributed to the scientific discussion regarding the 
project, especially Russell D. Salter who also majorly contributed to the critical reading and 
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editing of the manuscript.  Also to be acknowledged are Chengqun Sun (Department of 
Immunology, University of Pittsburgh School of Medicine), Michelle Heid (Immunology 
Graduate Program, University of Pittsburgh School of Medicine), and Sarita Singh (Department 
of Immunology, University of Pittsburgh School of Medicine) who provided both technical 
support and scientific discussion.  Lastly, Lisa Borghesi (Department of Immunology, University 
of Pittsburgh School of Medicine) provided the wild type mouse bones used for this study. 
2.2 ABSTRACT 
Cholesterol-dependent cytolysins (CDC) are exotoxins secreted by many Gram-positive bacteria 
that bind cholesterol and oligomerize to form pores in eukaryotic cell membranes.  We 
demonstrate that the CDC tetanolysin O (TLO) induces caspase-1 cleavage and the rapid release 
of IL-1β from LPS-primed murine bone marrow-derived macrophages (BMDM).  IL-1β 
secretion depends on functional toxin pore formation since free cholesterol, which prevents TLO 
binding to cell membranes, blocks the cytokine release.  Secretion of the mature forms of IL-1β 
and caspase-1 occurs only at lower TLO doses, whereas at higher concentrations cells release the 
biologically inactive pro-forms.  IL-1β release at a low TLO dose requires potassium efflux, 
calcium influx, and the activities of calcium-independent phospholipase A2, caspase-1, and 
cathepsin B.  Additionally, mature IL-1β release induced by a low TLO dose is dependent on the 
NLRP3 inflammasome while pro-IL-1β release induced by a high TLO dose occurs 
independently of NLRP3.  These results further elucidate the mechanism of CDC-induced IL-1β 
release, and suggest a novel immune evasion strategy in which IL-1β-containing macrophages 
might release primarily inactive cytokine following exposure to high doses of these toxins.  
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2.3 INTRODUCTION 
Cholesterol-dependent cytolysins (CDC) are a class of protein exotoxins that are secreted by 
over twenty species of Gram-positive bacteria (Billington et al., 2000; Palmer, 2001).  Individual 
subunits bind to cholesterol in eukaryotic cell membranes and oligomerize to form 
transmembrane pores up to 30 nm in size (Bhakdi et al., 1985; Olofsson et al., 1993; Morgan et 
al., 1995; Billington et al., 2000; Palmer, 2001).  Approximately 40-80 CDC monomers 
assemble into a pre-pore complex before membrane insertion and final pore conversion, which 
results in osmotic imbalance that may lead to cell death.  Mice injected intravenously with 100 
pmol of purified forms of several different CDC underwent almost immediate death (Watanabe 
et al., 2006), demonstrating the potent biological activities of these toxins.  Pneumolysin (PLY)-
deficient S. pneumoniae have reduced virulence in mice, supporting a potential role for such 
toxins in bacterial pathogenesis (Berry et al., 1989; Benton et al., 1995).  In contrast, 
immunization of mice with anthrolysin O (ALO) or a genetic toxoid does not protect against B. 
anthracis infection (Cowan et al., 2007), suggesting that for some CDC-bearing pathogens the 
toxin plays a less important role.  It should be noted that at least one CDC, listeriolysin O (LLO), 
has a specialized role in allowing escape of Listeria from the phagosome into the cytosol and is 
maximally active at acidic pH (Geoffroy et al., 1987; Beauregard et al., 1997). While CDC such 
as ALO can substitute for LLO when manipulated experimentally (Wei et al., 2005), most CDC 
do not show a marked pH dependence and are believed to function primarily extracellularly 
following secretion by bacteria, acting on adjacent cells in the infected host.    
While all eukaryotic cells are susceptible to toxin-induced lysis, the amounts required for 
killing vary widely between cell types (Mosser & Rest, 2006).  This may be due to differential 
ability of distinct cell types to repair membranes damaged by pores.  Evidence for membrane 
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repair after toxin damage has been obtained by measuring cytoplasmic adenosine triphosphate 
(ATP) levels, which decrease drastically after exposure to sublethal concentrations of toxin 
before a return to normal levels (Walev et al., 2001b; Husmann et al., 2006).  At higher lytic 
levels of toxin, recovery of ATP levels is not observed.  The mechanism of repair involves 
removal of pores from the plasma membrane via an endocytic process (Idone et al., 2008).  Cells 
that have been exposed to sublytic doses of toxin and then recover may be altered 
phenotypically, and there are numerous examples of such sublethal effects of CDC (Billington et 
al., 2000).   
In immune cells, exposure to CDC toxins at concentrations that are not lytic induce 
release of cytokines and chemokines (Henderson et al., 1997; Billington et al., 2000).  Cytokine 
and chemokine secretion are particularly important for the recruitment and activation of 
inflammatory immune cells to the local site of bacterial infection.  One major cytokine family 
that plays a role in the inflammation process is the IL-1 family.  Included in this family are IL-1α 
and IL-1β, which are both released after treatment of cells with CDC.  Specifically, LLO induces 
the release of IL-1α from murine macrophages (Nishibori et al., 1996), while both streptolysin O 
(SLO) and PLY cause the secretion of IL-1β from human monocytes (Hackett & Stevens, 1992; 
Houldsworth et al., 1994).  The mechanism by which CDC induce release of IL-1 has not been 
fully characterized to date. 
IL-1α and IL-1β, as well as IL-18 and IL-33, are stored inside cells such as macrophages 
and dendritic cells as precursors whose synthesis is induced by exposure to TLR ligands (signal 
1) (Arend et al., 2008).  Unlike many other cytokines, efficient release requires exposure of cells 
to a second stimulus to initiate processing and the nonclassical secretion of the active cytokine.  
The second stimuli lead to the activation of inflammasome complexes, which consist of members 
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of the Nod-like receptor (NLR) family, for the activation of inflammatory caspases such as 
caspase-1 (for a review see (Franchi et al., 2009; Martinon et al., 2009; Pedra et al., 2009)).  The 
best known examples of these caspase-1-activating platforms are the NLRP1, NLRP3, and 
NLRC4 inflammasomes, which lead to the processing of the pro-form of IL-1β to its mature 
form.  To date, multiple second stimuli for these various inflammasomes have been identified 
(for a review see (Martinon et al., 2009)) and select ones will be discussed below.  
One of the best studied second stimuli is ATP, which acts by binding to the purinergic 
receptor P2X7, initiating calcium influx and potassium efflux via its ion channel function (Ferrari 
et al., 2006).  Calcium is also released from intracellular stores during this process and 
contributes to cytokine release (Brough et al., 2003).  Potassium efflux leads to activation of 
calcium-independent phospholipase A2 (iPLA2) (Andrei et al., 2004) and the NLRP3 
inflammasome, which contains dimeric caspase-1, adaptor ASC, and NLRP3 (also known as 
cryopyrin or NALP3) (Sutterwala et al., 2006).  Activation of this inflammasome leads to 
cleavage of caspase-1, which cleaves inactive pro-IL-1β to generate active mature IL-1β for 
release from the cell.  Additionally, P2X7 activation causes recruitment of pannexin-1 protein to 
form a non-selective pore for passage of molecules up to ~900Da across membranes (Pelegrin & 
Surprenant, 2006; Locovei et al., 2007).  This pannexin-1 pore is thought to allow ion fluxes as 
well as the passage of bacterial products from inside endosomes or phagosomes into the cytosol 
for the subsequent activation of one or more inflammasome complexes (Kanneganti et al., 2007).   
An additional stimulus that can activate the NLRP3 inflammasome and initiate IL-1β 
release is the potassium ionophore nigericin, which exerts its effects primarily through a 
potassium efflux mechanism (Mariathasan et al., 2006).  Much like ATP, it also relies on the 
activity of caspase-1, but acts independently of P2X7 (Le Feuvre et al., 2002).   Other stimuli 
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inducing IL-1β release from myeloid cells through a NLRP3 and caspase-1 dependent 
mechanism include uric acid crystals (Martinon et al., 2006), silica crystals (Dostert et al., 2008; 
Hornung et al., 2008), aluminum salt crystals (Hornung et al., 2008), and amyloid-β fibrils (Halle 
et al., 2008).  All of these can be phagocytosed by macrophages, and appear to disrupt 
lysosomes, resulting in leakage of their contents into the cytosol (Willingham & Ting, 2008).  It 
was recently reported that cathepsin B is required for release of IL-1β following stimulation with 
silica crystals, aluminum salt crystals, or amyloid-β (Halle et al., 2008; Hornung et al., 2008), 
which supports a scenario in which mislocalized cathepsin B is involved in aspects of NLRP3 
inflammasome activation or subsequent IL-1β release.  In fact, other groups have shown that 
cathepsin B activates caspase-11, which in turn acts as an upstream activator of caspase-1 
(Schotte et al., 1998; Wang et al., 1998). 
In this report, we describe the mechanism of rapid IL-1β release after exposure of LPS-
primed murine bone marrow-derived macrophages (BMDM) to the CDC tetanolysin O (TLO).  
Cytokine release occurs maximally within 2 hours of initial treatment with little additional 
release occurring by 20 hours post-treatment.  Though TLO-induced IL-1β secretion is 
dependent on functional toxin pore formation, this alone is not sufficient for the processing and 
secretion of IL-1β.  Lower TLO doses are required for release of mature IL-1β, as well as for the 
cleavage and release of mature caspase-1, as opposed to higher doses that enable the release of 
the inactive pro-IL-1β.  Similarly to ATP and nigericin, TLO-induced release is dependent on 
potassium efflux, calcium influx, and the activities of iPLA2, caspase-1, and cathepsin B as 
determined by pharmacological inhibition.  Moreover, TLO-induced release of mature IL-1β is 
dependent on the NLRP3 inflammasome and independent of the NLRC4 inflammasome based 
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on studies employing BMDM deficient in NLRP or NLRC4.  In summary, we further elucidate a 
mechanism for CDC-induced release of IL-1β. 
2.4 MATERIALS AND METHODS 
Reagents - Tetanolysin (TLO) was obtained from Biomol International (Plymouth Meeting, PA).  
Toxin was reduced with 10mM DTT (Sigma, St. Louis, MO) for 10min, 37oC before use unless 
indicated and untreated control samples were incubated in the same buffer lacking toxin.  
Adenosine triphosphate (ATP), nigericin, lipopolysaccharide (LPS), cholesterol, and pepstatin A 
were purchased from Sigma-Aldrich (St. Louis, MO), z-VAD-fmk/pan-caspase inhibitor VI, 
BAPTA-AM, Z-FF-fmk/cathepsin L inhibitor I, and CA-074 Me/cathepsin B inhibitor IV from 
EMD Biosciences (Gibbstown, NJ), Ac-YVAD-cmk/caspase-1 inhibitor II and bromoenol 
lactone (BEL) from Axxora, LLC (San Diego, CA), and triton X-100 from Fisher Scientific 
(Pittsburgh, PA).  Purified anti-mouse IL-1α and IL-1β capture antibodies, biotin-conjugated 
anti-mouse IL-1α and IL-1β detection antibodies, and recombinant IL-1α were acquired from 
eBioscience (San Diego, CA).  Purified and biotin-conjugated anti-mouse TNF-α antibodies, 
recombinant TNF-α, recombinant IL-1β, avidin-HRP, and 3, 3’, 5, 5’-tetramethyl benzidine 
(TMB) were obtained from Biolegend (San Diego, CA).   
Bone marrow-derived macrophage preparation – The following protocol was adapted 
from (Davies & Gordon, 2005). Tibiae and femurs from wild type (gifts from Dr. Lisa Borghesi, 
University of Pittsburgh), NLRP3-/-, or NLRC4-/- (provided by Dr. Gabriel Núñez, University of 
Michigan) C57BL/6 mice were collected.  Bone marrow cells were extracted using a 27 gauge 
needle and passed through a 21 gauge needle to obtain a homogenous mixture.  Cells were plated 
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in petri dishes (Day 1) in DMEM (Mediatech, Inc., Herndon, VA) supplemented with 20% 
Gemcell™ FBS (Gemini Bio-Products, West Sacramento, CA), 2mM L-glutamine, 500U 
Penicillin/500μg Streptomycin (Lonza Inc., Walkersville, MD), 1mM sodium pyruvate (MP 
Biomedicals, Solon, OH), and 30% L cell supernatant.  L cell supernatant was generated by 
incubating L cell fibroblasts (CCL-1 from ATCC, Manassas, VA) in DMEM supplemented with 
10% Gemcell™ FBS, 2mM L-glutamine, 500U Penicillin/500μg Streptomycin, 1X non-essential 
amino acids (Irvine Scientific, Santa Ana, CA), and 1mM sodium pyruvate until confluent.  
Supernatant was collected and filtered through a 0.22um filter.  Differentiation media for 
BMDM was changed every 3-4 days and BMDM were used for experiments Days 8-22.  For 
experiments, BMDM were cultured in IMDM (Lonza, Inc.) containing 10% Gemcell™ FBS, 
2mM L-glutamine, and 500U Penicillin/500μg Streptomycin. 
Western blotting – 2x106 BMDM (plated the day before) were treated for 4 h in serum-
containing IMDM with 1μg/ml LPS, various concentrations of TLO, or were left untreated.  In 
some cases, following LPS priming, BMDM were incubated for 30 min in serum-free media 
with DTT control buffer, various doses of TLO, 3mM ATP, 20μM nigericin, or 1% triton X-100.  
Where indicated, 1ml supernatants were collected and TCA/cholic acid-precipitated as described 
by Qu and colleagues (Qu et al., 2007).  Cells were harvested, washed, and lysed or directly 
lysed in wells with NP-40 lysis buffer containing a protease inhibitor cocktail (Sigma).  Bradford 
assay (Bio-rad, Hercules, CA) was conducted to determine protein concentration of lysates and 
20-50μg of protein lysate was run on SDS-PAGE gels along with concentrated supernatants 
(where indicated).  Proteins were transferred to PVDF membrane using Towbin buffer transfer or 
the iBlot™ system (Invitrogen) and probed for IL-1β with mouse anti-IL-1β primary antibody 
(3ZD, National Cancer Institute Biological Resources Branch, Frederick Cancer Research and 
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Development Center) and goat anti-mouse IgG-HRP secondary antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) using the SNAP i.d. system (Millipore).  Membranes were also 
probed for caspase-1 with rabbit anti-caspase-1 primary antibody and donkey anti-rabbit IgG-
HRP secondary antibody (Biolegend).  In some cases, the same blot was stripped with Restore 
Plus Western Blot Stripping Buffer (Thermo Scientific) according to the manufacturer’s protocol 
and reprobed with rabbit anti-β-actin primary antibody (Biolegend) and donkey anti-rabbit IgG-
HRP secondary antibody.  Western blotting luminol reagent (Santa Cruz Biotechnology) was 
applied and membranes were imaged and analyzed (densitometry) with Kodak Image Station 
4000MM (Molecular Imaging Systems, Carestream Health, Inc.).  The net intensity of a single 
IL-1β protein band in a supernatant sample is expressed as a percentage of the total net 
intensities of IL-1β protein bands in all the supernatant samples for a given blot.   
Preparation of ELISA supernatants – 1x105 BMDM were plated/well of 24-well plates 
overnight in IMDM.  The next day, the spent media was removed and BMDM were primed with 
1ug/ml LPS for 4 h.  LPS was then removed and 300μl of the indicated treatments were added 
for the indicated times.  Since TLO pore forming activity is inhibited by free cholesterol present 
in FBS, TLO treatments were added in IMDM lacking FBS for 5 min followed by addition of 
10% FBS.  Cholesterol inhibition of TLO activity was conducted by pre-mixing 1ug/ml free 
cholesterol with TLO before addition to cells.  For all other inhibitor experiments, inhibitors 
were pre-incubated with BMDM for 1 h after LPS removal prior to the addition of TLO, ATP, or 
nigericin.  Inhibitors were prepared in serum-free IMDM containing 0.01% BSA.  Supernatants 
were collected, centrifuged 10000 rpm for 10min, and stored at -20oC before analysis by ELISA. 
ELISA – High-bind polystyrene 96-well plates (Greiner Bio-One, Monroe, NC) were 
coated with 100μl/well of 1μg/ml of purified anti-mouse IL-1α, 4μg/ml of purified anti-mouse 
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IL-1β, or 1X purified anti-mouse TNF-α capture antibody overnight.  Wells were washed three 
times with 200μl/well wash buffer (0.05% Tween® 20 in PBS) and this step was repeated in 
between each of the following incubations: (1) 200μl/well of filtered 1% BSA in PBS for 1 h, 
RT.  (2) 100μl/well of standards or supernatant samples for 2 h, RT.  (3) 100μl/well of 1μg/ml 
biotinylated anti-mouse IL-1α, 6μg/ml biotinylated anti-mouse IL-1β, or 1X biotinylated anti-
mouse TNF-α detection antibody for 1 h, RT.  (4) 100μl/well of 1:5000 avidin-HRP for 30min, 
RT.  (5) 100μl/well of TMB substrate for 10min (IL-1α, TNF-α) or 20min (IL-1β) at RT. (6) 
50μl/well of 1M sulfuric acid to stop the reaction.  OD values were read at 450nm with a 570nm 
subtracted correction using a BioTek® PowerWave™ XS Microplate Spectrophotometer and 
data was analyzed using Gen5™ Data Analysis Software (BioTek® Instruments, Inc. Winooski, 
VT). 
LDH release assay – 4.5x105 BMDM were plated/35mm dish overnight in IMDM.  The 
next day, spent media was removed and BMDM were treated with 1ug/ml LPS for 4 h.  Cells 
were then washed with PBS and incubated for 30 min with DTT control buffer or various TLO 
concentrations in phenol red-free IMDM.  1% triton X-100 was used as a control of complete 
cell lysis and maximal LDH release.  Supernatants were collected and assayed in duplicate for 
LDH content using the LDH Cytotoxicity Assay Kit from Cayman Chemical Company (Ann 
Arbor, MI).  % cytotoxicity was calculated as follows: ((Mean OD value of experimental sample 
– Mean blank OD) / (Mean OD value of triton X-100 control sample – Mean blank OD)) * 100.  
BMDM from these experiments were harvested from dishes using CellStripper™ (Mediatech, 
Inc.) and stained with 5μM YO-PRO-1 dye (Invitrogen, Carlsbad, CA) before analysis using a 
BD Biosciences (San Jose, CA) LSR II flow cytometer and accompanying FACSdiva™ 
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software.  BMDM were also stained with YO-PRO-1 after 5 min of DTT control buffer or TLO 
treatments. 
Cy5 labeling of toxin – A monofunctional NHS-Ester Cy5 (GE Healthcare, Piscataway, 
NJ) vial was resuspended in 20μl PBS and diluted 1:100.  2.5μg TLO (2.5μl) or 2.5μg BSA 
control (2.5μl) was labeled with 0.5μl of PBS (control unlabeled TLO) or 0.5μl of 1:100 Cy5 
(TLO-Cy5) for 10min, RT, in the dark.  To quench each reaction, 2.5μg of BSA was added and 
incubated 10min, RT, in the dark.   
Toxin binding & pore formation flow cytometry assay – 4.5x105 BMDM were plated/35 
mm petri dish overnight in IMDM.  The next day, spent media was removed and BMDM were 
treated with 1ug/ml LPS for 4 h.  LPS was then removed and 1ml of each indicated inhibitor was 
added for 1 h.  Inhibitors were prepared in serum-free IMDM containing 0.01% BSA.  Then, 
TLO, TLO-Cy5, or BSA-Cy5 was added to cells in the presence or absence of 1μg/ml 
cholesterol for 5 min.  Cells were harvested from dishes and stained with 5μM YO-PRO-1 dye 
before analysis by flow cytometry.  FlowJo (Tree Star, Inc., Ashland, OR) was used for data 
analysis.  A similar protocol was followed for BMDM treated with unlabeled TLO in the 
presence or absence of 1μg/ml cholesterol.   
Live cell microscopy – 1x105 BMDM were plated/35 mm collagen-coated glass bottom 
culture dish (MatTek Corporation, Ashland, MA) overnight in IMDM.  The next day, cells were 
primed with 1μg/ml LPS for 4 h.  Cells were washed with serum-free IMDM and incubated for 
15 min with 0.5μM LysoTracker™ Green in serum-free IMDM.  BMDM were treated with a 
final concentration of 1.8nM TLO-Cy5 in serum-free media.  In indicated experiments, TLO-
Cy5 was pre-incubated with 1μg/ml cholesterol before addition to cells.  Live cell imaging was 
performed using a Nikon TI inverted microscope with a 60X 1.49 NA oil immersion optic, a 
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NikonPiezo driven XYZ stage, a Prairie Sweptfield confocal head and Prairie Technology 
(Madison, WI) laser bench.  Images were collected using a QuantEM backthinned 512B camera 
(Photometrics, Tucson AZ).  Cells were maintained at 37oC in the microscope with a Tokai Hit 
Environmental Stage (Tokyo Japan).  Software control of the microscope was with Elements 
(Nikon, Melville NY).  Data analysis was performed using Metamorph software. 
Graphical and Statistical Analysis – All graphing analyses were completed using 
Microsoft Excel (Microsoft, Redmond, WA).  Statistical analysis (Student’s paired t-test) was 
conducted with GraphPad Prism (GraphPad Software, Inc., San Diego, CA).  P-values were 
denoted as follows: p-value < 0.05 = *, p-value < 0.01 = **, and p-value > 0.05 was not 
significant (ns). 
2.5 RESULTS 
2.5.1 TLO-induced IL-1β release occurs via a TLR-independent mechanism 
Previous studies reporting IL-1 induction by CDC did not fully characterize the mechanism 
involved.   Since CDC have been reported to activate toll-like receptor 4 (TLR4) (Malley et al., 
2003; Park et al., 2004a; Ito et al., 2005; Srivastava et al., 2005; Shoma et al., 2008), we 
considered whether non-lytic doses of TLO could prime BMDM to synthesize pro-IL-1β 
similarly to LPS.  Release of IL-1β might be expected to occur at low levels following such 
treatment, particularly if some cell death occurred over the time course of the experiment.   To 
test this, western blotting was first used to measure pro-IL-1β levels in lysates of cells exposed to 
varying doses of TLO or 1μg/ml LPS.  At all concentrations of TLO tested, after a 4 h period, no 
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pro-IL-1β could be detected while large amounts were induced by LPS (Figure 2-1).  In addition, 
there was little to no detectable release of IL-1β from TLO-primed cells over this 4 h time period 
as measured by a sensitive ELISA assay to test culture supernatants (detection limit 16pg/ml) 
(data not shown).  Thus, TLO cannot replace LPS for the priming of cells to synthesize pro-IL-
1β.   
 
 
Figure 2-1: TLO cannot replace LPS as signal 1.   
BMDM were treated with control (DTT-containing buffer), 1μg/ml LPS, 1.8nM TLO (100ng/ml TLO), 4.6nM TLO 
(250ng/ml TLO), 9.1nM TLO (500ng/ml TLO), or 18.3nM TLO (1μg/ml TLO) for 4 h in serum-containing media.  
Lysates were prepared from these cells, 50μg of protein run on an SDS-PAGE gel, and western blot conducted for 
IL-1β protein.  Only LPS treatment induces the detectable expression of 35kDa pro-IL-1β.  Data shown is a 
representative example of two independent experiments. 
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We next tested if LPS-primed cells could release IL-1 after exposure to TLO.  A time 
course of IL-1β (Figure 2-2A) as well as IL-1α (Figure 2-2B) release demonstrates the rapid 
rates at which these cytokines are exported after TLO exposure, with near maximal secretion 
seen by 2 hours.   Non-primed BMDM, as well as cells exposed to TLO for 4 h without LPS, 
could not be induced to secrete IL-1β following addition of TLO, ATP, or nigericin (data not 
shown).  This rapid secretion contrasts to the release of another pro-inflammatory cytokine, 
TNF-α, from LPS-primed BMDM that have been exposed to control buffer, TLO, ATP, or 
nigericin for up to 2 hours (Figure 2-2C).  LPS priming induces background levels of TNF-α as 
seen for the control, but additional treatment with TLO, ATP, or nigericin does not raise these 
levels significantly above background.  These results are consistent with TLO acting to induce 
rapid release of IL-1β and IL-1α, and suggest that this occurs independently of TLR activation.  
The kinetics of the response were similar to those for ATP and nigericin, suggesting possible 
mechanistic similarities. 
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Figure 2-2: LPS-primed BMDM treated with TLO rapidly release IL-1β and IL-1α.   
(A) IL-1β and (B) IL-1α content in supernatants from 4 h LPS-primed BMDM treated with control (DTT-containing 
buffer), 1.8nM TLO, 3mM ATP, and 20μM nigericin for 20 min, 30 min, 2 h, or 20 h was measured by ELISA.  The 
majority of IL-1β and IL-1α are released by 2 h post-treatment.  Data represents mean +/- SEM for 3 independent 
experiments each for IL-1β and IL-1α. (C) TNF-α content in supernatants from 4 h LPS-primed BMDM treated with 
control (DTT-containing buffer), 1.8nM TLO, 3mM ATP, and 20μM nigericin for 20 min or 2 h was measured by 
ELISA.  Significant levels of TNF-α are not induced by TLO, ATP, or nigericin above control background levels.  
Data represents mean +/- SEM for 3 independent experiments. 
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2.5.2 Pore formation is required for TLO-induced IL-1β secretion 
To further address the mechanism of CDC-induced cytokine release, we determined whether 
TLO pore formation was required to induce IL-1β release.   Free cholesterol was added to TLO 
at a concentration shown previously to inhibit its ability to bind cholesterol on cell membranes 
and subsequently form pores (Mosser & Rest, 2006).  Cholesterol-inhibited TLO was not able to 
induce IL-1β release from BMDM (Figure 2-3).  To confirm that pore formation was blocked 
under these conditions, uptake of YO-PRO-1 dye, which does not cross intact cell membranes 
but readily enters permeabilized cells (Solini et al., 1999; Locovei et al., 2007), was measured 
(Figure 2-3, inset).  Thus, TLO-induced pore formation is required for the release of IL-1β. 
 
 49 
 
Figure 2-3: TLO-induced pore formation is required for IL-1β release from BMDM.   
Four-hour LPS-primed BMDM were treated with control (DTT-containing buffer), control plus 1μg/ml cholesterol, 
1.8nM TLO, or 1.8nM TLO plus 1μg/ml cholesterol for 20 min, 30 min, 2 h, or 20 h.  Supernatants were collected 
and assayed by ELISA for IL-1β.  Free cholesterol inhibits TLO- induced IL-1β release.  Data represents mean +/- 
SEM for 3 independent experiments.  Student’s paired t-test was applied for comparison of 1.8nM TLO group with 
cholesterol versus without cholesterol; * = p < 0.05, ** = p< 0.01.  Inset: 4 h LPS-primed BMDM were treated with 
DTT control buffer or 1.8nM TLO in the presence or absence of 1μg/ml cholesterol for 5 min.  TLO-induced 
perforation as measured by YO-PRO-1 dye uptake was assessed by flow cytometry.  Free cholesterol blocks TLO 
from forming pores and allowing dye uptake.  Data represents mean +/- SEM for 2 independent experiments.   
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2.5.3 Lower TLO doses are required for the release of mature IL-1β   
A straightforward explanation for the above results might be that TLO exposure could passively 
lead to release of IL-1β from BMDM through toxin-induced pores.  To begin to test this 
possibility, toxin-induced pore formation in BMDM membranes, measured by YO-PRO-1 
uptake, was compared to toxin-induced passive spilling of intracellular contents as measured by 
LDH release.  BMDM became perforated within 5 min of treatment by even the lowest dose of 
TLO tested (0.9nM TLO) and the percentage of cells perforated increased in a dose-dependent 
manner (Figure 2-4A).  These cells appeared to undergo membrane recovery by 30 min post-
treatment as dye uptake did not change from background for all TLO concentrations tested 
(Figure 2-4B).  Significant LDH release was not evident until exposure of BMDM to a much 
higher dose of 18.3nM TLO (Figure 2-4C).  Thus, it appears that though cells become perforated 
starting at low levels of toxin, a high threshold of toxin must be reached before passive release of 
intracellular components occurs.  IL-1β release in response to varying concentrations of TLO 
was then measured by ELISA (Figure 2-4D).  Maximal secretion of IL-1β occurred at 9.1nM, a 
concentration that resulted in less than 10% LDH release.  Strikingly, high levels of TLO that 
resulted in correspondingly higher LDH release induced lower levels of IL-1β secretion.   
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Figure 2-4: Determination of sublytic versus lytic CDC doses.   
(A-B) Four-hour LPS-primed BMDM were treated with DTT control buffer or a range of TLO doses in serum-free 
media for 5 min or 30 min.  BMDM were harvested and stained with YO-PRO-1 dye as a measure of TLO-induced 
perforation and dye uptake was assessed by flow cytometry.  BMDM are perforated after 5 min of exposure to 
0.9nM TLO and this process occurs in a dose-dependent manner.  By 30 min post-TLO treatment, BMDM are no 
longer perforated.  Data represents mean +/- SEM for 3 independent experiments for each time point.  (C) 
Supernatants were collected from 4 h LPS-primed BMDM treated for 30 min with DTT control buffer or various 
TLO doses in serum-free media.  TLO-induced passive spilling of contents (i.e. LDH) was determined by taking the 
ratio of LDH released from TLO-treated BMDM to LDH released from triton X-100-treated BMDM (see Materials 
and Methods).  In comparison to perforation at lower doses of TLO, BMDM do not release LDH until much higher 
doses (18.3nM) of TLO.  Data represents mean +/- SEM for 3 independent experiments.  Student’s paired t-test was 
applied for comparison of control versus TLO conditions; ** = p< 0.01.  (D) Four-hour LPS-primed BMDM were 
treated with a range of concentrations of TLO for 30 min.  Supernatants were collected and assayed by ELISA for 
IL-1β.  Release of IL-1β from BMDM occurs after treatment with 0.9nM TLO to 36.5nM TLO.  Data represents 
mean +/- SEM for 3 independent experiments.   
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We next determined whether IL-1β released from cells was processed to the mature 
bioactive form by analyzing supernatants using western blotting.  A majority of the IL-1β was 
fully processed in supernatants from cells treated with 1.8nM TLO, whereas in supernatants from 
cells treated with 9.1nM or 18.3nM TLO, much of the IL-1β was in the pro-form and less mature 
form was detected (Figure 2-5A).  We also confirmed that 3mM ATP and 20μM nigericin 
induced the release of mostly mature IL-1β while 1% triton X-100 lysed cells for complete 
release of pro-IL-1β content.  Since caspase-1 is known to cleave pro-IL-1β to its mature form 
and undergo cleavage and release itself after activation, we further tested for release of the p20 
caspase-1 cleavage product after exposure to TLO.  Mature p20 caspase-1 release only occurred 
at the low 1.8nM TLO dose while pro-caspase-1 was released from cells treated with high 9.1nM 
or 18.3nM TLO doses (Figure 2-5B).  ATP and nigericin controls also induced caspase-1 
cleavage, but mature caspase-1 stayed inside the cells after ATP treatment while nigericin 
treatment induced most of it to be secreted from the cells. Triton X-100 caused complete lysis 
and release of pro-caspase-1 stores.  We found the same pattern of IL-1β content in these 
samples (data not shown).  Thus, cleavage of pro-caspase-1 for release of mature caspase-1 and 
secretion of mature bioactive IL-1β by BMDM occur selectively at concentrations of toxin that 
are sublytic.         
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Figure 2-5: Lower concentrations of TLO are required to elicit mature IL-1β release from BMDM.   
(A)  Four-hour LPS-primed BMDM were treated with control (DTT-containing buffer), 1.8nM, 9.1nM, and 18.3nM 
doses of TLO, 3mM ATP, 1% triton X-100, and 20μM nigericin for 30 min in serum-free IMDM.  20µg of whole 
cell protein lysate or entire 1ml TCA/cholic acid precipitated supernatants were run on an SDS-PAGE gel and 
western blot conducted for mature (17kDa) or pro- (35kDa) IL-1β protein.  Supernatants from 1.8nM TLO-treated 
BMDM contain mostly mature IL-1β while 9.1nM and 18.3nM TLO-treated BMDM supernatants contain mostly 
pro-IL-1β.  ATP and nigericin controls induce the release of mostly mature IL-1β while triton X-100 lyses cells for 
release of pro-IL-1β.  Data shown in the left panels are representative examples of three independent experiments.  
The right panels show the densitometry (see Materials and Methods) of the pro- and mature IL-1β bands in 
supernatants expressed as mean % of total IL-1β in supernatants +/- SEM for 3 independent experiments.  The 
asterisk (*) refers to a non-specific protein band. (B) BMDM were treated as in part A.  20µg of whole cell protein 
lysate or entire 1ml TCA/cholic acid precipitated supernatants were run on an SDS-PAGE gel and western blot 
conducted for pro-caspase-1 (45kDa) or the cleaved p20 caspase-1 subunit (20kDa).  Supernatants from 1.8nM 
TLO-treated BMDM contain mostly p20 caspase-1 while 9.1nM and 18.3nM TLO-treated BMDM supernatants 
contain pro-caspase-1.  ATP and nigericin controls induce the cleavage of pro-caspase-1 with release of the p20 
subunit from nigericin-treated cells and retained p20 for ATP-treated cells.  Triton X-100 lyses cells for release of 
pro-caspase-1.  Data shown is a representative example of two independent experiments.   
2.5.4 IL-1β induced by low doses of TLO requires potassium efflux, calcium influx, and 
the activities of calcium-independent phospholipase A2, caspase-1, and cathepsin B 
To further elucidate the mechanism of IL-1β secretion induced by sublytic doses of TLO, we 
used a pharmacologic approach to inhibit different processes known to play a role in IL-1β 
secretion induced by other stimuli.  Potassium efflux from cells, shown to be important for both 
ATP and nigericin-induced IL-1β release, can be inhibited by addition of excess exogenous KCl 
to the medium.  Figure 2-6A demonstrates that KCl also inhibited IL-1β release induced by TLO.  
It has also been shown that IL-1β secretion induced by ATP requires calcium influx.  Treatment 
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of BMDM with intracellular calcium chelator BAPTA-AM (Figure 2-6B) prior to TLO exposure 
blocked IL-1β secretion similarly to that for ATP and nigericin.  Another event that occurs 
during ATP-induced IL-1β release is the activation of iPLA2, which is also involved in TLO-
induced IL-1β secretion as determined with the iPLA2 inhibitor BEL (Figure 2-6C).  Lastly, ion 
fluxes and iPLA2 activity are thought to be involved in the activation of caspase-1, which in turn 
cleaves pro-IL-1β to the mature form before its release.  Pan-caspase inhibitor z-VAD-fmk and 
caspase-1-specific inhibitor Ac-YVAD-cmk each inhibited TLO-induced IL-1β secretion (Figure 
2-6D).  Similar inhibition was seen with ATP and nigericin controls.  All of the above 
pharmacological inhibitors were tested for toxicity against BMDM using YO-PRO-1 dye uptake 
(data not shown).  It was found that BMDM exposed to 50mM KCl, 30μM BAPTA-AM, 10μM 
BEL, 20μM z-VAD-fmk, 100μM Ac-YVAD-cmk, 100μM pepstatin A, 100μM CA-074-Me, or 
10μM Z-FF-fmk for 1 hour did not take up YO-PRO-1 above background levels observed for 
untreated BMDM.  Thus, the inhibitors used at these concentrations were not toxic to BMDM.  
Overall, these results demonstrate that sublytic TLO doses induce IL-1β secretion through 
similar mechanisms to that for ATP and nigericin. 
It was recently reported that IL-1β released from cells exposed to silica and alum crystals, 
and also amyloid-β fibrils, required cathepsin B activity (Halle et al., 2008; Hornung et al., 
2008).  Both groups proposed the novel hypothesis that cathepsin B localization to the cytosol 
might participate in IL-1β processing.  We therefore investigated the role of cathepsin B activity 
in toxin-induced IL-1β release by utilizing the highly selective cathepsin B inhibitor CA-074-
Me.  IL-1β release induced by a low dose of TLO was substantially blocked by this inhibitor 
(Figure 2-6E).  We also tested the contribution of other cathepsins in IL-1β release by using 
specific inhibitors pepstatin A (Figure 2-6E) and Z-FF-fmk (Figure 2-6F) to inhibit cathepsin D 
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and cathepsin L activities, respectively.  Little if any effect on TLO-induced IL-1β was observed 
with these inhibitors, suggesting that cathepsin D and L do not participate in toxin-induced 
cytokine release.  ATP and nigericin showed a similar dependence on cathepsin B, with a partial 
contribution of cathepsin L evident for both of these stimuli.  These results demonstrate that 
cathepsin B activity is required for release of IL-1β induced by sublytic TLO doses. 
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Figure 2-6: TLO-induced IL-1β release from BMDM relies on K+ efflux, Ca2+ influx and the activities of 
iPLA2, caspase-1, and cathepsin B.   
Four-hour LPS-primed BMDM were treated with no inhibitor (buffer only) versus 50mM KCl (K+ efflux inhibitor) 
(A), 30μM BAPTA-AM (intracellular calcium chelator) (B), 10μM BEL (iPLA2 inhibitor) (C), 20μM z-VAD-fmk 
(pan-caspase inhibitor) or 100μM Ac-YVAD-cmk (caspase-1 inhibitor) (D), 100μM pepstatin A (cathepsin D 
inhibitor) or 100μM CA-074-Me (cathepsin B inhibitor) (E), or 10μM Z-FF-fmk (cathepsin L inhibitor) (F) for 1 h.  
Control (DTT-containing buffer), 1.8nM TLO, 3mM ATP, or 20μM nigericin treatments were then added for 30 
min.  Supernatants were collected and assayed by ELISA for IL-1β.  KCl, BAPTA-AM, BEL, z-VAD-fmk, and Ac-
YVAD-cmk almost completely abrogate IL-1β secretion induced by TLO, ATP, and nigericin.  Cathepsin B 
inhibitor CA-074-Me has a major effect on IL-1β secretion induced by all three stimuli while the other cathepsins 
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play a lesser role.  It should be noted that all inhibitors were not toxic to cells as assessed by YO-PRO-1 dye uptake 
(data not shown).  Data represents mean +/- SEM for 5 independent experiments for parts A, D, and E, 6 
independent experiments for part B, 3 independent experiments for part C, and 4 independent experiments for part 
F.  Student’s paired t-test was applied for comparison of no inhibitor versus inhibitor conditions; * = p < 0.05, ** = 
p< 0.01.  
2.5.5 TLO-induced mature IL-1β release is dependent on the NLRP3 inflammasome  
Since ion fluxes, iPLA2, caspase-1, and the release of IL-1β have all been linked to 
inflammasome activation, specifically the NLRP3 inflammasome, we sought to determine if 
NLRP3 played a role in TLO-induced IL-1β secretion.  To test this, we compared the response of 
wild type, NLRP3-deficient, and NLRC4-deficient BMDM to a low dose of TLO (1.8nM).  We 
observed that 1.8nM TLO induced mature IL-1β release from LPS-primed wild type BMDM as 
well as NLRC4-/- BMDM, but not NLRP3-/- BMDM (Figure 2-7A).  Similar results were 
obtained with the nigericin control while triton X-100 lysis caused release of pro-IL-1β 
regardless of an NLRC4 or NLRP3 deficiency.  Furthermore, a high dose of TLO (18.3nM) 
induced release of the pro form from both wild type and NLRP3-/- BMDM (Figure 2-7B). Taken 
together, these results demonstrate NLRP3 dependence for mature IL-1β release caused by a low 
dose of TLO, but NLRP3 independence for pro-IL-1β secretion after exposure to a high TLO 
dose. 
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Figure 2-7: IL-1β release induced by low TLO doses is NLRP3-dependent.   
(A) Four-hour LPS-primed wild type, NLRC4-/-, or NLRP3-/- BMDM were treated with control (DTT-containing 
buffer), 1.8nM TLO, 20uM nigericin, or 1% triton X-100 for 30 min in serum-free IMDM.  20µg of whole cell 
protein lysate or entire 1ml TCA/cholic acid precipitated supernatants were run on an SDS-PAGE gel and western 
blot conducted for mature (17kDa) or pro- (35kDa) IL-1β protein.  Mature IL-1β was released from wild type and 
NLRC4-/- BMDM after exposure to the low TLO dose and nigericin, but not from NLRP3-/- BMDM.  Triton X-100 
lysis caused release of pro-IL-1β stores from all cell types, including NLRP3-/- BMDM.  Data shown is a 
representative example of two independent experiments.  The asterisk (*) refers to a non-specific protein band. (B) 
Four-hour LPS-primed wild type or NLRP3-/- BMDM were treated with control (DTT-containing buffer), 1.8nM 
TLO (low dose), 18.3nM TLO (high dose), or 1% triton X-100 for 30 min in serum-free IMDM.  20µg of whole cell 
protein lysate or entire 1ml TCA/cholic acid precipitated supernatants were run on an SDS-PAGE gel and western 
blot conducted for mature (17kDa) or pro- (35kDa) IL-1β protein.  Mature IL-1β was released from wild type 
BMDM after exposure to the low TLO dose, but not from NLRP3-/- BMDM.  The high TLO dose as well as Triton 
X-100 caused release of pro-IL-1β stores from both wild type and NLRP3-/- BMDM.  Data shown is a representative 
example of three independent experiments.  The asterisk (*) refers to a non-specific protein band. 
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2.5.6 Toxin-induced pore formation is necessary but not sufficient for IL-1β release  
We hypothesized based on the above results that pore formation would not be sufficient to 
induce IL-1β release by TLO in the absence of other components of the signaling pathway we 
identified.  First, we assessed the ability of toxin to bind BMDM in the presence and absence of 
cholesterol, using live cell confocal imaging to characterize the interaction.  Cy5-labeled TLO 
was generated for this purpose and BMDM were labeled with LysoTracker™ green as a marker 
of internal compartments.  Active TLO-Cy5 (non-cholesterol treated) bound predominantly to 
the surface of BMDM (Figure 2-8A).  On the other hand, BMDM internalized cholesterol-bound 
TLO-Cy5 to mostly non-acidic compartments, as there was little co-localization observed with 
LysoTracker™ green-labeled vesicles (Figure 2-8B).  To next test if binding and pore formation 
could occur in the presence of inhibitors of IL-1β release, the interaction between Cy5-labeled 
TLO and BMDM was measured by flow cytometry.  Pore formation was measured by uptake of 
YO-PRO-1 dye.  Fluorescently-labeled TLO binds to cells and perforates them, as evidenced by 
increased YO-PRO-1 uptake (Figure 2-8C) and increased Cy5 signal (Figure 2-8D), relative to 
cells exposed to labeled BSA used as a control.  In the presence of BAPTA-AM or KCl, which 
impairs IL-1β secretion as previously discussed, binding of TLO and subsequent pore formation 
is essentially unaffected.  It can again be seen that Cy5-labeled TLO pre-incubated with 
cholesterol associates with BMDM despite the lack of pore forming activity.  Taken together 
with the microscopy data, these results show that cholesterol-bound TLO can be efficiently 
internalized by BMDM without causing deleterious effects and without inducing biological 
responses such as IL-1β secretion.  Overall, these results demonstrate that TLO-induced pore 
formation is required, but not sufficient for IL-1β release from BMDM.   
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Figure 2-8: TLO binding and pore formation still occur in the presence of inhibitors of IL-1β secretion.   
(A-B) Four-hour LPS-primed BMDM were labeled with LysoTracker™ Green dye (green) for intracellular tracking 
purposes and then treated with 1.8nM TLO-Cy5 (red) inactivated with 1µg/ml cholesterol or left untreated.  BMDM 
were imaged by live cell microscopy to track active or cholesterol-inactivated TLO-Cy5 after addition.  These 
midplane sections taken at 10 min post treatment show that active toxin binds primarily to the surface of BMDM (A) 
while cholesterol-bound toxin is internalized by BMDM (B).  The bottom panels show magnifications of boxed cells 
displayed in the top panels.  The white bar scales indicate a 10μm length.  (C-D) Four-hour LPS-primed BMDM 
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were treated with no inhibitor (buffer only), 50mM KCl, or 30μM BAPTA-AM for 1 h followed by addition of 
control (DTT-containing buffer), 1.8nM TLO, 1.8nM TLO-Cy5, or 1.8nM BSA-Cy5 in the presence or absence of 
1μg/ml cholesterol for 5 min.  BMDM were analyzed by flow cytometry for TLO-induced pore formation (YO-
PRO-1 uptake) (A) and TLO binding (Cy5 signal) (B).  BMDM bind to pore-inducing TLO-Cy5, but not control 
BSA-Cy5 in the absence of IL-1β inhibitors as well as in the presence of BAPTA-AM or KCl.  Data represents 
mean +/- SEM for 3 independent experiments.  Control background values were subtracted out from the data.   
2.6 DISCUSSION 
We show here that TLO, a toxin of the CDC family, induces the rapid release of IL-1β from 
LPS-primed murine BMDM.  Release of this cytokine typically requires two stimuli: (1) TLR 
pathway activation to generate the inactive IL-1β precursor and (2) a stimulator of the 
inflammasome for the activation of caspase-1 to cleave pro-IL-1β to its mature form before 
release.  It has been observed that signal 1 (e.g. LPS) alone or signal 2 (e.g. ATP) alone 
stimulates IL-1β release from macrophages at low levels (pg/ml range for in vitro cultures) 
usually over long time periods (up to 24 h) (Mehta et al., 2001; Shoma et al., 2008).  However, 
when both signals are applied sequentially, IL-1β can be secreted from macrophages in much 
greater amounts (ng/ml range) within 30 min (Kahlenberg et al., 2005; Sutterwala et al., 2006).  
Our results are consistent with TLO acting as a type of signal 2, and are inconsistent with TLO 
providing signal 1 to BMDM. 
   Shoma, et al. recently reported that the CDC pneumolysin (PLY) induced the release of 
IL-1β and IL-1α from murine peritoneal macrophages, a TLR4-dependent process not inhibited 
by cholesterol (Shoma et al., 2008).  The PLY doses used in those experiments were similar to 
those for TLO used in our experiments.  Additionally, other groups have found that PLY induces 
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IL-1β secretion from monocytes (Houldsworth et al., 1994) and that CDC listeriolysin O (LLO) 
induces IL-1 (type not defined) release from peritoneal macrophages (Yoshikawa et al., 1993), a 
process also unaffected by free cholesterol. In contrast, we tested whether TLO could induce 
release of IL-1β from LPS-primed BMDM, which carry pre-formed stores of the cytokine.  Our 
results demonstrate that TLO-induced pore formation, requiring binding of the toxin to cellular 
cholesterol, stimulates the rapid release of large amounts of cytokine through a mechanism 
dependent on K+ efflux, Ca2+ influx, and the activation of iPLA2, NLRP3, caspase-1, and 
cathepsin B.  It should be noted that there was some variation in the amounts of TLO-induced 
IL-1β (mean amount per experiment ranged from 1975-3973 pg/ml; minimum = 803 pg/ml, 
maximum = 7569 pg/ml).  The variability is most likely due to several factors, including 
differences in macrophage preparation, length of macrophage culture (up to three weeks), sample 
collection day, and assay day. 
It appears that TLO-induced pore formation causes K+ efflux and subsequent IL-1β 
release.  However, mature IL-1β release only occurs when pore formation is balanced by the 
ability of cells to maintain function, required presumably for the activation of appropriate 
signaling pathways that will lead to the activation of caspase-1, the protease responsible for the 
conversion of inactive pro-IL-1β to active mature IL-1β.  Evidence for this is seen at low 
concentrations of TLO, which induced release of primarily mature IL-1β as well as generation of 
mature caspase-1, whereas higher doses caused release of predominantly the pro-forms of 
caspase-1 and IL-1β, which are biologically inactive.  We suggest that at high concentrations of 
toxin, a cell may undergo rapid release of cellular contents (e.g. pro-caspase-1 and pre-formed 
pro-IL-1β stores) through a passive process, outpacing the ability of the cell to activate caspase-
1, required for processing of the pro- to mature form.  This finding may explain a difference 
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between our results and those of Kanneganti, et al., who reported that CDC streptolysin O (SLO) 
does not activate caspase-1 (Kanneganti et al., 2007).  In their study, SLO was used at a high 
dose of 5μg/ml or 72.5nM. 
In addition to a requirement for K+ efflux, we also identified calcium influx and the 
activities of iPLA2, NLRP3, and caspase-1 as key players in TLO-induced IL-1β release.  To our 
knowledge, this is the first study to address the mechanism of CDC-induced IL-1β release and to 
differentiate the effects of low versus high doses of toxin.  Non-cholesterol binding, pore-
forming toxins (PFTs) from other families such as A. hydrophila aerolysin, which binds to GPI-
anchored protein receptors, and S. aureus alpha toxin that binds specific lipid clusters (Gonzalez 
et al., 2008) also require K+ efflux for their downstream effects (Walev et al., 1995; Gurcel et 
al., 2006; Kloft et al., 2009).  Aerolysin has been implicated in the activation of the NLRP3 and 
NLRC4 inflammasomes as well as caspase-1 for the activation of Sterol Regulatory Element 
Binding Proteins (SREBPs), which promote cell survival after cell membrane injury (Gurcel et 
al., 2006).  However, this study utilized non-immune cells and the role of aerolysin in IL-1β 
processing and release was not addressed.  Alpha toxin has also been shown to induce IL-1β 
secretion from LPS-primed monocytes, but the mechanism of release is unclear (Bhakdi et al., 
1989; Walev et al., 1995).  It should be stressed that although these other toxins may share some 
similarities to CDC in their ability to form pores in cells and initiate K+ efflux, they also differ in 
the size of the pore they induce (2nm for aerolysin and alpha toxin; 30nm for CDC) (Gonzalez et 
al., 2008) and therefore could have divergent downstream pathways.  One such example is the 
response of cells to alpha toxin-mediated versus CDC-mediated cell injury.  It has been observed 
that membrane repair after CDC-induced injury involves a p38-independent mechanism and 
occurs in less than 1 hour, compared to alpha toxin-mediated repair, which requires p38 activity 
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and may take many hours for full recovery (Bhakdi et al., 1996; Husmann et al., 2006).  Thus, it 
will be interesting to see if IL-1β processing and release mechanisms are similar or disparate for 
PFTs that form small pores (alpha toxin, aerolysin) versus large ones (CDC). 
While the involvement of ion fluxes and the activities of iPLA2, NLRP3, and caspase-1 in 
IL-1β release induced by ATP and nigericin is well established (Lich et al., 2006), the 
mechanism for direct activation of the NLRP3 inflammasome complexes has remained unclear.  
Recent studies (Halle et al., 2008; Hornung et al., 2008) have suggested that cathepsin B may 
activate the NLRP3 inflammasome either directly or indirectly through other factors.  In their 
studies, they show that IL-1β-inducing stimuli such as silica crystals, alum salt crystals, and 
amyloid-β fibrils are phagocytosed, and that these cargos disrupt lysosomal integrity.  This 
would allow subsequent release of cathepsin B into the cytosol, which is proposed to cause 
activation of the NLRP3 inflammasome by an unknown mechanism.  We also observe a 
dependence on cathepsin B activity for TLO-induced IL-1β secretion.  Studies are underway to 
determine if this toxin relies on similar pathways as silica crystals, alum salt crystals, and 
amyloid-β fibrils, which lead to active cytosolic cathepsin B.   
In addition to understanding how caspase-1 is directly activated in this system, there is 
much interest in determining the general mechanism by which mature IL-1β is secreted from 
cells.  IL-1β lacks signal sequences for localization to the Golgi and other classical secretory 
compartments and therefore must be secreted by non-classical means.  The data available suggest 
several possible pathways for IL-1β release, including release of exosomes carrying mature IL-
1β after fusion of multivesicular bodies with the plasma membrane, Ca2+-dependent secretory 
lysosome exocytosis, microvesicle shedding from the plasma membrane, and direct translocation 
of cytosolic cytokine through unknown plasma membrane transporters to the extracellular 
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environment (Qu et al., 2007).  It is possible that multiple pathways may be involved for a single 
cell type or that a particular pathway is designated to each specific cell type.  At this time, it is 
unknown what pathway(s) TLO utilizes to cause the export of mature IL-1β.   
This is the first study to identify the mechanism of IL-1β release induced by a family of 
cholesterol-binding, large pore-forming toxins and to tease apart differences in the IL-1β 
response to lower versus higher toxin doses.  This IL-1β release mechanism may differ from that 
for other families of PFTs that bind different receptors, form much smaller pores, and utilize 
different pathways to achieve the same goal (i.e. pore resealing processes).  Moreover, to our 
knowledge this is the first observation of cathepsin B involvement in IL-1β release induced by a 
PFT.  In summary, we find that low TLO concentrations induce the rapid release of relatively 
high amounts of active mature IL-1β from LPS-primed murine macrophages in a process 
dependent on toxin-induced perforation, potassium efflux, calcium influx, and activation of 
iPLA2, NLRP3, caspase-1, and cathepsin B.  On the other hand, high TLO doses induce the 
release of inactive pro-IL-1β, which may be an evasion mechanism employed by bacteria during 
infection.  This study addresses in detail the mechanisms of CDC-induced rapid IL-1β release 
and may help to explain the effects of these toxins in bacterial infections and the subsequent host 
immune responses.   
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3.0  NLRP3 INFLAMMASOME-DEPENDENT AND NLRP3 INFLAMMASOME-
INDEPENDENT HMGB1 RELEASE INDUCED BY A BACTERIAL PORE-FORMING 
TOXIN 
3.1 ABSTRACT 
The NLRP3 inflammasome is a pro-inflammatory caspase-1-containing complex involved in the 
maturation of pro-inflammatory cytokines IL-1β and IL-18.  NLRP3, independent of its 
inflammasome functions, has been demonstrated to play a role in a cathepsin B-dependent, 
caspase-1-independent necrotic cell death process known as pyronecrosis.  We have previously 
shown that the cholesterol-dependent, pore-forming toxin tetanolysin O (TLO) causes IL-1β 
release from LPS-primed murine bone marrow-derived macrophages (BMDM) in a NLRP3 
inflammasome- and cathepsin B-dependent manner.  The work contained herein supports an 
additional role for TLO in the necrosis of LPS-primed BMDM.  Both a low and a high TLO dose 
induce release of lactate dehydrogenase (LDH) and high mobility group box 1 (HMGB1) and 
this release is NLRP3-dependent for the low toxin dose.  Low dose TLO-induced HMGB1 
release is also dependent on the activities of caspase-1 and cathepsin B, suggesting a novel form 
of cell death that is distinct from caspase-1-independent pyronecrosis.  We also observe via fixed 
cell microscopy that TLO causes relocalization of HMGB1 from the nucleus to the cytoplasm in 
LPS-primed BMDM and that NLRP3 plays a role in HMGB1 release from the cells.  To our 
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knowledge, this is the first study to visualize HMGB1 localization in cells lacking NLRP3.  
These results provide some understanding as to how HMGB1 release is regulated and could 
eventually lead to new therapeutic approaches to target HMGB1, which contributes to many 
inflammatory diseases.   
3.2 INTRODUCTION 
The NLR (nucleotide binding domain, leucine rich repeat-containing) family of proteins 
plays a significant role in innate immune sensing of danger signals derived both from pathogens 
and the host (Martinon et al., 2009).  In particular, NLR family member NLRP3 has been well 
studied for its ability to promote inflammatory responses.  Genetic mutations in the 
NLRP3/CIAS1 human gene encoding for this protein lead to autoinflammatory diseases known as 
CIAS1-associated periodic syndromes (CAPS) that include familial cold autoinflammatory 
syndrome (FCAS) (Hoffman et al., 2001), Muckle-Wells syndrome (MWS) (Hoffman et al., 
2001), and neonatal-onset multi-inflammatory disease (NOMID) (Aksentijevich et al., 2002), 
which is also known as Chronic Infantile Neurologic Cutaneous Articular Syndrome (CINCA).  
NLRP3 oligomerizes to form a platform for the activation of caspase-1, known as the NLRP3 
inflammasome, which ultimately leads to pro-inflammatory IL-1β and IL-18 secretion (Cassel et 
al., 2009).  Cells must be exposed to a TLR priming signal for the generation of pro-IL-1β and 
pro-IL-18 followed by a second NLRP3 inflammasome-activating signal that enables the 
activation of caspase-1 and release of the mature forms of these cytokines.  To date, many 
pathogen-, host-, and environmental toxin-related second stimuli have been identified (Figure 3-
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1).  Some of these studies also implicated lysosomal protease cathepsin B activity in IL-1β 
release, but the mechanism of action is unclear. 
 
 
Figure 3-1: NLRP3 inflammasome stimulators 
Bacteria, particulates, pore-forming agents, protein aggregates, viruses, yeasts, nucleic acids, and malarial hemozoin 
stimulate the NLRP3 inflammasome.  The studies where each inflammasome stimulator was identified are noted. 
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Aside from its role in pro-inflammatory cytokine secretion, NLRP3 has also been found 
to play a role in pathogen-induced cell death of monocytes and macrophages.  S. flexneri 
(Willingham et al., 2007) and K. pneumoniae (Willingham et al., 2009) infection of monocytes 
or macrophages or exposure of these cells to S. aureus α-hemolysin (Craven et al., 2009) results 
in NLRP3- and cathepsin B-dependent necrotic cell death termed as pyronecrosis.  However, this 
pathway is independent of caspase-1 unlike a form of cell death known as pyroptosis that relies 
on caspase-1, but not cathepsin B (Bergsbaken et al., 2009).  This would suggest that NLRP3 is 
acting independently of its inflammasome function to bring about a program of cell death.  
Pyronecrosis is similar to necrosis in that a major hallmark is the loss of an intact plasma 
membrane that leads to the spilling of cellular contents that promote inflammation.   
One such molecule known to be released during necrosis and pyronecrosis is high 
mobility group box 1 (HMGB1).  HMGB1 is a nuclear protein, present in all nucleated cells, 
which was initially recognized for its role as a DNA binding protein that regulates transcription 
(Javaherian et al., 1978; Singh & Dixon, 1990; Lange & Vasquez, 2009).  More recently, 
HMGB1 has been shown to act as a cytokine after being passively released from necrotic cells 
(Scaffidi et al., 2002) or actively released from activated monocytes or macrophages stimulated 
with LPS, TNF, IL-1β, or IFN-γ (Wang et al., 1999; Rendon-Mitchell et al., 2003).  Following 
release, HMGB1 can bind to its receptor RAGE (receptor for advanced glycation-end products) 
to elicit additional pro-inflammatory cytokine release (e.g. IL-1β, TNF-α) (Andersson et al., 
2000; Kokkola et al., 2005).  Toll-like receptors (TLRs) 2 and 4 have also been suggested to be 
receptors for HMGB1, but these findings are controversial (Park et al., 2004b; Kokkola et al., 
2005; van Zoelen et al., 2009).  HMGB1-mediated inflammation can be detrimental to the host 
 72 
and contribute to lung and liver injury, gut epithelial-cell barrier leakage, sepsis, arthritis, and 
cancer (Dumitriu et al., 2005; Lotze & Tracey, 2005). 
The mechanism by which HMGB1 localizes from the nucleus to the extracellular space is 
not well understood.  HMGB1 is a leaderless peptide that cannot translocate from the Golgi to 
the cell membrane after protein synthesis, much like IL-1β.  It has been suggested (Gardella et 
al., 2002) that upon 18h of LPS stimulation of monocytes, HMGB1 moves out of the nucleus 
into the cytoplasm, whereupon it enters cytoplasmic secretory vesicles before final exocytosis 
from the cells.  Hyperacetylation seems to be required for HMGB1 to move out of the nucleus 
and this acetylation state prevents re-entry into the nucleus due to blocked interaction with the 
nuclear-importer complex (Bonaldi et al., 2003).  Contrary to active HMGB1 secretion, passive 
HMGB1 release results from the breakdown of cellular membranes during necrotic or 
pyronecrotic cell death.  Since actively secreted HMGB1 requires acetylation while passively 
released HMGB1 does not, differences in post-translational modification of HMGB1 may result 
in differences in its downstream biological activities.   
Our laboratory recently demonstrated that bacterial pore-forming toxin tetanolysin O 
(TLO), from the cholesterol-dependent cytolysin (CDC) family (Billington et al., 2000; Palmer, 
2001), rapidly activates caspase-1 and induces the secretion of IL-1β in a NLRP3- and cathepsin 
B-dependent manner from murine bone marrow-derived macrophages (BMDM) (Chu et al., 
2009).  We observed these phenomena only with a sublytic dose of TLO, defined as a TLO 
concentration that perforates cells, but does not induce enough damage to make the cells 
immediately metabolically inactive.  On the other hand, a lytic TLO dose induced rapid passive 
release of inactive pro-caspase-1, inactive pro-IL-1β (independently of NLRP3), and lactate 
dehydrogenase (LDH), a common marker of cell death.  These studies were conducted in a 
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relatively short amount of time (30 min) and the ultimate fate (i.e. cell death) of TLO-exposed 
BMDM was not determined.  It has been shown previously by Srivastava, et al. (Srivastava et 
al., 2005) that high doses of purified CDC pneumolysin (PLY) cause apoptosis of macrophages 
via a TLR4-dependent mechanism.  However, in the context of infection with CDC-secreting 
bacteria, macrophages undergo various types of cell death ranging from caspase-1-dependent 
pyroptosis (Cervantes et al., 2008) and caspase-1-dependent apoptosis (Timmer et al., 2009) to 
calpain-dependent oncosis (Goldmann et al., 2009).  The role of CDC in these bacterially 
induced cell death pathways is unclear. 
Given that NLRP3 has been observed to play a role in pyronecrotic cell death initiated by 
other inflammasome-activating stimuli, we asked if TLO could also trigger NLRP3-dependent 
cell death in macrophages.  We show here that low and high doses of TLO both cause cell death 
in BMDM, which is characterized by membrane permeability and plasma membrane breakdown 
that enables passive spilling of LDH and rapid HMGB1 release.  At the low TLO dose, HMGB1 
release is dependent on LPS priming, NLRP3, caspase-1, and cathepsin B, while these factors 
have no impact on HMGB1 release induced by the high TLO dose.  After exposure of LPS-
primed BMDM to the low TLO dose, NLRP3 appears to be required for the release of HMGB1 
from cytoplasmic vesicles to the extracellular space and NLRP3-deficient BMDM are protected 
from plasma membrane damage, as evidenced by a lack of LDH release.  These results suggest 
that the high TLO dose causes uncontrolled necrotic cell death in BMDM, while the low dose of 
TLO initiates a NLRP3 inflammasome-dependent necrotic cell death program.  This is the first 
study to identify a NLRP3-dependent mode of cell death that relies both on cathepsin B and 
caspase-1 and to visualize the impact of NLRP3 on HMGB1 release.   
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3.3 MATERIALS AND METHODS 
Reagents - Tetanolysin (TLO) was obtained from Biomol International (Plymouth Meeting, PA).  
Toxin was reduced with 10mM DTT (Sigma, St. Louis, MO) for 10min, 37oC before use unless 
indicated and untreated control samples were incubated in the same buffer lacking toxin.  
Adenosine triphosphate (ATP), nigericin, and lipopolysaccharide (LPS) were purchased from 
Sigma-Aldrich (St. Louis, MO), CA-074 Me/cathepsin B inhibitor IV from EMD Biosciences 
(Gibbstown, NJ), Ac-YVAD-cmk/caspase-1 inhibitor II from Axxora, LLC (San Diego, CA), 
triton X-100 from Fisher Scientific (Pittsburgh, PA), and glycerol from Invitrogen (Carlsbad, 
CA).     
Bone marrow-derived macrophage preparation – The following protocol was adapted 
from (Davies & Gordon, 2005). Tibiae and femurs from wild type (gifts from Dr. Lisa Borghesi, 
University of Pittsburgh) and NLRP3-/- (gifts from Dr. Gabriel Nunez, University of Michigan) 
C57BL/6 mice were collected.  Bone marrow cells were extracted using a 27 gauge needle and 
passed through a 21 gauge needle to obtain a homogenous mixture.  Cells were plated in petri 
dishes (Day 1) in DMEM (Mediatech, Inc., Herndon, VA) supplemented with 20% Gemcell™ 
FBS (Gemini Bio-Products, West Sacramento, CA), 2mM L-glutamine, 500U Penicillin/500μg 
Streptomycin (Lonza Inc., Walkersville, MD), 1mM sodium pyruvate (MP Biomedicals, Solon, 
OH), and 30% L cell supernatant.  L cell supernatant was generated by incubating L cell 
fibroblasts (CCL-1 from ATCC, Manassas, VA) in DMEM supplemented with 10% Gemcell™ 
FBS, 2mM L-glutamine, 500U Penicillin/500μg Streptomycin, 1X non-essential amino acids 
(Irvine Scientific, Santa Ana, CA), and 1mM sodium pyruvate until confluent.  Supernatant was 
collected and filtered through a 0.22um filter.  Differentiation media for BMDM was changed 
every 3-4 days and BMDM were used for experiments Days 8-22.  For experiments, BMDM 
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were cultured in IMDM (Lonza, Inc.) containing 10% Gemcell™ FBS, 2mM L-glutamine, and 
500U Penicillin/500μg Streptomycin. 
Western blotting – 2x106 BMDM (plated the day before in 6-well plates) were treated for 
4 h with 1μg/ml LPS or were left untreated.  BMDM were then washed with serum-free IMDM 
and incubated for 30 min in serum-free IMDM with DTT control buffer, 1.8nM TLO, 18.3nM 
TLO, 3mM ATP, 20μM nigericin, or sterile purified water.  In some cases, BMDM were pre-
treated with various inhibitors for 1 h in serum-free media after LPS priming.  1ml supernatants 
were collected and TCA/cholic acid-precipitated as described by Qu and colleagues (Qu et al., 
2007).  Cells were lysed in wells with 1% triton X-100 lysis buffer (1% triton X-100, 10% 
glycerol, 50mM Hepes, 150mM NaCl, 1.5mM MgCl2) containing a protease inhibitor cocktail 
(Sigma).  Bradford assay (Bio-rad, Hercules, CA) was conducted to determine protein 
concentration of lysates and 20μg of protein lysate was run on SDS-PAGE gels along with 
concentrated supernatants.  Proteins were transferred to PVDF membrane using Towbin buffer 
transfer or the iBlot™ system (Invitrogen) and probed for HMGB1 with mouse anti-HMGB1 
primary antibody (Abcam, Cambridge, MA) and goat anti-mouse IgG-HRP secondary antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA) using the SNAP i.d. system (Millipore, Billerica, 
MA).  Western blotting luminol reagent (Santa Cruz Biotechnology) was applied and membranes 
were imaged with Kodak Image Station 4000MM (Molecular Imaging Systems, Carestream 
Health, Inc.).   
LDH release assay – 4.5x105 BMDM (plated the day before in 35mm petri dishes) were 
treated for 4 h with 1μg/ml LPS.  Cells were then washed with PBS and incubated with DTT 
control buffer, 1.8nM TLO, or 18.3nM TLO in phenol red-free serum-free IMDM.  TLO was 
incubated with cells for 5 min in this serum-free media (since serum contains cholesterol that can 
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inhibit TLO interaction with cells) followed by addition of 10% FBS and further incubation for 5 
min – 6 h.  1% triton X-100 was used as a control of complete cell lysis and maximal LDH 
release.  Supernatants were collected and assayed in duplicate for LDH content using the LDH 
Cytotoxicity Assay Kit from Cayman Chemical Company (Ann Arbor, MI).  % cytotoxicity was 
calculated as follows: ((Mean OD value of experimental sample – Mean blank OD) / (Mean OD 
value of triton X-100 control sample – Mean blank OD)) * 100.   
Live/dead flow cytometry assay – 4.5x105 BMDM (plated the day before in 35mm petri 
dishes) were treated for 4 h with 1μg/ml LPS.  BMDM were then washed with serum-free 
IMDM and treated with DTT control buffer, 1.8nM TLO, or 18.3nM TLO in serum-free IMDM.  
TLO was incubated with cells for 5 min followed by addition of 10% FBS and cells were 
immediately harvested or further incubated for 30 min – 4 h.  At each time point, cells from 
dishes and supernatants were harvested and stained using a calcein-AM and ethidium 
homodimer-1 LIVE/DEAD® Viability/Cytotoxicity Kit for mammalian cells according to the 
manufacturer’s protocol (Invitrogen).  Samples were analyzed on a BD™ LSR II flow cytometer 
(BD Biosciences) and FlowJo (Tree Star, Inc., Ashland, OR) was used for data analysis.   
Fixed cell microscopy – 1.5x105 BMDM (plated overnight in 35mm glass bottom culture 
dishes (MatTek Corporation, Ashland, MA)) were primed with 1μg/ml LPS for 4 h.  Cells were 
then washed with serum-free IMDM and immediately analyzed or incubated with 1.8nM TLO in 
serum-free IMDM.  For the latter case, TLO was incubated with the cells for 5 min followed by 
addition of 10% FBS and cells were immediately harvested or further incubated for 15 – 30 min.  
At each time point, cells were washed with PBS and fixed with 2% PFA made in PBS for 10 
minutes.  Cells were washed with PBS, permeabilized for 15min with 0.1% Triton X-100 made 
in PBS, washed five times with 0.5% BSA, and blocked with 2% BSA for 45min.  Cells were 
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again washed five times with 0.5% BSA, incubated with rabbit anti-mouse HMGB1 (generously 
provided by Michael T. Lotze, University of Pittsburgh) or rabbit IgG isotype control antibody 
(Jackson ImmunoResearch) in 0.5% BSA for 60min, washed five times with 0.5% BSA, and 
incubated with goat anti-rabbit Alexa Fluor® 488 (Invitrogen) in 0.5% BSA for 60min.  Cells 
were washed five times with 0.5% BSA and five times with PBS followed by staining with 
Hoescht stain and rhodamine-phalloidin (Invitrogen) for 30s.  Cells were washed twice with 
PBS, covered with gelvatol and dried in the dark at 4oC overnight.  Fixed cell imaging was 
performed using an Olympus FluoView 1000 scanning confocal microscope (Olympus America 
Inc., Center Valley, PA).  Images were viewed with Adobe® Photoshop® (Adobe Systems Inc., 
San Jose, CA). 
Graphical and Statistical Analysis – All graphing analyses were completed using 
Microsoft Excel (Microsoft, Redmond, WA).  Statistical analysis (Student’s paired t-test) was 
conducted with GraphPad Prism (GraphPad Software, Inc., San Diego, CA).  P-values were 
denoted as follows: p-value < 0.05 = *, p-value < 0.01 = **, and p-value > 0.05 was not 
significant (ns). 
3.4 RESULTS 
3.4.1 Low dose TLO causes plasma membrane permeability and breakdown that is 
NLRP3-dependent 
Our previous study showed that a low TLO dose (1.8nM) induced NLRP3 inflammasome-
dependent secretion of mature IL-1β, while a high dose (18.3nM) caused passive release of 
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inactive proteins from LPS-primed BMDM.  Since that study was conducted over a relatively 
short time period (30 min), we wanted to further characterize the state of these LPS-primed 
BMDM over longer time points.  To first assess membrane permeability, a two-color viability 
dye flow cytometry assay was employed.  LPS-primed BMDM were control- or TLO-treated for 
various times and stained with calcein-AM, which is cleaved to a fluorescent form and retained 
only in viable cells, and ethidium homodimer-1 (EthD-1), which enters plasma membrane-
compromised cells and fluorescently labels DNA.  As shown in Figure 3-2A, control cells are 
predominantly intact up to 4h with the majority falling into the calcein-AM-positive cell gate.  In 
comparison, 18.3nM TLO-treated BMDM are rapidly permeabilized up to 4h, allowing bright 
EthD-1 staining.  Treatment with 1.8nM TLO also causes rapid permeabilization as evidenced by 
strong EthD-1 staining at 5min, but a percentage of this population recovered from plasma 
membrane damage as shown by a shift of cells to the calcein-AM-positive cell gate from the 
EthD-1-positive cell gate at 30min and onward.  Lactate dehydrogenase (LDH) release was also 
used as a measure of membrane permeability and breakdown.  Both 1.8nM and 18.3nM TLO 
induced LDH release with a higher percentage of LDH release for the high TLO dose compared 
to the low one (Figure 3-2B).  Taken together, these results suggest that the high dose of TLO 
causes cell death of the entire cell population compared to the low dose of TLO that kills a 
percentage of the exposed cells, while a portion recover from initial cell damage.   
Passive spilling of LDH suggests a necrotic cell death program.  Since other second 
stimuli of the NLRP3 inflammasome have been shown to induce NLRP3-dependent necrotic cell 
death in monocytes and macrophages, we assessed if TLO-induced cell death was also dependent 
on NLRP3.  Using LDH release as a readout, the magnitude of cell death was compared for wild 
type (WT) and NLRP3 knockout (KO) BMDM exposed to a low and a high dose of TLO.  A 
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high dose (18.3nM) of TLO induced large amounts of LDH release with equivalent levels for 
WT and NLRP3 KO BMDM (Figure 3-2C).  However, 1.8nM TLO only elicited LDH release 
from WT BMDM while BMDM lacking NLRP3 released levels of LDH that were comparable to 
control background levels.  These data suggest that NLRP3 plays a role in the cell death program 
initiated in LPS-primed BMDM by the low dose of TLO. 
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Figure 3-2: Low dose TLO induces membrane permeability and breakdown in LPS-primed BMDM that is 
NLRP3-dependent. 
(A) Four-hour LPS-primed BMDM were treated with control buffer, 1.8nM TLO, or 18.3nM TLO for 5min – 4hr.  
Cells were then harvested and stained with calcein-AM and ethidium homodimer-2 (EthD-1) followed by flow 
cytometry analysis.  Control-treated cells mostly fall into the calcein-AM (+) gate at all time points tested while 
18.3nM TLO-treated cells fall mainly in the EthD-1(+) cell gate over time.  1.8nM TLO-treated BMDM initially 
stain EthD-1 (+) at 5min post-treatment, but a portion of the cells shift to the calcein-AM (+) gate at the later time 
points.  This data is one representative example of three independent experiments. (B) Four-hour LPS-primed 
BMDM were treated with control buffer, 1.8nM TLO, or 18.3nM TLO up to 6hr.  LDH release was assessed and 
normalized to the maximal amount of LDH released after 1% Triton X-100 treatment.  TLO induced LDH release in 
a dose- and time-dependent manner.  Data represents mean +/- SEM for 3 independent experiments.  Student’s 
paired t-test was applied for comparison of control versus TLO conditions; * = p< 0.05, ** = p< 0.01.  (C) Four-
hour LPS-primed WT or NLRP3 KO BMDM were treated with control buffer, 1.8nM TLO, or 18.3nM TLO up to 
4hr.  LDH release was assessed as in (B).  TLO-induced LDH release was dependent on NLRP3 at the lower dose of 
TLO tested.  Data represents mean +/- SEM for 3 independent experiments.  Student’s paired t-test was applied for 
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comparison of control versus TLO conditions (* = p< 0.05, ** = p< 0.01) or WT vs. NLRP3 KO BMDM (# = p< 
0.05, ## = p< 0.01). 
3.4.2 Low or high dose TLO induces the release of HMGB1 from BMDM 
Several groups have recently shown that NLRP3-dependent necrotic cell death is characterized 
by the release of high mobility group box 1 (HMGB1) protein, which is a well known marker of 
necrotic cell death in general.  Release of HMGB1 into supernatants of LPS-primed BMDM 
treated with a low and high dose of TLO was tested.  Both the high and low dose of toxin caused 
the release of HMGB1, as did NLRP3 inflammasome stimulators nigericin and ATP (though to a 
lesser degree) (Figure 3-3).  As a control, LPS-primed BMDM were treated with purified water 
to cause necrosis and, as expected, HMGB1 was released.  These results confirm that TLO 
induces some form of necrotic cell death in LPS-primed BMDM. 
 
 
Figure 3-3: TLO induces HMGB1 release from LPS-primed BMDM. 
Four-hour LPS-primed BMDM were treated with control buffer, 1.8nM TLO, 18.3nM TLO, 3mM ATP, 20µM 
nigericin, or purified water for 30min.  20µg of whole cell protein lysate or entire 1ml TCA/cholic acid precipitated 
supernatants were run on an SDS-PAGE gel and western blot conducted for HMGB1 (25kDa).  All stimulators 
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except for the control induced HMGB1 release into cell supernatants.  This data is a representative example of three 
independent experiments.   
3.4.3 Low dose TLO-induced HMGB1 release is dependent on LPS priming and the 
activities of NLRP3, caspase-1, and cathepsin B  
TLR priming of macrophages is a critical first step to license the NLRP3 inflammasome in terms 
of the upregulation of NLRP3 expression.  It might be expected then that TLR stimulation (i.e. 
LPS priming) would be important for TLO-induced, NLRP3-dependent cell death.  To test this, 
we stimulated BMDM that were either not primed or LPS primed with 1.8nM or 18.3nM TLO 
and probed for HMGB1 in supernatants.  LPS priming was required for HMGB1 release induced 
by the low 1.8nM TLO dose, but not the high 18.3nM TLO dose (Figure 3-4A).  It was also 
notable that LPS priming alone (LPS plus control buffer), did not result in any HMGB1 release.  
To visualize the localization of HMGB1 after 4 hours of LPS priming, fixed cell 
immunofluorescence microscopy was conducted.  It can be seen in Figure 3-4B that cells 
exposed to media only retain HMGB1 in the nucleus.  Interestingly, HMGB1 also localizes to 
the nucleus after 4 hours of LPS stimulation.  This would suggest that a pathway initiated by 
TLO is responsible for the release of HMGB1 rather than LPS by itself. 
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Figure 3-4: LPS priming is critical for low dose TLO-induced HMGB1 release. 
(A) BMDM were left alone or LPS primed for 4 hours followed by treatment with control buffer, 1.8nM TLO, or 
18.3nM TLO for 30min.  20µg of whole cell protein lysate or entire 1ml TCA/cholic acid precipitated supernatants 
were run on an SDS-PAGE gel and western blot conducted for HMGB1 (25kDa).  LPS priming is required for the 
release of HMGB1 into supernatants after exposure to the low dose of TLO.  This data is a representative example 
of multiple independent experiments.  (B) BMDM were left alone or LPS primed for 4 hours.  They were then fixed, 
permeabilized, and stained with rabbit anti-mouse HMGB1 or rabbit IgG isotype control and then goat anti-
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rabbit Alexa Fluor® 488  (green), rhodamine-phalloidin (red) to label actin, and Hoescht stain (blue) to label the 
nucleus.  Localization patterns were visualized with fixed cell fluorescence microscopy.  HMGB1 co-localizes to the 
nucleus when exposed to media only or 1µg/ml LPS over 4 hours.  Data are one representative example of two 
independent experiments. 
 
To further characterize the role of NLRP3 and other inflammasome pathway components 
in TLO-induced cell death, we assessed HMGB1 release from WT BMDM in comparison to that 
released from NLRP3 KO BMDM or WT BMDM pre-treated with pharmacological inhibitors of 
caspase-1 (Ac-YVAD-cmk) or cathepsin B (CA-074-Me).  HMGB1 release was abrogated in 
low dose TLO-exposed NLRP3 KO BMDM (Figure 3-5A), caspase-1-inhibited WT BMDM 
(Figure 3-5B), and cathepsin B-inhibited WT BMDM (Figure 3-5C).  NLRP3 and caspase-1 only 
played a minimal role, if any, in HMGB1 induced by the high TLO dose.  These results support a 
role for the NLRP3 inflammasome (NLRP3 and caspase-1) and cathepsin B in low dose TLO-
induced HMGB1 release. 
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Figure 3-5: Low dose TLO-induced HMGB1 release is dependent on NLRP3, caspase-1, and cathepsin B. 
Four-hour LPS-primed BMDM were treated with control buffer, 1.8nM TLO, or 18.3nM TLO for 30min.  20µg of 
whole cell protein lysate or entire 1ml TCA/cholic acid precipitated supernatants were run on an SDS-PAGE gel and 
western blot conducted for HMGB1 (25kDa).  HMGB1 release was compared for WT vs. NLRP3 KO BMDM (A), 
WT BMDM treated with no inhibitor vs. caspase-1 inhibitor Ac-YVAD-cmk (B), or WT BMDM treated with no 
inhibitor vs. cathepsin B inhibitor CA-074-Me (C).  HMGB1 release into supernatants is dependent on NLRP3, 
caspase-1, and cathepsin B for the low dose of TLO.  Data are single representative examples of multiple 
independent experiments. 
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3.4.4 HMGB1 translocates from the nucleus to the cytoplasm after exposure to low dose 
TLO and its release depends on NLRP3 activity 
Since 4 hours of LPS priming did not cause HMGB1 to re-localize from the nucleus to the 
cytoplasm or to be released from the cell (Figure 3-4B), we wanted to explore the role that TLO 
had on the localization pattern of HMGB1 in the cell.  Additionally, the role of NLRP3 in this 
localization process was assessed by comparing WT to NLRP3 KO BMDM.  Since TLO-
induced HMGB1 release is observed from BMDM by 30 min post-treatment with TLO, a shorter 
time course was conducted in order to track the localization of intracellular HMGB1.  It can be 
observed at 0 min, before low dose TLO addition, that HMGB1 is localized to the nucleus both 
in WT and NLRP3 KO BMDM (Figure 3-6A).  This pattern remains 5 min after TLO addition, 
but at 15 min the HMGB1 distribution pattern changes.  Zoomed images of the 15 min time point 
(Figure 3-6B) show that HMGB1 translocates from the nucleus to the cytoplasm both in the WT 
and NLRP3 KO BMDM.  Additionally, some of the HMGB1 staining appears punctate 
especially in the NLRP3 KO BMDM.  By 30 min post-TLO treatment, some of the WT BMDM 
lack HMGB1 staining while the majority of the NLRP3 KO BMDM show HMGB1 localized to 
the nucleus again (Figure 3-6A).  This data would suggest that NLRP3 plays a role in the release 
of HMGB1 from BMDM. 
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Figure 3-6: HMGB1 translocates from the nucleus to the cytoplasm after low dose TLO stimulation. 
(A) Four-hour LPS-primed WT or NLRP3 KO BMDM were left untreated (0min) or treated with 1.8nM TLO for 5-
30min.  Cells were then fixed, permeabilized, and stained with rabbit anti-mouse HMGB1 or rabbit IgG isotype 
control and then goat anti-rabbit Alexa Fluor® 488 (green), rhodamine-phalloidin (red) to label actin, and Hoescht 
stain (blue) to label the nucleus.  Localization patterns were visualized with fixed cell fluorescence microscopy.  
Two fields of view are shown for each time point and cell type.  At 0min and 5min, HMGB1 localizes to the nucleus 
in WT and NLRP3 KO BMDM.  By 15min, HMGB1 localizes to the cytoplasm.  Zoomed images show some 
punctate HMGB1 staining in both WT and NLRP3 KO BMDM (B).  Finally, at 30min, some WT BMDM lack 
HMGB1 staining while others exhibit nuclear HMGB1.  Most NLRP3 KO BMDM show nuclear HMGB1.  
3.5 DISCUSSION 
We have shown here that both low and high doses of TLO induce membrane permeabilization 
and membrane damage in LPS-primed BMDM, which is characterized by LDH and HMGB1 
release.  In particular, the low dose of TLO causes NLRP3-dependent LDH release and HMGB1 
release.  HMGB1 release is also dependent on LPS priming and the activities of caspase-1 and 
cathepsin B.  Since HMGB1 is a common marker for necrotic cell death (Scaffidi et al., 2002) 
and TLO induces HMGB1 from BMDM, this would suggest that these cells are undergoing 
some form of necrotic cell death.  In the case of the high dose of TLO, BMDM passively release 
LDH and HMGB1 in a manner independent of NLRP3 inflammasome components, which would 
support a role for classical necrotic cell death rather than the specialized form of pyronecrotic 
cell death that relies on the activities of cathepsin B and NLRP3 (Willingham et al., 2007; 
Willingham et al., 2009).  On the other hand, the low dose of TLO brings about a form of 
necrotic cell death that is dependent on cathepsin B and NLRP3.  However, this cell death 
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program cannot be characterized as pyronecrosis either since caspase-1 activity plays a role.  It 
should be noted that low dose TLO-induced cell death is also different from pyroptosis 
(Bergsbaken et al., 2009), which relies on caspase-1 activity, but not cathepsin B activity and has 
not been linked to HMGB1 release.  We believe that different NLRP3 inflammasome stimuli 
bring about distinct types of cell death that may share some, but not necessarily all of the same 
characteristics.  Our data supports a model of necrotic cell death initiated by a low dose of TLO 
that is characterized by HMGB1 release that is dependent on the NLRP3 inflammasome 
(including NLRP3 and caspase-1) and cathepsin B activity.  This is the first report to 
demonstrate a role for the caspase-1-containing NLRP3 inflammasome and cathepsin B in 
BMDM cell death caused by a pore-forming toxin. 
As opposed to prior studies assessing cell death pathways using only purified CDC 
(Srivastava et al., 2005), BMDM in our studies were first LPS primed before exposure to TLO.  
We found that LPS priming was essential for low dose TLO-induced release of HMGB1 from 
BMDM.  TLR priming has been shown to license the NLRP3 inflammasome by causing the 
upregulation of NLRP3 expression (Bauernfeind et al., 2009).  Additionally, this priming step is 
required for the translocation of adaptor ASC from the nucleus to the cytoplasm where it can 
bridge NLRP3 and caspase-1 to form an inflammasome complex (Bryan et al., 2009).  This may 
explain our findings of the requirement for TLR priming since we also found a significant role 
for the NLRP3 inflammasome in low dose TLO-induced HMGB1 release.  Many groups have 
previously found that LPS alone can induce HMGB1 secretion from monocytes and 
macrophages after 8-18 hours of stimulation (Wang et al., 1999; Gardella et al., 2002; Chen et 
al., 2004).  Moreover, LPS initiates the re-localization of HMGB1 from the nucleus to 
cytoplasmic vesicles (Gardella et al., 2002; Liu et al., 2006).  In comparison, when we stimulate 
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murine macrophages with LPS, we do not see HMGB1 translocation from the nucleus nor do we 
observe HMGB1 externalization from the cells.  However, these discrepancies may be explained 
by the kinetics of the experiments used in each study.  In our experiments, the time of LPS 
stimulation is limited to 4 hours while previous studies have demonstrated HMGB1 localization 
and release after longer time points.  According to Wang, et al. (Wang et al., 1999), accumulated 
HMGB1 release from LPS-stimulated macrophage cultures is not detectable until 8 hours after 
stimulation.  Additionally, they showed that in in vivo models of endotoxemia, where mice are 
administered LPS, serum HMGB1 levels do not increase until 12-18 hours post-LPS treatment, 
which is much later than other cytokines like TNF and IL-1 that reach peak levels by 2 hours and 
4-6 hours, respectively.  Thus, the lack of HMGB1 secretion after 4 hours of LPS stimulation 
may be explained by the short exposure period, but nevertheless is required for HMGB1 release 
induced by TLO. 
It is well accepted that during necrotic cell death, membrane breakdown enables passive 
diffusion of HMGB1 from the nucleus to the external environment (Gauley & Pisetsky, 2009).  
However, the pathway(s) that govern HMGB1 translocation from the nucleus to the cytoplasm 
before active secretion are not well understood.  First, the movement of HMGB1 from the 
nucleus to the cytoplasm is the hyperacetylation of HMGB1 on many of its 43 lysine residues 
(Bonaldi et al., 2003).  It is unknown what occurs downstream of cellular activation to bring 
about HMGB1 hyperacetylation.  Second, once HMGB1 is out of the nucleus, it must enter the 
cytoplasm or compartments within the cytoplasm.  After 18 hours of LPS stimulation, HMGB1 
has been observed to re-localize from the nucleus to cytoplasmic Lamp-1+EEA-1- 
endolysosomes in primary human monocytes (Gardella et al., 2002).  In another study, a Caco-2 
enterocyte cell line stimulated with a mix of IFN-γ, IL-1β, and TNF over 24h showed HMGB1 
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localization to multivesicular bodies (Liu et al., 2006).  Third and last, HMGB1 must be 
externalized to the extracellular environment.  Data on mechanisms of HMGB1 secretion is 
limited, but one such mechanism has been suggested in the above Caco-2 study where HMGB1 
was found to be associated with exosomes.  It cannot be excluded that other mechanisms are also 
responsible for the active secretion of HMGB1.   
In our study, we observe HMGB1 relocalization from the nucleus to the cytoplasm within 
15 minutes post-treatment with the low dose of TLO.  The punctate staining of HMGB1 in the 
cytoplasm suggests localization to vesicular compartments, but additional study will be required 
to test this hypothesis.  Up to this point, the localization pattern of HMGB1 is similar in both the 
WT and NLRP3 KO BMDM.  However, by 30 minutes post-TLO treatment, HMGB1 relocalizes 
to the nucleus for most of the NLRP3 KO BMDM and some of the WT BMDM.  However, a 
portion of the WT BMDM lack strong HMGB1 staining in the nucleus or cytoplasm, suggesting 
HMGB1 release from the cells.  These results are in line with the western blotting data showing 
that low dose TLO-induced HMGB1 release occurs for WT, but not NLRP3 KO BMDM.  
Furthermore, these findings implicate NLRP3 in the process for HMGB1 to exit the cell.  It is 
possible that NLRP3 plays an active role in shuttling HMGB1 out of the cells once it is in the 
cytoplasm or cytoplasmic vesicles by some unknown mechanism.  However, given that we found 
a role for NLRP3 in causing LDH release, it may be more likely that NLRP3 mediates a slower 
breakdown of cellular structures (compared to the NLRP3-independent rapid necrosis initiated 
by a high dose of TLO) such that LDH and HMGB1 can diffuse out.  Further study is needed to 
determine the exact role that NLRP3 is playing to allow HMGB1 release after exposure to lower 
doses of TLO. 
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In summary, we have shown that TLO, a pore-forming toxin from the cholesterol-
dependent cytolysin (CDC) family, initiates different cell death programs in LPS-primed murine 
macrophages based on dosage.  A high dose of toxin leads to rapid necrotic cell death 
characterized by passive release of LDH and HMGB1.  On the other hand, a low dose of toxin 
causes a necrotic cell death program characterized by NLRP3-dependent LDH release and 
HMGB1 release that is regulated by NLRP3, caspase-1, and cathepsin B activities.  This is the 
first study to find a role for both caspase-1 and cathepsin B in BMDM cell death initiated by a 
NLRP3 inflammasome stimulator, to visualize HMGB1 localization in cells expressing or 
lacking NLRP3, and to identify a member of the CDC family as an inducer of HMGB1 release 
and a novel cell death pathway.  The findings of these studies contribute to the understanding of 
how HMGB1 release is regulated, which could be useful for the development of therapeutics 
aimed to control HMGB1 release into the extracellular environment.  This would be important 
given that HMGB1 contributes to many inflammatory diseases.  Additionally, understanding 
how innate immune cells sense and respond to bacterial virulence factors such as CDC could be 
useful in understanding both bacterial pathogenesis as well as subsequent host responses. 
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4.0  EXPLORING THE ROLE OF P2X7 ACTIVATION IN THE POTENTIATION OF 
CHOLESTEROL-DEPENDENT CYTOLYSIN-INDUCED PORE FORMATION  
4.1 HYPOTHESIS 
We generated a toxin-resistant variant of a myeloid cell line that while able to bind toxin, was 
inefficiently perforated, with reduced adenosine triphosphate (ATP) release.  Diminished 
sensitivity to exogenous ATP was also observed in the variant and was associated with decreased 
expression of purinergic receptor P2X7, known to initiate pannexin-1-mediated pore formation.  
Pharmacologic inhibition of ATP or P2X7 reduced toxin-induced functional pore formation in 
the parental cell line. These data implicate ATP release and P2X7 activation as important 
components in the response of myeloid cells to CDC toxins, with potential roles in the 
potentiation of toxicity during Gram-positive bacterial infection.  We hypothesize that CDC-
induced pore formation is potentiated by the activities of ATP and P2X7. 
4.2 INTRODUCTION 
The cholesterol-dependent cytolysin (CDC) family of exotoxins plays an important role in 
bacterial pathogenesis.  Expressed by more than twenty species of gram-positive bacteria 
(Billington et al., 2000; Palmer, 2001), CDC confer virulence to the bacteria that secrete them.  
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Such examples are Bacillus anthracis anthrolysin O (ALO) (Shannon et al., 2003), Clostridium 
tetani tetanolysin O (TLO) (Mitsui et al., 1982), Streptococcus pyogenes streptolysin O (SLO) 
(Herbert & Todd, 1941; Bernheimer, 1948), and Streptococcus pneumoniae pneumolysin (PLY) 
(Shumway & Klebanoff, 1971; Johnson et al., 1980). In mice infected with bacteria expressing 
non-active forms of CDC toxins, survival is enhanced relative to mice infected with bacteria 
expressing wild type toxin. Direct toxicity of several CDC family members has been shown in 
vivo (Berry et al., 1989; Paton et al., 1993; Benton et al., 1995; Berry et al., 1995; Paton, 1996), 
and intravenous injection of 100 pmol of purified forms of several different CDC into mice was 
shown to cause almost immediate death (Watanabe et al., 2006).  
How CDC toxins bind to cells is generally well understood.  Interaction with cholesterol 
typically mediates attachment to the plasma membrane (Billington et al., 2000; Palmer, 2001), 
although the CDC family member intermedilysin (ILY) binds exclusively to human CD59 
(Giddings et al., 2004; Polekhina et al., 2005; Soltani et al., 2007), a late stage complement 
inhibitor on mammalian cells.  After binding to cholesterol in a lipid bilayer, CDC monomers 
undergo a conformational change from a soluble to hydrophobic form followed by 
oligomerization of monomers into a pre-pore complex and then membrane insertion for final 
pore conversion (Tweten, 2005; Cocklin et al., 2006).  Between 40 and 80 monomers assemble 
to form a full-sized pore up to 30nm in size, but in some cases incomplete pores or arcs are 
formed particularly at low concentrations of toxin monomers (Billington et al., 2000).  Each 
monomer contains four domains that mediate assembly and pore formation.  Domain four, which 
contains a conserved undecapeptide sequence, is important for binding to cholesterol, while 
regions of other domains participate in oligomerization. It should be noted that ALO and several 
other CDC have also been shown to stimulate rapid IκBα degradation and p38 MAPK 
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phosphorylation in mouse macrophages, which was associated with increased transcription of IL-
1β, IL-6, and TNF-α genes and later apoptotic death (Malley et al., 2003; Park et al., 2004a; Ito 
et al., 2005).  The signaling pathway was shown to involve a TLR4-dependent pathway that was 
independent of toxin lytic activity.  In fact, CDC have been shown to bind directly to TLR4 
(Srivastava et al., 2005).   
Formation of pores in the plasma membrane leads to disruption in osmotic balance and if 
left unrepaired, ultimately cell death.  The lethal effects of CDC on cells can be demonstrated 
using assays measuring uptake of fluorescent or colorimetric dyes by exposed cells (Mosser & 
Rest, 2006).  This has revealed large differences in susceptibility of different cells to these toxins 
that cannot be readily explained by minor differences in cellular cholesterol content, which is 
relatively constant between cell types.  Since CDC-perforated cells are capable of resealing their 
pores (Walev et al., 2001b; Husmann et al., 2006; Idone et al., 2008), it is possible that 
differences in pore-resealing machinery are responsible for resistance or susceptibility of cells to 
these toxins.  This has not yet been demonstrated however.  It is also possible that pores formed 
by CDC might cause release of soluble factors that could act in an autocrine or paracrine fashion 
to trigger cellular responses, leading to death.   
Using a previously described cell line (FSDC) (Girolomoni et al., 1995) derived from 
fetal mouse skin with myeloid dendritic cell properties, we generated a toxin-resistant cell line 
by selection with increasing concentrations of CDC family member TLO.  We used this variant 
cell line to identify a potential role for ATP and its purinergic receptor P2X7 in CDC-induced 
pore formation.  CDC may utilize this endogenous P2X7 pathway in order to bring about rapid 
cell death at the site of bacterial infection.  Studies were also conducted with primary cells or cell 
lines manipulated to express or lack P2X7 in order to define its role in CDC-induced perforation.       
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4.3 MATERIALS AND METHODS 
Toxins – Anthrolysin O (ALO) was generated as described  (Shannon et al., 2003). Tetanolysin 
(TLO) was obtained from Biomol International (Plymouth Meeting, PA).  Toxins were reduced 
with 10mM DTT (Sigma, St. Louis, MO) for 10min, 37oC before use unless indicated.  
Untreated control samples were incubated in the same buffer lacking toxin.  For reference, TLO 
has a molecular weight of 55kDa, so 1000ng/ml is equivalent to 18.3nM. 
Cell culture – The mouse fetal skin-derived dendritic cell line (FSDC) (from Dr. Paola 
Ricciardi-Castagnoli, Milan) (Girolomoni et al., 1995) was cultured in IMDM (Lonza Inc, 
Walkersville, MD) supplemented with 10% Gemcell™ FBS (Gemini Bio-Products, West 
Sacramento, CA), 2mM L-glutamine, and 500U Penicillin/500μg Streptomycin (Lonza Inc.).  
FSDC were harvested from flasks using CellStripper™ (Mediatech, Inc, Herndon, VA).  Bone 
marrow-derived macrophages were created from femurs and tibiae from wild type (gifts from 
Lisa Borghesi) and P2X7-/- (gifts from George Dubyak, Case Western Reserve University) 
C57BL/6 mice using the protocol discussed in section 2.4.  
TLO-resistant and ATP-resistant variant selection process – Wild type FSDC were 
washed with HBSS plus Ca2+/Mg2+ (Mediatech, Inc), treated with TLO for 1-2hr, 37oC in HBSS, 
washed, and cultured in fresh IMDM.  Cells were selected at bi-weekly intervals in 18.3nM, 
36.4nM, 72.7nM, and 109.1nM TLO successively. After the final selection, limiting dilution 
cloning was performed and single colonies tested for resistance to TLO-induced dye uptake.  
Clone 4 was selected from several resistant clones for subsequent use and thereafter called TLO-
resistant FSDC (TLO-r).  A similar protocol was conducted for the generation of ATP-resistant 
D2SC-1 (abbreviated D2) cells except that cells were treated with increasing concentrations of 
ATP (3mM, 6mM, 6mM, 12mM, 15mM, 15mM, and 20mM) over time.  Each treatment was 
 99 
administered for 1hr, 37oC in DMEM media supplemented with 10% Gemcell™ FBS, 2mM L-
glutamine, and 500U Penicillin/500μg Streptomycin (Lonza Inc.).  Cells were then washed, 
cultured in fresh DMEM, and grown to confluency before the next selection.  After the final 
selection, limiting dilution cloning was performed and single colonies tested for P2X7 expression 
via western blot and flow cytometry.  A final clone called D2-C1 was selected and used for 
experiments. 
Cloning and construction of cDNA encoding the mouse P2X7 receptor and mouse 
pannexin-1 – Total RNA was extracted and purified from FSDC cells using an RNeasy Mini Kit 
and RNase-Free DNase Set, as recommended by the manufacturer (QIAGEN, Valencia, CA). 
MuLV Reverse Transcriptase (Applied Biosystems, Foster City, CA) was used to synthesize first 
strand cDNA with an oligo-dT16-18 primer (Invitrogen, Carlsbad, CA) from 1µg of the purified 
total RNA at 42oC for 60 min. For mouse P2X7, a pair of the sequence specific primers with 
XhoI or EcoRI sites, respectively, were designed based on the published mouse P2X7 cDNA 
sequence (GenBank accession number NM_011027) to amplify the entire coding sequence of the 
mouse P2X7 subunit by PCR. The primers were as follows: forward primer, 5’-
AGCCTCGAGCCATGCCGGCTTGCTGCAGCT-3’; reverse primer, 5’-
CAGCGAATTCATCAGTAGGGATACTTGAAGCCACT-3’. AmpliTaq® DNA polymerase 
was used for amplification as described by the manufacturer (Applied Biosystems, Foster City, 
CA). The cycling reaction was modified as 1cycle of 95oC for 2 min, 35 cycles of 95oC for 1 
min, 62.6oC for 1min, 72oC for 3 min, with a final extension at 72oC for 10 min. PCR products 
were separated in a 1% agarose gel containing 1ug/ml ethidium bromide (Sigma, Saint Louis, 
MO) and purified with the Wizard® SV Gel and PCR Clean-Up System (Promega, Madison, 
WI). The purified PCR products were then cloned into the pGEM®-T vector (Promega, Madison, 
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WI). The screened clones were identified by XhoI and EcoRI. The resulting clones were finally 
sequenced and analyzed using DNAStar software.  The mouse P2X7 fragment from the positive 
clones was fused with double flag epitopes at the N-terminals using semi-nested PCR and cloned 
into a p2CI vector or retroviral pFB/H+ vector. The p2CI vector was derived from PCR2.1 by 
insertion of a cytomegalovirus promoter, PCR-amplified IRES-neomycin-resistant sequences 
from the pFB-Neo-LacZ vector, and poly(A) signal sequences from pcDNA3.1. The pFB/H+ 
vector was modified from a retroviral pFB/neo vector by replacement of a neomycin-resistant 
gene with a hygromycin-resistant gene. Primers with sequences of the flag epitope were designed 
based on the corresponding sequences from the pCMV-Tag 1 vector (Stratagene, La Jolla, CA). 
The Expand high fidelity PCR system (Roche Applied Science, Indianapolis, IN, USA) was used 
for all the PCR reactions. The final PCR amplicons were cloned into the p2CI vector or pFB/H+ 
vector using the appropriate restriction enzymes and the Rapid DNA ligation Kit (Roche Applied 
Science, Indianapolis, IN, USA).  
For mouse pannexin-1, a pair of the sequence specific primers with NotI or EcoRI sites, 
respectively, were designed based on the published mouse pannexin-1 cDNA sequence 
(GenBank accession number NM_019482) to amplify the entire coding sequence of mouse 
pannexin-1 by PCR. The primers were as follows: forward primer, 5’- 
TTAATTGCGGCCGCCTTGACCATGGCCATCGCCCACTTGG -3’; reverse primer, 5’- 
TGTGGAATTCGTGGGATCCTCATTAGCAGGACGGATTCAG -3’. The above AmpliTaq® 
DNA polymerase was used for amplification. The cycling reaction was modified as 1 cycle of 
95oC for 2 min, 35 cycles of 95oC for 1 min, 64.4oC for 1min, 72oC for 3 min, with a final 
extension at 72oC for 10 min. The PCR-amplified pannexin-1 fragment was cloned into a 
retroviral pFB/neo vector with NotI and EcoRI. Pannexin-1 fused with an HA tag at its C-
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terminals was generated by semi-nested PCR and cloned into the pFB/neo vector. Detailed 
plasmid maps and sequences of primers are available upon request. All of the mutants and 
corresponding sequences subcloned into vectors were verified by DNA sequencing. 
Transfection and transduction – HEK-293, gp293, D2SC-1 (abbreviated D2), and NRK 
cells were grown in complete (DMEM).  For transfection, HEK-293 cells were plated in six-well 
plates and transfected with mouse P2X7 expression constructs using LipofectamineTM LTX 
Reagent, as recommended by the manufacturer (Invitrogen, Carlsbad, CA). 2.5μg of DNA, 2.5μl 
of PlusTM reagent, and 6.25μl of LipofectamineTM LTX Reagent in 500μl of Opti-MEM® I 
Reduced Serum Medium were used per well. The cells were selected with 1 mg/ml G418 for 3-5 
weeks to generate stably transfected cell lines and maintained in 500µg/ml G418. 
For making retroviruses, retrovirus-packaging gp293 cells were plated in 6-well plates for 
1 day before co-transfection with retroviral constructs containing P2X7 or Pannexin-1 and VSV-
G vector using LipofectamineTM LTX Reagent.  4μg of retroviral constructs, 2μg of VSV-G 
vector, 5μl of PlusTM reagent, and 10μl of LipofectamineTM LTX Reagent in 500μl of Opti-
MEM® I Reduced Serum Medium were used per well with 2 ml media. Then the plates were 
incubated at 37oC for 4 hour, media replaced with 3ml of fresh media, and again incubated for 2-
3 days.  The media containing retroviruses was harvested, filtered, aliquoted, and stored at - 80oC 
prior to transduction.  For transduction, 3-4x105 D2SC-1 or NRK cells were plated in 12-well 
plates for a day before infection.  Media was replaced with 1ml of retroviral preparation 
containing 3μg polybrene and cells were incubated for 1 day.  Then, media was replaced with 
media containing selection drugs; hygromycin for mouse P2X7 and G418 for mouse pannexin-1 
to make stable cell lines.  Expression of P2X7 was assessed using surface staining with a 
monoclonal rat anti-mouse P2X7 antibody (Axxora) and goat anti-rat-Cy5 secondary antibody 
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(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) followed by flow cytometry 
analysis, by permeabilization and staining for the HA tag followed by flow cytometry, or by 
western blotting analysis as described below (P2X7 Western Blot section).     
Cholesterol assay – Cells were washed with PBS (Ca2+, Mg2+-free), lysed with 1X 
reaction buffer, and 50μg of protein equivalent (determined by Bio-Rad Bradford assay) run for 
each of two replicates using the Amplex Red Cholesterol Assay Kit (Invitrogen).  Samples were 
read at 570nm. 
ATP bioluminescence assay – 6x105 FSDC/well were adhered to 12-well plates for 2hr, 
37oC, PBS washed, and PBS control or TLO treated for 5min.  300μl supernatants were 
collected, cells were lysed with 300μl lysis buffer (Dojindo ATP kit, Gaithersburg, MD), and 
both were centrifuged 10000rpm, 10min, 4oC and assayed in duplicate using the ATP 
Determination Kit (Invitrogen).  Each well was read immediately after D-luciferin injection 
using the Berthold Orion microplate luminometer and Simplicity 2.1 software. 
Cell surface phenotyping – Cells were incubated with FITC –labeled anti-mouse I-Ab, I-
Ad, CD40, CD11c, or CD86 (BD Biosciences Pharmingen).  Flow cytometry analysis was 
conducted on a BD LSR II system with FACSDiva software (BD Biosciences) and Flow Jo 
(Tree Star, Inc., Ashland, OR). 
Bacterial phagocytosis assay – E. Coli GFP (Salter et al., 2004), grown in 100μg/ml 
ampicillin (Sigma) LB broth, was added to 2.5x105 FSDC/well for 1hr, 37oC.  Bacterial uptake 
by cells was analyzed with flow cytometry.  Plating dilutions were used to determine bacterial 
cell counts. 
LDH release assay – 4.5x105 cells were plated/well of 12-well plates overnight.  The next 
day, spent media was removed and cells were washed with PBS and incubated for 30 min with 
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DTT control buffer, various TLO concentrations, various doses of ATP, or 20μM nigericin in 
phenol red-free IMDM.  TLO was pre-bound to cells for 5 min before addition of 10% FBS to all 
wells.  1% triton X-100 was used as a control of complete cell lysis and maximal LDH release.  
Supernatants were collected and assayed in duplicate for LDH content using the LDH 
Cytotoxicity Assay Kit from Cayman Chemical Company (Ann Arbor, MI).  % cytotoxicity was 
calculated as a percentage of LDH release from experimental samples over total Triton X-100 
LDH release, which was set to 100%.  
Dye uptake pore assays – Flow cytometry:  Cells were washed with PBS containing Ca2+ 
and Mg2+ (Lonza Inc.), an equivalent volume of cells (62.5μl, 2.5x105) was incubated with toxin 
or ATP dilution in filtered 0.1% BSA (Sigma) (62.5μl), for indicated times at 37oC.  Cells were 
washed in PBS, stained with 5μM propidium iodide (Sigma), 5μM ethidium bromide (Sigma), 
5μM YO-PRO-1 (Invitrogen), or 5μM DAPI and analyzed by flow cytometry.  Trypan blue 
staining on plates: Cells plated at 3.0-4.0x105/well of 12-well plates were PBS washed and 
exposed to 350μl toxin or ATP dilutions made in filtered 0.05% BSA for 2hr, 37oC.  
Supernatants were removed, cells were stained with 5% trypan blue (Sigma), and >100 cells/well 
counted.  For inhibition experiments: 15mM methyl-β-cyclodextrin (MβCD, Sigma) in serum-
free IMDM was pre-incubated with cells for 30min; 0.6mM oxidized ATP (oATP, Sigma) was 
pre-incubated with cells for 2hr; and 24U/ml apyrase (Sigma) was added simultaneously with 
toxin or ATP. 
P2X7 Western Blot – Protein concentration of lysates was normalized with Bradford assay 
and lysates loaded onto SDS-PAGE.  Following electrophoretic transfer, membranes were 
probed with 1:200 primary rabbit anti-mouse P2X7 (Sigma), 1:5000 secondary donkey anti-
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rabbit Ig-HRP (Biolegend), and proteins detected with ECL substrate (PerkinElmer Life 
Sciences).  Blots were imaged with the KODAK Image Station 2000R. 
Preparation of ELISA supernatants and IL-1β ELISA – See section 2.4. 
Toxin-binding assays – Adsorption assay:  This assay was adapted from (Duncan & 
Buckingham, 1978).  2.5x105 FSDC/well of a 12-well plate adhered for 2hr, 37oC were treated 
with serum-free IMDM or 15mM MβCD for 30min, 37oC.  A TLO pore assay was carried out 
and supernatants were collected, centrifuged 10min, 1200xg, 4oC, and tested on THP-1 in a 
separate pore assay.  As a control, cell-free wells were treated with toxin before application on 
THP-1 and this represents maximum toxin carryover.  TLO-Cy5 labeling and direct binding 
assay:  A monofunctional NHS-Ester Cy5 (GE Healthcare) vial was resuspended in 20μl DMSO 
and diluted 1:100.  10μg TLO (10μl) or 10μg BSA control (10μl) was labeled with 2μl of PBS 
(control) or 2μl of 1:100 Cy5 for 10min, RT, in the dark.  To quench the reactions, 10μg of BSA 
was added and incubated 10min, RT, in the dark.  Labeling reactions were used in flow 
cytometry binding and pore assays where Cy5 signal and YO-PRO-1 uptake were measured.   
Live cell imaging of toxin-cell interactions – Live cell imaging was performed using a 
Nikon 2000E inverted microscope with a 60X 1.45 NA oil immersion optic, an ASI (Eugene, 
OR) Piezo driven XYZ stage, a Yogagawa spinning disk confocal head and Prairie Technology 
(Madison WI) laser bench.  Images were collected using a Cascade II backthinned 512B camera 
(Photometrics, Tucson AZ).  Cells were maintained at 37oC in the microscope with a PDMI2 
stage (Harvard Scientific, Holliston MA).  Software control of the microscope was with 
Metamorph 7.0, (Molecular Devices, Downingtown, PA).  Cells were grown overnight in 
collagen-coated glass-bottomed #1.5 MatTek culture dishes (MatTek, Ashland, MA).   Images 
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were collected every 10 sec both before and after addition of Cy5-labeled toxin.  Data analysis 
was performed using Metamorph software.   
Immunofluorescent staining of fixed cells – Cells were allowed to adhere on collagen-
coated glass-bottomed MatTek culture dishes before washing with PBS and fixation using 2% 
paraformaldehyde, followed by permeabilization with 0.1% triton x-100 in PBS.   Samples were 
then incubated with phalloidin-texas red (actin stain), Hoescht 33258 (nuclear stain), and anti- 
P2X7 monoclonal antibody (HANO43, Axxora, San Diego, CA) followed by Alexa488-labeled 
anti-rat IgG.   Confocal z-sections at the mid-plane of cells were collected using an Olympus 
Fluoview 1000 microscope.    
Graphical and Statistical Analysis – All graphing analyses were completed using 
Microsoft Excel (Microsoft, Redmond, WA), GraphPad Prism (GraphPad Software, Inc., San 
Diego, CA), and FlowJo (Tree Star, Inc.).  Statistical analysis (student’s paired t-test) was 
conducted with GraphPad Prism.  P-values < 0.05 = *, p-values < 0.01 = **, and p-values > 0.05 
= not significant (ns). 
4.4 RESULTS 
4.4.1 Isolation of a toxin-resistant dendritic cell line variant 
A toxin-resistant cell line was generated from wild type FSDC as described in Experimental 
Procedures and Figure 4-1.  One of the clones selected (TLO-r) was highly resistant to TLO 
compared to wild type cells, as shown by PI uptake in Figure 4-2A.  TLO-r was approximately 
four-fold more resistant to toxin-induced dye uptake, suggesting that this phenotype allowed the 
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cell to avoid lysis during the selection process.  TLO-r was also less susceptible to pore 
formation induced by ALO (Figure 4-2A), demonstrating that the resistance phenotype was not 
TLO-specific.  Moreover, inhibiting the pore-forming activity of these toxins with free 
cholesterol prevented dye uptake presumably because the toxins could no longer interact with the 
cell surface cholesterol (Figure 4-2A).  To test whether exposure to CDC might result in pores 
too small to admit PI into TLO-r, ethidium bromide (394Da) and YO-PRO-1 (629Da) were 
tested in addition to PI (668.4Da) (Figure 4-2B).  Similar results were obtained, suggesting that 
differences in pore size relative to the wild type cells are unlikely to explain TLO-r resistance to 
CDC. To visualize toxin-induced responses in wild type and variant cells, live cell imaging was 
used (Figure 4-2C).  We observed that WT FSDC underwent extensive blebbing and loosened 
attachment from culture dishes within minutes of exposure to TLO, while TLO-r cells appeared 
unaffected.  These results demonstrate that responses of variant TLO-r cells to CDC are 
profoundly different from that of the wild type parental FSDC.  
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Figure 4-1: Schematic diagram of the selection process.   
Wild type FSDC cells were first subjected to a toxic dose of 18.3nM TLO.  Surviving cells were cultured and 
subjected to further rounds of selection with increasing concentrations of TLO over a period of several months.   
Following limiting dilution cloning, isolates were screened for sensitivity to toxins by measuring propidium iodide 
(PI) uptake. 
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Figure 4-2: Generation of a toxin-resistant dendritic cell line variant.   
(A) Cells were exposed to TLO (upper panels) or ALO (lower panels), with or without pre-exposure to 1ug/ml free 
cholesterol (right panels), for 30 min at the indicated concentrations followed by PI staining and flow cytometry 
analysis, with the percentage of PI+ cells indicated.  TLO-r are insensitive to TLO and ALO amounts that induce 
pore formation in wild type FSDC.  Data represents mean +/- SEM for 3 independent experiments each for TLO and 
ALO; student’s paired t-test comparing FSDC and TLO-r for TLO or ALO treatment; * = p<0.05, ** = p<0.01. (B) 
Cells were exposed to TLO for 30 min at the indicated concentrations followed by staining with ethidium bromide 
(EtBr), YO-PRO-1, or propidium iodide (PI) and flow cytometry analysis with the percentage of % dye-positive 
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cells indicated.  There was no difference in dye uptake for all three dyes tested, which represents a range of different 
sized molecules capable of entering through toxin-induced pores.  Again, TLO-r are more resistant to dye uptake 
compared to FSDC regardless of dye type.  Data represents mean +/- SEM for 3 independent experiments for each 
of the three dyes. (C) Live cell microscopy of FSDC and TLO-r treated with 54.5nM TLO (non-reduced).  
Differential Interference Contrast (DIC) imaging was performed every 5s with the images shown collected 5 min 
after toxin addition.  FSDC parental cells show blebbing and eventual detachment from the substrate while TLO-r 
maintain normal morphology and attachment to the dish.  Data are representative of multiple experiments. 
4.4.2 TLO-r does not differ from wild type cells in cholesterol content or ability to bind 
TLO 
Since cholesterol is the major cell surface receptor for CDC, we hypothesized that lower levels 
of cholesterol in TLO-r could explain their apparent defect in pore formation after CDC 
treatment.  Whole cell lysates of WT and TLO-r cells were tested for cholesterol content using a 
standard colorimetric assay.  When normalized to total protein (Figure 4-3A) no significant 
differences in cholesterol content were observed.  This suggests that wild type and variant cells 
do not differ significantly in the major cell surface receptor for CDC.  To directly test CDC 
binding to cells, two different assays were used.  In the first, the ability of wild type or variant 
cells to deplete toxin in solution by adsorption was determined.  WT and TLO-r cells were 
exposed to TLO for 30 min to allow binding, and supernatants were harvested and subsequently 
incubated with a reporter cell line highly sensitive to CDC toxicity.  Pore formation was then 
measured in the reporter cell line.  Figure 4-3B shows that WT and TLO-r were equally able to 
adsorb TLO at all concentrations tested.  In this assay, ability of cells to adsorb TLO was 
dependent on cholesterol, since it could be inhibited using the cholesterol chelating compound 
methyl-β-cyclodextrin (MβCD).  The second method used to test binding was to label TLO with 
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the fluorescent dye Cy5 followed by incubation with cells and flow cytometry or fluorescence 
microscopy to measure cell-associated fluorescence.  TLO-Cy5 bound to both WT and TLO-r 
cells similarly, above levels seen with a control protein BSA that was Cy5-labeled using the 
same protocol (Figure 4-3C).   Preparations of Cy5-labeled TLO induced pore formation at 
similar concentrations as unlabeled TLO, suggesting that dye conjugation did not affect the pore 
forming ability of the protein.  Binding was inhibited by MβCD, establishing cholesterol 
dependence (Figure 4-3C).  Interaction of Cy5-TLO with the cell surface was determined using 
live cell microscopy (Figure 4-3D).  Punctate staining of the plasma membrane was observed for 
both WT and TLO-r within 30 sec of Cy5-TLO addition, with subsequent internalization seen 
primarily in TLO-r, suggestive of pinocytosis.   In summary, these data show that variant TLO-r 
cells do not have reduced levels of cholesterol, the major receptor for CDC, and exhibit no 
apparent defects in toxin binding.   
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Figure 4-3: Total cholesterol levels and TLO binding levels are unaltered in TLO-r mutant cells.   
(A) Total cholesterol content was measured using an Amplex Red assay and results normalized to total protein 
content.  Cholesterol levels do not differ significantly between FSDC and TLO-r (mean +/- SEM, n = 6, student’s 
paired t-test where p = 0.0551).  (B) FSDC and TLO-r have a similar capacity to adsorb TLO from supernatants.  
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FSDC or TLO-r were incubated 30 min with TLO concentrations indicated on the x-axis or left untreated.  As a 
control for maximum carryover of TLO in supernatants, TLO was incubated in wells containing no cells (cell-free).  
Where indicated, 15mM MβCD was incubated in wells containing FSDC, TLO-r, or no cells 30min prior to TLO 
treatment.  Supernatants were collected from wells, centrifuged, and added to reporter THP-1 cells for 30 min.  
THP-1 were PI-stained and analyzed by flow cytometry.  These results represent data obtained in 2 independent 
experiments.  (C)  TLO binds both FSDC and TLO-r at similar levels.  TLO was labeled with Cy5 and incubated 30 
min with cells before analysis of binding (Cy5) and pore formation (YO-PRO-1) by flow cytometry.  TLO does not 
lose activity as a consequence of labeling as indicated by comparable pore formation relative to unlabeled TLO.   
BSA was also labeled with Cy5 and incubated with cells in parallel to show that the labeling reaction does not 
generate non-specific products toxic to cells.  TLO-Cy5 binding to cells and subsequent pore formation are both 
inhibited by pre-incubation of cells with 15mM MβCD, confirming cholesterol-dependence.  These results represent 
data obtained in 2 independent experiments. (D) Visualization of Cy5-labeled TLO binding to FSDC (panels 1 and 
3) and TLO-r (panels 2 and 4) by live cell imaging.  Cells were imaged continuously before and after addition of 
54.5nM TLO-Cy5 (non-reduced), with confocal z-stacks collected at approximately 10s intervals over 15 min.  
Images shown were collected 5 min after addition of labeled toxin, and represent mid-plane z-sections (panels 1 and 
2) and maximal projections (panels 3 and 4).   Binding to both cell types is similar in intensity, consistent with (C) 
above, but internalization of the toxin is evident for TLO-r (panel 2) and absent in FSDC (panel 1).  Data are 
representative of multiple experiments. 
4.4.3 Phenotypic characterization of TLO-r cells relative to wild type 
The results described above demonstrate that the pore forming ability of CDC can be dissociated 
from their ability to bind to cells.  This was unexpected and prompted us to further explore 
phenotypic changes that might be associated with the toxin-resistant phenotype of TLO-r.  A 
panel of monoclonal antibodies reactive against surface markers was tested for reactivity with 
both variant and wild type, and expression of MHC class II (I-Ab, I-Ad), CD40, CD11c, and 
CD86 were unchanged in TLO-r (Figure 4-4A).  Phagocytosis of bacteria, a characteristic of 
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myeloid lineage cells such as FSDC (Figure 4-4B) was also unchanged as shown by measuring 
uptake of EGFP-expressing E. coli. These data combined with the similar morphology observed 
for the wild type and TLO-r cells before toxin exposure suggest that the variant has not 
undergone any gross changes in phenotype that can readily explain toxin resistance. 
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Figure 4-4: TLO-r retain the surface phenotype and phagocytic function of the FSDC parental cell line.  
(A)  FSDC and TLO-r were left unstained or stained with antibodies against MHC class II (I-Ab, I-Ad), CD40, 
CD11c, and CD86 followed by flow cytometry analysis.  Profiles are similar for FSDC and TLO-r.  These results 
are representative of 2 independent experiments.  (B) FSDC and TLO-r were incubated with E. coli-expressing GFP 
at various doses for 1hr to allow phagocytosis followed by flow cytometry analysis.  E. coli-GFP amounts were 
determined by plating in order to calculate a ratio of E. coli-GFP to cells.  A similar percentage of FSDC and TLO-r 
phagocytose bacteria at all ratios tested. 
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4.4.4 TLO induces higher levels of ATP release from wild type cells compared to TLO-r 
Since toxin-exposed TLO-r cells are perforated less than wild type cells as determined by dye 
uptake assays, we considered it likely that release of cytosolic contents from the variant cells into 
the extracellular environment might also be reduced.  To test this, we measured ATP levels, a 
commonly used marker of cell viability (Petty et al., 1995; Walev et al., 2001b) in cell fractions 
and supernatants of both wild type and variant cells exposed to TLO.  As shown in Figure 4-5, 
TLO treatment induced higher levels of ATP release from WT cells as compared to the variant.  
Inversely, variant cells retained more of their cellular ATP compared to wild type cells.  
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Figure 4-5: TLO induces ATP release from FSDC, a process impaired in TLO-r.   
TLO induces more ATP release from FSDC compared to TLO-r.  FSDC and TLO-r were treated for 5min with 
various concentrations of TLO as indicated.  300μl supernatants were collected from wells and cells were lysed with 
300μl of lysis buffer.   ATP in equivalent volumes of supernatants and cell lysates was measured by an ATP 
bioluminescence assay.  Actual amounts of ATP (pmol) in supernatants or lysates are shown in the bottom panel 
while the percentage of ATP in supernatants or lysates was calculated based on total ATP, which is the combined 
amount of ATP in supernatants and lysates (top panel).  With increasing TLO dose, the cells release ATP and this is 
mirrored in the decreased percentage ATP inside cells.  FSDC show greater ATP release and greater loss of cellular 
ATP compared to TLO-r (mean +/- SEM, n = 3, student’s paired t-test; ** = p<0.01). 
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4.4.5 TLO-initiated pore formation in FSDC is potentiated by extracellular ATP and may 
require P2X7 activity 
Release of ATP from cells can be considered a marker of viability, but it is also known that ATP 
in the extracellular environment can have profound effects on cells expressing purinergic 
receptors.  This includes myeloid lineage cells, which express multiple members of this family 
(Di Virgilio et al., 2001; Bours et al., 2006) including the P2X7 receptor that can form pores in 
cells after prolonged exposure to millimolar concentrations of ATP (Chessell et al., 2001; Aga et 
al., 2002).  Recently, pannexin-1 has been identified as a protein that binds to P2X7 in 
membranes as part of the pore forming complex (Pelegrin & Surprenant, 2006; Kanneganti et al., 
2007; Locovei et al., 2007).  We hypothesized that CDC might exert their effects on myeloid 
cells such as FSDC through the release of ATP, which could then act in an autocrine or paracrine 
fashion to stimulate P2X7-dependent pore formation.  This suggests that exogenous dye influx 
and ATP efflux from intracellular stores would be maximal when pores generated both by 
assembled toxin subunits and by activated P2X7 receptors were present on cells.  To address this 
question, we used the enzyme apyrase to degrade ATP (Cohn & Meek, 1957) in extracellular 
medium during exposure of FSDC cells to TLO, and measured subsequent pore formation.  As 
shown in Figure 4-6, apyrase treatment reduced TLO-induced dye uptake by cells, consistent 
with a role for ATP in toxin-induced pore formation.  Additionally, we used irreversible P2X7 
inhibitor oxidized ATP (oATP) and measured pore formation via trypan blue dye uptake.  
Though not statistically significant, a trend was observed where TLO-induced dye uptake was 
decreased in the presence of oATP, especially at lower TLO doses, whereas no difference was 
observed at higher TLO doses (Figure 4-7).  These data suggest a possible role for P2X7 in CDC-
induced pore formation. 
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Figure 4-6: Apyrase inhibits TLO-induced pore formation in FSDC.   
Pore formation in FSDC caused by TLO can be reduced by ATP-degrading enzyme apyrase.  Wild type parental 
FSDC were treated with TLO or ATP (control) in the presence or absence of 24U/ml apyrase for 30min.  Cells were 
then incubated with PI and analyzed by flow cytometry for PI uptake.  Apyrase inhibited PI uptake by FSDC treated 
with both TLO and ATP (mean +/- SEM, n = 4, student’s paired t-test; * = p<0.05). 
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Figure 4-7: oATP inhibits TLO-induced trypan blue uptake by FSDC.   
Pore formation in FSDC caused by TLO can be reduced by irreversible P2X7 inhibitor oATP.  Wild type parental 
FSDC were treated with TLO in the presence or absence of 0.6mM oATP for 30min.  Cells were then incubated 
with trypan blue and at least 100 cells counted to calculate percentage of trypan blue-positive cells.  oATP inhibited 
trypan blue uptake by FSDC treated with low doses of TLO (mean +/- SEM, n = 5, student’s paired t-test). 
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4.4.6 TLO-r variant cells have reduced levels of P2X7 receptor and reduced 
responsiveness to ATP   
A role for both ATP and P2X7 in toxin-induced pore formation is suggested by the previous data 
showing that toxin-induced dye uptake was decreased in the presence of inhibitors of ATP and 
P2X7.  Moreover, the data above also suggested that the defect in ATP release observed in the 
toxin-resistant variant might result from loss of P2X7 expression, since activation of this receptor 
by ATP can induce further ATP release (Anderson et al., 2004; Suadicani et al., 2006).  Western 
blot analysis showed that TLO-r cells expressed 10-15% of wild type P2X7 levels and reduced 
levels were also observed by fluorescence microscopy of fixed and permeabilized cells stained 
with anti-P2X7 antibody (Figure 4-8A).   P2X7 deficiency would be expected to impair ATP-
induced pore formation and as shown in Figure 4-8B, TLO-r cells treated with 3mM ATP were 
indeed less susceptible to ATP-induced pore formation than wild type cells.   
Taking all of the data together, a model (Figure 4-9) can be suggested whereby CDC 
form pores in cell membranes, which allows the release of ATP that can act in an autocrine or 
paracrine fashion on P2X7-expressing cells.  P2X7 activation leads to recruitment of pannexin 1, 
which has been implicated in large pore formation (Pelegrin & Surprenant, 2006; Locovei et al., 
2007) and has also been linked to the activation of the inflammasome (Pelegrin & Surprenant, 
2006; Kanneganti et al., 2007), which is responsible for the maturation of pro-IL-1β to its mature 
17kDa form.   
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Figure 4-8: TLO-r express less purinergic receptor P2X7 compared to FSDC, which affects downstream ATP-
mediated pore formation.   
(A) Total P2X7 expression is decreased in TLO-r compared to FSDC.  For western blotting (top panel), equivalent 
amounts of total protein (20μg) for FSDC and TLO-r were probed for P2X7, which is approximately 85kDa in size.  
The 85kDa band is much reduced in intensity for TLO-r compared to FSDC.  It should be noted that TLO-r and 
FSDC lysates were run on two different parts of the same gel.  For fluorescence microscopy, FSDC and TLO-r were 
fixed, permeabilized, and stained with phalloidin-texas red actin stain (red), Hoescht 33258 nuclear stain (blue), and 
anti-P2X7 monoclonal antibody followed by Alexa488-labeled anti-rat IgG (green).  These confocal z-sections at the 
mid-plane of cells show brighter P2X7 staining in FSDC as opposed to the dim staining seen in TLO-r. (B) The pore 
formation response of TLO-r to ATP treatment is decreased compared to FSDC.  FSDC or TLO-r were left 
untreated or treated with 3mM ATP over various time points (top panel) or with varying ATP doses for 30min 
(bottom panel).  Cells were incubated with PI and analyzed by flow cytometry.  PI uptake increases for FSDC with 
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time and at all doses tested whereas dye uptake by TLO-r is closer to background levels.  Data was analyzed with 
the student’s paired t-test comparing ATP-treated FSDC versus ATP-treated TLO-r at each time point or each dose 
for 3 independent experiments.  Data represented as mean +/- SEM.  Student’s paired t-test; * = p<0.05, ** = 
p<0.01.  
 
 
Figure 4-9: Model of CDC-initiated, P2X7-potentiated pore formation.   
Gram-positive bacteria secrete CDC that bind cholesterol on eukaryotic cells, leading to pore formation and 
subsequent intracellular ATP release.  Extracellular ATP then binds (in an autocrine or paracrine manner) to 
purinergic receptor P2X7, causing pannexin-1-mediated pore formation that allows a feedback loop of ATP release 
through these pores.  P2X7 activation has also been coupled to the activation of the inflammasome, a molecular 
platform for the processing of pre-formed stores of cytokines such as IL-1β. 
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4.4.7 Determination of the role of P2X7 in CDC-induced pore formation using P2X7-
deficient or P2X7-expressing cell lines 
Aside from the ATP and P2X7-related variations in TLO-r already discussed, we also observe 
defects in pro-IL-1β, TNF-α, and IL-6 production and/or secretion after LPS stimulation 
compared to FSDC (Figure 4-10).  As a result of the defect in pro-IL-1β production, TLO-r also 
lack the ability to secrete processed IL-1β (data not shown).  Due to the many identified and 
potentially unidentified defects in TLO-r, it is difficult to solely attribute the perforation-
resistance phenotype to P2X7 expression and function.  Therefore, we engineered several P2X7-
deficient or P2X7lo-expressing cell lines to express or overexpress, respectively, P2X7 and 
assessed pore formation via dye uptake as measured by flow cytometry or LDH release.  
Expression of P2X7 was verified using immunostaining and flow cytometry (Figure 4-11).  
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Figure 4-10: TLO-r have defects in pro-inflammatory cytokine production.  
(A) FSDC and TLO-r were left untreated or treated with 1μg/ml LPS for 24hr in complete media, lysed, and 20μg of 
protein sample immunoblotted for pro-IL-1β content.  LPS-treated FSDC, but not LPS- treated TLO-r produce pro-
IL-1β. (B-C) FSDC and TLO-r were left untreated or treated with 1μg/ml LPS for 24hr in complete media and 
supernatants were collected analyzed by ELISA for (B) TNF-α or (C) IL-6.  TLO-r produce less of both cytokines 
compared to FSDC. 
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Figure 4-11: P2X7 expression on transfected or transduced cell lines 
(A) P2X7 expression on WT or C1 (ATP-resistant) D2SC-1 (D2) cells that were not transduced or transduced with 
vector only or a P2X7-expressing retrovirus.  Cells were left unstained or stained with a P2X7 antibody followed by 
addition of a goat anti-rat-Cy5 secondary antibody and analysis via flow cytometry.  Relative MFI represents the 
ratio of MFI (P2X7 antibody staining) to MFI (No antibody). (B) P2X7 expression, represented as % positive cells, 
on HEK 293 cells transfected with vector only or a P2X7 construct.  Staining and analysis were conducted as in part 
A. (C) P2X7 and pannexin-1 expression, represented as % positive cells, on NRK cells transduced with mock, P2X7, 
pannexin-1-HA (panx1-HA), P2X7-pannexin-1-HA (P2X7-panx1-HA), pannexin-1 (panx1), or P2X7-pannexin-1 
(P2X7-panx-1) retrovirus.  P2X7 staining and analysis were conducted as in part A.  Pannexin-1 expression was 
assessed through permeabilization and staining for the HA tag, followed by flow cytometry.  Reliable reagents to 
directly test the expression of pannexin-1 are not currently available, so only P2X7 expression could be assessed for 
NRK expressing panx1 or P2X7-panx1. 
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We observed no difference in PI uptake by the D2 dendritic cell line transduced with 
control vector or P2X7 for any of the TLO concentrations tested (Figure 4-12A).  As expected, 
ATP induced more PI uptake by P2X7-overexpressing D2 compared to vector only control.  
Similar amounts of PI uptake were observed with wild type D2 cells and D2-C1 treated with 
various TLO doses (Figure 4-12B).  D2-C1 cells represent an ATP-resistant cell line selected 
using a similar scheme as shown in Figure 4-1, except that ATP was used as the selection agent. 
These cells take up little PI compared to wild type D2 after exposure to ATP.  Similarly, P2X7-
negative HEK 293 cells were transfected with control vector or P2X7 and PI uptake (Figure 4-
12C) or LDH release (Figure 4-12D) was assessed. BzATP and ATP induce modestly more PI 
uptake and LDH release, respectively, in HEK293-P2X7 compared to HEK293-vector.  
However, no differences in PI uptake or LDH release were observed with various doses of TLO.  
Lastly, the roles of both P2X7 and pannexin-1 in TLO-induced pore formation were tested using 
P2X7- and pannexin-1-negative NRK cells transduced with vector alone, P2X7 alone, pannexin-1 
alone, or P2X7 and pannexin-1 together.  No major differences in PI (Figure 4-12E, upper panel) 
or DAPI (Figure 4-12F, upper panel) uptake were observed between all cell lines treated with 
various doses of TLO.  On the other hand, P2X7-expressing NRK took up DAPI, but not PI, after 
ATP treatment (Figure 4-12E-F, bottom panels).  Unexpectedly, pannexin-1 appeared to play no 
role in dye uptake.  Together, these data suggest that P2X7 does not play a role in TLO-induced 
pore formation.     
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Figure 4-12: No difference in CDC-induced pore formation for P2X7-expressing versus P2X7-deficient cell 
lines.  
(A-B) Dendritic cell line D2 (D2-WT) were retrovirally transduced to express P2X7 (D2-P2X7) or control vector 
(D2-vector) or were selected for resistance to ATP-induced pore formation (D2-C1).  Each cell type was treated 
with DTT control buffer, various concentrations of TLO, or 3mM ATP and analyzed for PI uptake via flow 
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cytometry.  D2-P2X7 and D2-WT were more sensitive to ATP-induced dye uptake compared to D2-vector and D2-
C1, respectively.  There was no difference in TLO-induced dye uptake for either pair of cells.  Data represents mean 
+/- SEM for three independent experiments.  (C-D) HEK 293 cells were stably transfected to express P2X7 (HEK 
293-P2X7) or control vector (HEK 293-vector) and treated with DTT control and various concentrations of TLO, 
BzATP, ATP, or nigericin.  Cells were analyzed for PI uptake via flow cytometry (C) or LDH release as compared 
to total after Triton X-100 treatment (D).  BzATP and ATP induce somewhat more PI uptake and LDH release, 
respectively, from HEK293-P2X7 while no difference is observed for all TLO concentrations tested. (E-F) NRK 
cells were retrovirally transduced to express control vector (mock), P2X7, pannexin-1 (panx), HA-tagged pannexin-1 
(panx-HA), P2X7 + pannexin-1 (P2X7-Panx), or P2X7 + HA-tagged pannexin-1 (P2X7-Panx-HA) and treated with 
various doses of TLO (top panels) or 3mM ATP (bottom panels).  PI (left panels) or DAPI (right panels) dye uptake 
was assessed via flow cytometry.  Little difference in PI or DAPI uptake was observed after TLO treatment for all 
cell lines while DAPI uptake was evident for P2X7-expressing NRK treated with ATP.  
4.4.8 Determination of the role of P2X7 in CDC-induced IL-1β release using P2X7-
deficient primary macrophages 
We next explored the role of P2X7 in another downstream effect of TLO: IL-1β release (see 
section 1.2 for a review and chapter 2).  To test this, we used primary macrophages, which have 
the capacity to generate large stores of pro-IL-1β after TLR priming, that normally express P2X7 
or ones that were deficient in this receptor.  As shown in Figure 4-13, ATP, nigericin, and TLO 
induce the secretion of IL-1β from LPS-primed BMDM, but only ATP-induced IL-1β secretion 
is dependent on P2X7.  These data serve as further evidence that P2X7 does not play a role in 
TLO-induced effects.  
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Figure 4-13: TLO-induced IL-1β release from BMDM is P2X7-independent.  
BMDM generated from wild type (WT) or P2X7-/- mice were primed with LPS for 4 h and then treated with control 
(DTT-containing buffer), ATP, TLO, or nigericin for 30 min.  Supernatants were collected and assayed by ELISA 
for IL-1β.  As expected, P2X7-/- BMDM treated with ATP did not produce IL-1β, but when treated with nigericin 
they produced similar amounts of IL-1β to WT BMDM.  TLO also induced equivalents amounts of IL-1β from WT 
compared to P2X7-/- BMDM, showing that it does not depend on P2X7 activity.  Data represents mean +/- SEM for 3 
independent experiments.  Student’s paired t-test was applied for comparison of WT versus P2X7-/- conditions.  * = p 
< 0.05.  
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4.5 DISCUSSION 
It has been observed that the lethal concentration of a single CDC family member varies 
depending on the cell type being exposed to it (Mosser & Rest, 2006).  Pore formation largely 
contributes to this cell death, but the pathways that are involved after pore formation but before 
final cell death are not well understood.  In order to identify critical pathways or molecules that 
contribute to CDC-induced pore formation, we generated a dendritic cell line resistant to CDC 
TLO (TLO-r).  We observed that these variant cells were more resistant to TLO-induced pore 
formation and maintained a healthy morphology, as opposed to the parental cell line (FSDC) that 
underwent cell death.  It was ruled out that differences in pore size, cholesterol content, CDC 
binding to the plasma membrane, or changes in phenotype (surface markers, phagocytosis of 
bacteria) were responsible for the pore resistance phenotype of the variant.  Instead, we identified 
ATP and its receptor P2X7 as potential candidates using the following observations: (1) TLO 
induces ATP release from FSDC, (2) TLO-induced ATP release is greatly reduced in TLO-r, (3) 
TLO-induced dye uptake in FSDC is partially inhibited by apyrase (degrades ATP) and oATP 
(inhibits P2X7), (4) TLO-r express less P2X7 than FSDC, and (5) TLO-r are more resistant to 
ATP-induced dye uptake.  From these data, we proposed the model shown in Figure 4-9.  
However, we identified other defects in TLO-r, which prompted us to study the role of P2X7 in 
TLO-induced pore formation and IL-1β release using more straightforward cell systems (P2X7-
expressing or –deficient cell lines or primary macrophages).  Using these latter systems, we have 
concluded that P2X7 does not play a role in TLO-induced pore formation or IL-1β secretion. 
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The generation of the ATP-resistance phenotype may have occurred in a parallel, but 
unrelated way during the generation of the TLO-resistance phenotype.  ATP is present inside 
cells at a concentration of 5-10mM and can be released upon membrane damage (Di Virgilio, 
2005; Bours et al., 2006).  We show with our data that high doses of CDC perforate cells and 
allow the release of ATP.  If this were to occur during the TLO selection process, high 
concentrations of ATP would be locally present around the cells and would be capable of 
binding to and activating P2X7, which would ultimately lead to cell death. Thus, ATP itself 
would apply its own selective pressures (as shown in the ability to create ATP-resistant D2 cells) 
so that cells with low levels of P2X7 and therefore, less responsiveness to ATP would be favored.  
This phenomenon would explain the phenotype observed in TLO-r and would suggest that 
another factor or pathway is responsible for the TLO-induced pore resistance phenotype.  
The factor or pathway responsible for the pore formation resistance phenotype is 
currently unknown.  It could be speculated that pore resealing machinery may be more active in 
TLO-r than FSDC such that TLO-r can deal with membrane attack much more rapidly than 
FSDC.  It was originally demonstrated by Walev, et al. that CDC pores can be repaired or 
resealed (Walev et al., 2001b; Husmann et al., 2006) and it was later suggested that these 
resealing processes may involve calcium- or calmodulin-mediated signaling pathways (Aroian & 
van der Goot, 2007).  Recent work by Idone, et al. supports the role of calcium signaling in pore 
resealing and further shows that endocytosis is responsible for the removal of pores from the cell 
surface (Idone et al., 2008).  Though there are no noticeable differences in phagocytic activity 
between FSDC and TLO-r, it is possible that TLO-r have enhanced endocytic machinery 
expression and/or activity. 
 133 
Interestingly, we also observed that TLO-r had defects in proinflammatory cytokine 
secretion (Figure 4-10).  This phenotype could be a reflection of the selection for TLR4 low to 
negative cells since TLR4 has been reported to act as a CDC receptor (Malley et al., 2003; Park 
et al., 2004a; Ito et al., 2005; Srivastava et al., 2005) and its activation results in 
proinflammatory cytokine secretion from myeloid cells.  However, the expression levels of 
TLR4 on TLO-r have not been assessed.  Another explanation for this phenotype is that there is a 
defect on the transcription factor level.  Such transcription factors known to play a role in 
cytokine secretion are p38 MAPK and NF-κB.  Both transcription factors have been shown to 
participate in an osmotic stress response to CDC that results in cytokine secretion (Walev et al., 
2001b; Husmann et al., 2006; Ratner et al., 2006; Kloft et al., 2009).  Thus, TLO-r may have a 
defect in p38 MAPK or NF-κB activation, which would result in secretion of lower cytokine 
levels.  This has yet to be determined.   
In general, TLO-r could be a useful tool to initially identify potential candidates involved 
in CDC-induced pore formation and possibly other pathways induced by CDC that have yet to be 
discovered.  Many candidates could be simultaneously identified using a proteomic approach to 
compare the differential protein expression between FSDC and TLO-r.  Similarly, differential 
expression of mRNA or protein levels could be determined by using RT-PCR or proteomics, 
respectively, for untreated versus CDC-treated cells.  Once candidate factors were identified, it 
would be essential to test their contribution, if any, to the host cellular response to CDC.  As 
demonstrated by the work in this chapter, it would also be critical to use primary cells or 
engineered cells that lack or express the proteins of interest.  Identifying new pathways initiated 
by CDC will help us to better understand their interactions with host cells and generate specific 
therapies to supplement antibiotic treatments in bacterially infected patients. 
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5.0  SUMMARY & INTERPRETATIONS 
5.1 PROPOSED MODEL AND THERAPEUTIC IMPLICATIONS 
The work contained herein implicates CDC in triggering distinct pathways regulated by the 
NLRP3 inflammasome in murine macrophages.  One pathway is characterized by ion fluxes and 
the activation of iPLA2, the NLRP3 inflammasome, and cathepsin B for the maturation of pro-
IL-1β and subsequent secretion.  The other pathway results in necrotic cell death, marked by 
LDH and HMGB1 release, that is dependent on the NLRP3 inflammasome and cathepsin B 
activity.  These NLRP3 inflammasome-dependent events only occur after exposure to lower 
toxin doses whereas higher toxin doses induce passive spilling of contents such as LDH, 
HMGB1, pro-caspase-1, and pro-IL-1β.   
A model (Figure 5-1) can be postulated where invading bacteria secrete many CDC 
monomers that exist at a high concentration closest to the bacterial source, but as the toxin 
diffuses outwards, its concentration decreases.  These higher doses would be expected to 
perforate nearby cells and bring about necrotic cell death characterized by LDH and HMGB1 
release.  These cells would also lose contents such as pro-caspase-1 and pro-IL-1β before 
activation and processing, respectively, could occur.  This environment would most likely be 
advantageous to the pathogen since innate immune cells would be killed before having a chance 
to notify the rest of the immune system of a pathogenic threat.  Moreover, extracellular HMGB1 
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could lead to uncontrolled inflammation, which occurs in the case of sepsis (Wang et al., 1999; 
Wang et al., 2004).  On the other hand, lower CDC doses would activate the NLRP3 
inflammasome for mature IL-1β secretion and regulated HMGB1 release.  Though these cells 
would ultimately succumb to cell death, IL-1β and HMGB1 could still serve to recruit other 
innate inflammatory immune cells for the initiation of an immune response.  However, this is 
purely speculative and it is difficult to predict if extracellular IL-1β and HMGB1 would play 
more of a detrimental or beneficial role.  Additional work must be conducted in vivo to 
determine the contribution of the NLRP3 inflammasome, IL-1β, and HMGB1 in the host 
response to infection with CDC-secreting gram-positive bacteria.  The NLRP3 inflammasome, 
IL-1β, and HMGB1 could be potential therapeutic targets if they did significantly contribute to 
disease in the context of gram-positive bacterial infection. 
     
 
Figure 5-1: Model for TLO-induced IL-1β and HMGB1 release in the context of bacterial infection. 
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Bacterial infection by TLO-producing C. tetani might occur at a local site such as the skin where various cells such 
as keratinocytes, dermal dendritic cells (DC), Langerhans cells, and macrophages are present.  Macrophages closest 
to the bacterial source would be exposed to the high concentrations of TLO, leading to necrotic cell death 
characterized by the release of HMGB1, LDH, inactive pro-caspase-1, and inactive pro-IL-1β.  On the other hand, 
macrophages further from the bacterial source would encounter lower concentrations of TLO, which would enable 
NLRP3 inflammasome activation. This would then lead to HMGB1 release and mature IL-1β secretion, two factors 
that could enhance inflammation through the generation of additional pro-inflammatory molecules and recruitment 
of other innate immune cells such as neutrophils.  This might be a last effort for these cells to stimulate immunity 
before also undergoing necrotic cell death. 
 
Not only can this work enable a better understanding of the role of CDC in bacterial 
pathogenesis and the host response, but it is clear that CDC can serve as a useful tool to identify 
new intracellular pathways linked to NLRP3 and the inflammasome complex.  Already, IL-1β 
and HMGB1 release have been identified as factors linked to the NLRP3 inflammasome that can 
contribute to disease.  IL-1β has been shown to initiate inflammation for the generation of robust 
immune responses, but uncontrolled release can contribute to autoinflammatory disease.  Disease 
can arise when mutations in the NLRP3 inflammasome lead to overactivation and subsequent 
constitutive IL-1β secretion (Masters et al., 2009).  Treatments such as anakinra (IL-1Ra) have 
been useful in controlling IL-1β levels in patients with autoinflammatory syndromes (Leslie et 
al., 2006; Maksimovic et al., 2008).  Similarly, HMGB1 has been implicated in contributing to 
disease states such as sepsis and arthritis and neutralizing antibodies to HMGB1 help to lessen 
the severity of disease (Wang et al., 1999; Andersson & Erlandsson-Harris, 2004; Andersson & 
Tracey, 2004; Wang et al., 2004; Lotze & Tracey, 2005).  Another disease thought to be 
impacted by HMGB1-induced inflammation is systemic lupus erythematosus (SLE) (Ardoin & 
Pisetsky, 2008).  SLE is characterized by the formation of immune complexes, activation of 
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autoreactive B cells, generation of autoantibodies to nuclear factors, and production of high 
levels of interferon-α (IFN-α).  Increased cell death in the setting of autoimmune disease would 
lead to increased release of HMGB1, which has been shown to participate in immune complexes 
that induce IFN-α secretion and B cell activation.  This would suggest that HMGB1 plays a 
potential role in the pathogenesis of SLE.  HMGB1 may also contribute to cancer where necrotic 
tumor cells would be expected to release HMGB1 for the mediation of tumor cell invasion, 
migration, growth, and spread via RAGE signaling (Ellerman et al., 2007).  Thus, identifying 
new targets using CDC could lead to the development of new treatments for patients with 
overactive inflammation, autoimmune diseases, and cancer.   
 Lastly, we have isolated a CDC-resistant dendritic cell line that may serve as a useful tool 
in the future to identify factors and pathways involved in CDC-induced pore formation and cell 
damage.  These pathways could be specific to CDC and other pore-forming toxins or could 
extend to general mechanisms for defense against cell stress.  Targeting these pathways would be 
useful not only in combating bacterial infections, but also under circumstances of exposure to 
environmental insults, oxidative stress, and hypoxia/ischemia.    
5.2 COMPARISON OF TLO TO OTHER CDC FAMILY MEMBERS 
CDC share 30-60% homology in primary amino acid sequence (Billington et al., 2000), so while 
they share many similarities there could also be differences in function.  Most CDC share 
complete homology in the domain 4 undecapeptide sequence (consensus sequence: 
ECTGLAWEWWR), which is important for CDC membrane insertion, the prepore to pore 
transition, and sensitivity to reducing agents (Billington et al., 2000; Soltani et al., 2007).  
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However, vaginolysin (VLY; EKTGLVWEPWR), intermedilysin (ILY; GATGLAWEPWR), 
and pyolysin (PLO; EATGLAWDPWW) all lack the cysteine residue in the undecapeptide 
sequence, making them insensitive to reducing agents (Gelber et al., 2008).  Differences in 
overall amino acid sequence can also lead to unique functions for CDC.  VLY and ILY both 
require binding to human CD59 for cytolytic activity (Soltani et al., 2007; Gelber et al., 2008) 
and listeriolysin O (LLO) is highly active at acidic pH (Beauregard et al., 1997).  TLO contains 
the consensus undecapeptide sequence (Genbank accession number YP_001921918) and 
therefore, would be expected to form pores in cell membranes and be sensitive to reducing 
agents.  We believe that TLO binds cholesterol, since free cholesterol can block its actions, and 
we observe dye uptake by cells after exposure to TLO, which would suggest that TLO also 
induces pore formation.  Additionally, cells have increased sensitivity to dye uptake after 
exposure to TLO that has been reduced with dithiothreitol (DTT).  Thus, TLO is similar to most 
other CDC in its ability to bind cholesterol, form pores in the plasma membrane, and become 
more active in a reduced state.  
General downstream pathways of cell surface pore formation might be expected to occur 
for all CDC that bind cholesterol and form pores.  These pathways include pore sensing (calcium 
fluxes, transcription factor activation, cytokine release) and membrane resealing (Walev et al., 
2001a; Walev et al., 2001b; Uhlik et al., 2003; Husmann et al., 2006; Ratner et al., 2006; Idone 
et al., 2008; Kloft et al., 2009).  We have observed TLO-induced calcium fluxes as measured 
with calcium-sensitive dyes (data not shown), but fail to observe transcription factor activation 
(NF-κB, p38 MAPK) and cytokine release (data not shown), other than IL-1β.  Transcription 
factor activation and cytokine release can occur both at high toxin doses where pores are formed 
and at low toxin doses where minimal membrane damage is evident.  The latter effect is thought 
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to be caused by TLR4 activation, which has been shown for a few other CDC like ALO (Malley 
et al., 2003; Park et al., 2004a; Ito et al., 2005; Srivastava et al., 2005).  In our hands, ALO does 
not induce transcription factor activation or cytokine release when applied in the presence of free 
cholesterol (data not shown), suggesting that CDC do not act as TLR4 agonists.  This disparity 
may be explained by contamination of CDC with well accepted TLR agonists such as endotoxin.  
In the former case, it is unclear why TLO does not elicit these cellular responses.  It is possible 
that a more careful titration must be conducted to identify a high enough toxin dose where pores 
are formed, but cells still retain their functions.  Lastly, we have not yet fully assessed membrane 
resealing processes after TLO exposure, but have observed viability dye exclusion from a 
population of TLO-treated cells after an initial time point of complete viability dye staining.  
These results would suggest that a portion of TLO-treated cells recover from initial membrane 
damage.  Taken together, many processes related to pore formation observed for other CDC (e.g. 
calcium flux, IL-1β release, membrane repair) seem to hold for TLO.  Differences observed 
between TLO and other CDC could be explained by mere technical challenges or may in fact be 
due to slight differences in amino acid sequence.  Thus, it is important to test each CDC for a 
specific function (pore-dependent or pore-independent) before making conclusions about the 
CDC family as a whole. 
5.3 APPLICATION OF FINDINGS TO OTHER CELL SYSTEMS AND 
DOWNSTREAM PRO-INFLAMMATORY PATHWAYS 
Though our work focused on the response of the macrophage to CDC, it would be expected that 
other TLR-primed, NLRP3 inflammasome-containing cells would also be capable of making IL-
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1 after toxin exposure.  NLRP3 inflammasome-dependent release of IL-1β has been 
demonstrated for murine DC exposed to Candida albicans (Gross et al., 2009; Kumar et al., 
2009b) and particulate adjuvants (Sharp et al., 2009), human THP-1 monocytes exposed to α-
hemolysin from S. aureus (Craven et al., 2009), and human keratinocytes treated with contact 
sensitizers like trinitro-chlorobenzene (Watanabe et al., 2007).  Epithelial cells also appear to 
have the potential for NLRP3-dependent IL-1β release as supported by two studies.  First, human 
airway epithelial cells upregulate Nlrp3 mRNA and secrete IL-1β after exposure to Influenza A 
Virus (Allen et al., 2009).  This would suggest that NLRP3 plays a role in IL-1β secretion during 
influenza infection, but this was not directly tested.  Second, human cervical epithelial cells 
(HeLa 229) contain a functional NLRP3 inflammasome that becomes activated during infection 
with Chlamydia trachomatis (Abdul-Sater et al., 2009), but IL-1β secretion was not assessed.  It 
might also be expected that other cell types containing a functional NLRP3 inflammasome could 
mediate HMGB1 release after low dose CDC exposure.  However, there is an added level of 
complexity in that any stimulator of necrosis (e.g. high dose CDC) could also cause HMGB1 
release in a manner independent of the NLRP3 inflammasome.  Since HMGB1 is present in all 
nucleated cells, most cells are capable of releasing HMGB1.  Thus, release of mature IL-1β is 
more selective than HMGB1 release, since the former event only occurs in NLRP3 
inflammasome-containing cells. 
Aside from IL-1β and HMGB1, we have also observed that TLO induces the secretion of 
IL-1α from macrophages.  It is likely that TLO causes NLRP3-dependent IL-18 release, but this 
has yet to be tested.  In contrast, we have no evidence that TLO can induce other pro-
inflammatory cytokines such as TNF-α and IL-6.  This difference may be explained by the 
mechanisms of cytokine processing and release required for leaderless peptides such as IL-1α, 
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IL-1β, IL-18, and HMGB1.  Ligation of IL-1RI, which is highly expressed on many cell types, 
with IL-1α and IL-1β, would lead to the secretion of additional pro-inflammatory factors such as 
COX-2, iNOS, chemokines, cytokines, and matrix metalloproteinases (Apte & Voronov, 2008) 
to create a positive feedback loop of inflammatory responses.  IL-1 also causes the upregulation 
of adhesion molecules on endothelial cells, stromal cells, and leukocytes, enabling the 
recruitment of inflammatory cells (e.g. neutrophils) from the blood into the tissues (Apte & 
Voronov, 2008).  In terms of adaptive immunity, IL-1 contributes to Th2 polarization (Nakae et 
al., 2003), antibody production (Nakae et al., 2001), and Th17 responses (Sutton et al., 2006; 
Acosta-Rodriguez et al., 2007).  Similarly to IL-1, IL-18 also amplifies the inflammatory 
response by inducing pro-inflammatory cytokines and chemokines like GM-CSF, TNF-α, IL-1β, 
IL-6, and IL-8 and upregulating adhesion molecules (Puren et al., 1998; Arend et al., 2008).  IL-
18 stimulates the activity of innate immune cells like neutrophils and NK cells and adaptive 
immune cells such as CD8+ effector T cells, Th1 cells, Th2 cells, and Th17 cells (Arend et al., 
2008).  These T helper responses depend on other cytokines that act in concert with IL-18, 
namely IL-12 for Th1 responses (Robinson et al., 1997), IL-2 for Th2 responses (Hoshino et al., 
1999), and IL-23 for IL-17 responses (Weaver et al., 2006).  Well known for its IFN-γ-
promoting ability, IL-18 synergizes with IL-12 to induce IFN-γ from Th1 cells (Robinson et al., 
1997), CD8+ T cells (Okamoto et al., 1999), and activated B cells (Yoshimoto et al., 1997). IL-1 
and IL-18 impact so many cell types and inflammatory processes that overexpression often leads 
to disease.  The list of these diseases includes, but is not limited to: (1) For IL-1 – 
autoinflammation (Masters et al., 2009), sepsis (Dinarello, 1991), rheumatoid arthritis (RA) 
(Gabay, 2000), type 2 diabetes (Maedler et al., 2009), cancer (Apte & Voronov, 2008), 
cardiovascular disease (Kleemann et al., 2008; Vicenova et al., 2009), and neurodegeneration 
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(Simi et al., 2007), (2) For IL-18 – multiple sclerosis (Karni et al., 2002), RA (Matsui et al., 
2003), inflammatory bowel diseases (Lochner & Forster, 2002; Reuter & Pizarro, 2004), 
psoriasis (Companjen et al., 2004), atherosclerosis (Kleemann et al., 2008), and cancer (Park et 
al., 2007).  Understanding the mechanisms that regulate the release of pro-inflammatory 
molecules, identifying the cell types that release these factors and determining their impact on 
other cells will be invaluable in identifying multiple therapeutic targets to treat many of these 
diseases. 
5.4 TRANSLATING IN VITRO RESULTS TO IN VIVO MODELS 
Precise amounts of CDC needed to induce pathways such as cytokine secretion or cell death are 
most likely different in vitro versus in vivo, but this is difficult to measure.  Differences may 
arise due to several factors such as cell number, homogeneity vs. heterogeneity of cell 
populations, and amount of exogenous cholesterol present.  In vitro settings allow for a 
controlled environment where cell number is fixed and exogenous cholesterol can be excluded to 
allow for more efficient toxin interaction with cells.  Moreover, only one cell type is present so 
there is no impact of other cell types that would normally be present in vivo.  Obtaining an 
accurate quantitative measurement of CDC concentrations at exact time points and locations in 
vivo would be difficult since the act of collecting the measurement could change the 
measurement.  Only qualitative assumptions can be made, where toxin dose is highest at the 
bacterial source and lower as toxin diffuses away from the source.  Due to this limitation, known 
in vitro doses cannot be compared to unknown amounts of CDC present in vivo. 
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Even more complicated is the comparison of different in vivo scenarios where the CDC 
dose required to bring about a specific effect could vary due to the site of bacterial infection.  
100pmol of various CDC administered i.v. can bring about the death of a mouse within seconds 
(Watanabe et al., 2006), but this could differ if CDC were administered through a non-systemic 
route.  A more likely site of initial infection might be the lungs or skin and probably more toxin 
would be required to kill an organism if administered through these entry ways.  Additionally, 
these locations would be expected to have more innate immune cells than the bloodstream such 
that immune responses might be more robust than if CDC-producing bacteria were only in the 
bloodstream.   
Though CDC and host cell interactions in vivo are complex and exact CDC 
concentrations cannot be compared between in vitro and in vivo situations, our in vitro data 
provides qualitative information that can be used as a starting point for studying the role of CDC 
in vivo.  Based on our in vitro data, we show that CDC at some concentration can induce mature 
IL-1β and HMGB1 release from murine macrophages.  This in vitro finding could be applied to 
an in vivo model where mice are infected with CDC-producing bacteria at various MOIs or 
directly injected with different toxin doses through a route such as the skin.  The contribution of 
CDC could be separated from that of whole bacteria by also infecting with a mutant CDC-
secreting strain or a strain that does not secrete CDC.  Tissue samples and serum samples could 
be collected and analyzed for mature IL-1β and HMGB1 content.  It might be expected that at 
some time point and concentration of bacteria or purified CDC, both of these pro-inflammatory 
cytokines would be produced.  To further test the role of the NLRP3 inflammasome, these 
experiments could be carried out in NLRP3-/-, caspase-1-/-, and ASC-/- mice.  These studies could 
be supplemented with additional experiments to assess bacterial titer, the degree of tissue 
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inflammation, other markers of inflammation, the cells producing these inflammatory molecules, 
and the cellular composition of the tissue samples.  Depending on these results, further studies on 
the generation of adaptive immune responses (e.g. antibody titers, antigen-specific T cells and 
their responses) would be warranted.  Ultimately, it would be important to assess the survival 
outcome after infection with CDC-producing bacteria in order to determine if subsequent 
NLRP3-dependent responses are beneficial or detrimental to the host.  Results of these studies 
would be the basis for generating novel anti-bacterial therapies. 
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